```
=> s (Growth (w) hormone) and crystal
           4   FILE AGRICOLA
           1   FILE ANABSTR
           1   FILE AQUASCI
           3   FILE BIOBUSINESS
          83   FILE BIOSIS
           3   FILE BIOTECHABS
           3   FILE BIOTECHDS
          49   FILE BIOTECHNO
           4   FILE CABA
          29   FILE CANCERLIT
         124   FILE CAPLUS
           2   FILE CEABA-VTB
           8   FILE CEN
           1   FILE CIN
  20 FILES SEARCHED...
           3   FILE DDFB
           3   FILE DDFU
           2   FILE DRUGB
           8   FILE DRUGU
           1   FILE EMBAL
          86   FILE EMBASE
          47   FILE ESBIOBASE
           5   FILE FEDRIP
           2   FILE FSTA
  38 FILES SEARCHED...
          15   FILE IFIPAT
           6   FILE JICST-EPLUS
          33   FILE LIFESCI
          73   FILE MEDLINE
           1   FILE NTIS
           1   FILE OCEAN
          20   FILE PASCAL
           6   FILE PHIN
          18   FILE PROMT
         301   FILE SCISEARCH
          51   FILE TOXCENTER
        1639   FILE USPATFULL
           7   FILE USPAT2
  59 FILES SEARCHED...
          22   FILE WPIDS
          22   FILE WPINDEX
           7   FILE BABS
           1   FILE COMPENDEX
          14   FILE INSPEC
  73 FILES SEARCHED...
          15   FILE INVESTEXT
           1   FILE IPA

  43 FILES HAVE ONE OR MORE ANSWERS,   86 FILES SEARCHED IN STNINDEX

L1   QUE (GROWTH (W) HORMONE) AND CRYSTAL

=> file hits
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.65       2.86

FILE 'USPATFULL' ENTERED AT 15:32:26 ON 24 MAY 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT  C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 15:32:26 ON 24 MAY 2002
```

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'EMBASE' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'BIOSIS' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'MEDLINE' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'TOXCENTER' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'BIOTECHNO' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'ESBIOBASE' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'LIFESCI' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'CANCERLIT' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'WPIDS' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'PASCAL' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'PROMT' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'IFIPAT' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'INVESTEXT' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'INSPEC' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'CEN' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'DRUGU' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'USPAT2' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'BABS' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'JICST-EPLUS' ENTERED AT 15:32:26 ON 24 MAY 2002

COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'PHIN' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'FEDRIP' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'AGRICOLA' ENTERED AT 15:32:26 ON 24 MAY 2002

FILE 'CABA' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'BIOBUSINESS' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'CEABA-VTB' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (c) 2002 DECHEMA eV

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DRUGB' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 International Food Information Service

FILE 'ANABSTR' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 15:32:26 ON 24 MAY 2002
(c) 2002 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'CIN' ENTERED AT 15:32:26 ON 24 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'EMBAL' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'NTIS' ENTERED AT 15:32:26 ON 24 MAY 2002
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2002)

FILE 'OCEAN' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'COMPENDEX' ENTERED AT 15:32:26 ON 24 MAY 2002
Compendex Compilation and Indexing (C) 2002
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'IPA' ENTERED AT 15:32:26 ON 24 MAY 2002
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

=> s l1

```
L2          1639 FILE USPATFULL
L3           301 FILE SCISEARCH
L4           124 FILE CAPLUS
L5            86 FILE EMBASE
L6            83 FILE BIOSIS
L7            73 FILE MEDLINE
L8            51 FILE TOXCENTER
L9            49 FILE BIOTECHNO
L10           47 FILE ESBIOBASE
L11           33 FILE LIFESCI
L12           29 FILE CANCERLIT
L13           22 FILE WPIDS
L14           20 FILE PASCAL
L15           18 FILE PROMT
L16           15 FILE IFIPAT
L17           15 FILE INVESTEXT
L18           14 FILE INSPEC
L19            8 FILE CEN
L20            8 FILE DRUGU
L21            7 FILE USPAT2
L22            7 FILE BABS
L23            6 FILE JICST-EPLUS
L24            6 FILE PHIN
L25            5 FILE FEDRIP
L26            4 FILE AGRICOLA
L27            4 FILE CABA
L28            3 FILE BIOBUSINESS
L29            3 FILE BIOTECHDS
L30            2 FILE CEABA-VTB
L31            2 FILE DRUGB
L32            2 FILE FSTA
L33            1 FILE ANABSTR
L34            1 FILE AQUASCI
L35            1 FILE CIN
L36            1 FILE EMBAL
L37            1 FILE NTIS
L38            1 FILE OCEAN
L39            1 FILE COMPENDEX
L40            1 FILE IPA

TOTAL FOR ALL FILES
L41         2694 L1

=> s l17 and 1980-1990/py
L42          122 FILE USPATFULL
L43            1 FILE SCISEARCH
L44           10 FILE CAPLUS
L45            4 FILE EMBASE
L46            6 FILE BIOSIS
L47            8 FILE MEDLINE
L48            1 FILE TOXCENTER
L49            2 FILE BIOTECHNO
L50            0 FILE ESBIOBASE
L51            3 FILE LIFESCI
L52            2 FILE CANCERLIT
L53            4 FILE WPIDS
L54            3 FILE PASCAL
L55            2 FILE PROMT
L56            2 FILE IFIPAT
L57            1 FILE INVESTEXT
L58            0 FILE INSPEC
L59            0 FILE CEN
L60            1 FILE DRUGU
L61            0 FILE USPAT2
L62            0 FILE BABS
```

```
L63           1 FILE JICST-EPLUS
L64           2 FILE PHIN
'PY' IS NOT A VALID FIELD CODE
L65           0 FILE FEDRIP
L66           0 FILE AGRICOLA
L67           1 FILE CABA
L68           0 FILE BIOBUSINESS
L69           3 FILE BIOTECHDS
L70           1 FILE CEABA-VTB
L71           0 FILE DRUGB
L72           0 FILE FSTA
L73           1 FILE ANABSTR
L74           0 FILE AQUASCI
L75           0 FILE CIN
L76           0 FILE EMBAL
L77           0 FILE NTIS
L78           0 FILE OCEAN
L79           0 FILE COMPENDEX
L80           0 FILE IPA

TOTAL FOR ALL FILES
L81         181 L17 AND 1980-1990/PY

=> dup rem l81
DUPLICATE IS NOT AVAILABLE IN 'INVESTEXT, FEDRIP'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L81
L82          146 DUP REM L81 (35 DUPLICATES REMOVED)

=> s l82 and (organic (w) solvent)
L83         122 S L82
L84          51 FILE USPATFULL
L85           1 S L82
L86           0 FILE SCISEARCH
L87          10 S L82
L88           0 FILE CAPLUS
L89           0 S L82
L90           0 FILE EMBASE
L91           1 S L82
L92           0 FILE BIOSIS
L93           0 S L82
L94           0 FILE MEDLINE
L95           0 S L82
L96           0 FILE TOXCENTER
L97           0 S L82
L98           0 FILE BIOTECHNO
L99           0 S L82
L100          0 FILE ESBIOBASE
L101          0 S L82
L102          0 FILE LIFESCI
L103          0 S L82
L104          0 FILE CANCERLIT
L105          4 S L82
L106          0 FILE WPIDS
L107          1 S L82
L108          0 FILE PASCAL
L109          2 S L82
L110          0 FILE PROMT
L111          0 S L82
L112          0 FILE IFIPAT
L113          1 S L82
L114          0 FILE INVESTEXT
L115          0 S L82
L116          0 FILE INSPEC
L117          0 S L82
```

```
L118            0 FILE CEN
L119            0 S L82
L120            0 FILE DRUGU
L121            0 S L82
L122            0 FILE USPAT2
L123            0 S L82
L124            0 FILE BABS
L125            1 S L82
L126            0 FILE JICST-EPLUS
L127            2 S L82
L128            0 FILE PHIN
L129            0 S L82
L130            0 FILE FEDRIP
L131            0 S L82
L132            0 FILE AGRICOLA
L133            0 S L82
L134            0 FILE CABA
L135            0 S L82
L136            0 FILE BIOBUSINESS
L137            0 S L82
L138            0 FILE BIOTECHDS
L139            0 S L82
L140            0 FILE CEABA-VTB
L141            0 S L82
L142            0 FILE DRUGB
L143            0 S L82
L144            0 FILE FSTA
L145            1 S L82
L146            0 FILE ANABSTR
L147            0 S L82
L148            0 FILE AQUASCI
L149            0 S L82
L150            0 FILE CIN
L151            0 S L82
L152            0 FILE EMBAL
L153            0 S L82
L154            0 FILE NTIS
L155            0 S L82
L156            0 FILE OCEAN
L157            0 S L82
L158            0 FILE COMPENDEX
L159            0 S L82
L160            0 FILE IPA

TOTAL FOR ALL FILES
L161           51 L82 AND (ORGANIC (W) SOLVENT)

=> d l161 1-52 ibib abs

L161 ANSWER 1 OF 51  USPATFULL
ACCESSION NUMBER:          90:98729  USPATFULL
TITLE:                     Biodegradable absorption enhancers
INVENTOR(S):               Wong, Ooi, Lawrence, KS, United States
                           Nishiahta, Toshiaki, Wadai Tukuba Ibaraki, Japan
                           Rytting, Joseph H., Lawrence, KS, United States
PATENT ASSIGNEE(S):        Odontex, Inc., Lawrence, KS, United States (U.S.
                           corporation)

                                NUMBER         KIND    DATE
                           -------------------- ------ --------
PATENT INFORMATION:        US 4980378                  19901225
APPLICATION INFO.:         US 1988-201029              19880601  (7)
DOCUMENT TYPE:             Utility
FILE SEGMENT:              Granted
PRIMARY EXAMINER:          Shippen, Michael L.
```

<--

LEGAL REPRESENTATIVE: Zarley, McKee, Thomte, Voorhees & Sease
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 843
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Biodegradable absorption enhancers, especially useful in pharmaceutical formulations, are compounds having the formula ##STR1## wherein R is hydrogen, C.sub.1 -C.sub.7 alkyl, benzyl or 4-hydroxybenzyl; n is a whole number from 4 to 18 inclusive; R.sub.1 and R.sub.2 are independently selected from hydrogen and C.sub.1 -C.sub.7 alkyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached are combined to form a substituted or unsubstituted heterocycloalkyl radical having a total of 5 to 7 ring atoms, optionally including a hetero ring atom selected from oxygen, sulfur and nitrogen in addition to the indicated nitrogen atom, the substituents when present being one to three C.sub.1 -C.sub.7 alkyl radicals, which may be the same or different; and R.sub.3 and R.sub.4 are independently selected from hydrogen, methyl and ethyl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 2 OF 51 USPATFULL
ACCESSION NUMBER: 90:74953 USPATFULL
TITLE: Method for delivering somatotropin to an animal
INVENTOR(S): Eckenhoff, James B., Los Altos, CA, United States
Magruder, Judy A., Mt. View, CA, United States
Cortese, Richard, Cupertino, CA, United States
Peery, John R., Palo Alto, CA, United States
Wright, Jeremy C., Los Altos, CA, United States
PATENT ASSIGNEE(S): Alza Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4959218		19900925	<--
APPLICATION INFO.:	US 1988-291930		19881228	(7)

DISCLAIMER DATE: 20060808
RELATED APPLN. INFO.: Division of Ser. No. US 1988-173209, filed on 25 Mar 1988, now patented, Pat. No. US 4855141, issued on 8 Aug 1989
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Horne, Leon R.
LEGAL REPRESENTATIVE: Mandell, Edward L., Sabatine, Paul L., Stone, Steven F.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 904
AB A delivery device is disclosed for delivering a beneficial agent to an animal. The device comprises a wall housing an internal space, a beneficial agent in the space, expandable means in the space for causing the beneficial agent to be delivered from the device and means in the space for shielding the beneficial agent from fluid.

L161 ANSWER 3 OF 51 USPATFULL
ACCESSION NUMBER: 90:69386 USPATFULL
TITLE: 2,3-methanoproline
INVENTOR(S): Stammer, Charles H., Athens, GA, United States
PATENT ASSIGNEE(S): University of Georgia Research Foundation, Inc., Athens, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4954158		19900904	
APPLICATION INFO.:	US 1988-285542		19881215 (7)	<--

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1987-41642, filed on 22 Apr 1987 which is a continuation of Ser. No. US 1986-879842, filed on 26 Jun 1986 which is a continuation of Ser. No. US 1984-636091, filed on 3 Aug 1984 which is a continuation-in-part of Ser. No. US 1983-523080, filed on 16 Aug 1983

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Tsung, Frederick F.
LEGAL REPRESENTATIVE: Kilpatrick & Cody
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,7
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is 2,3-methanoproline, derivatives thereof, and biologically active molecules incorporating 2,3-methanoproline. These compounds are useful as inhibitors of ethylene production in plant material, and as synthetic analogs of biologically active molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 4 OF 51 USPATFULL

ACCESSION NUMBER: 90:29840 USPATFULL

TITLE: Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation

INVENTOR(S): Katre, Nandini, El Cerrito, CA, United States
Knauf, Michael J., Oakland, CA, United States

PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4917888		19900417	
APPLICATION INFO.:	US 1987-131901		19871211 (7)	<--

RELATED APPLN. INFO.: Division of Ser. No. US 1986-866459, filed on 21 May 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-749955, filed on 26 Jun 1985, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hazel, Blondel
LEGAL REPRESENTATIVE: Hasak, Janet E., McGarrigle, Philip L., Halluin, Albert P.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not readily soluble in water at pH 6-8 without such solubilizing agent, is selectively conjugated to a water-soluble polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 5 OF 51 USPATFULL

ACCESSION NUMBER: 90:13251 USPATFULL
TITLE: Polylactide compositions
INVENTOR(S): Loomis, Gary L., Drexel Hill, PA, United States
Murdoch, Joseph R., Wilmington, DE, United States
PATENT ASSIGNEE(S): E. I. DuPont De Nemours and Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4902515		19900220	<--
APPLICATION INFO.:	US 1988-256471		19881012	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1988-187350, filed on 28 Apr 1988, now patented, Pat. No. US 4800219 which is a division of Ser. No. US 1987-108531, filed on 15 Oct 1987, now patented, Pat. No. US 4766182 which is a division of Ser. No. US 1986-944588, filed on 22 Dec 1986, now patented, Pat. No. US 4719246
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Foelak, Morton
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1043
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Systems for delivery of biologically active materials employing novel polylactide composition containing segments of poly(R-lactide) interlocked with segments of poly(S-lactide) as the carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 6 OF 51 USPATFULL
ACCESSION NUMBER: 89:100700 USPATFULL
TITLE: Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4888427		19891219	<--
APPLICATION INFO.:	US 1987-35648		19870407	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fan, Jane T.
LEGAL REPRESENTATIVE: Baumeister, Mary K., Clarke, Dennis P.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 2686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel amino acids and peptides containing them which comprise a dihydropyridine.revreaction.pyridinium salt-type redox system and which provide site-specific and sustained delivery of pharmacologically active peptides to the brain. These new amino acids contain a redox system appended directly or via an alkylene bridge to the carbon atom adjacent to the carboxyl carbon and may be incorporated into a peptide chain at a variety of positions, including non-terminal positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 7 OF 51 USPATFULL
ACCESSION NUMBER: 89:100450 USPATFULL
TITLE: Controlled drug delivery high molecular weight polyanhydrides

INVENTOR(S): Langer, Robert S., Sommerville, MA, United States
Domb, Abraham J., Brookline, MA, United States
Laurencin, Cato T., Cambridge, MA, United States
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4888176		19891219	<--
APPLICATION INFO.:	US 1987-61294		19870612 (7)	

DISCLAIMER DATE: 20050712
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1984-613001, filed on 21 May 1984 And a continuation-in-part of Ser. No. US 1987-49988, filed on 15 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-892809, filed on 1 Aug 1986 , said Ser. No. 613001 which is a continuation of Ser. No. US 1983-477710, filed on 22 Mar 1983, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schofer, Joseph L.
ASSISTANT EXAMINER: Kulkosky, Peter F.
LEGAL REPRESENTATIVE: Kilpatrick & Cody
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1023
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A bioerodible controlled drug release device is produced as a homogeneous polymeric matrix from a high molecular weight polyanhydride and a suitable biologically active substance. The high molecular weight polyanhydride is defined by a molecular weight greater than 20,000 and an intrinsic viscosity greater than 0.3 dl/g. The controlled drug release device is preferrably formed by solvent casting with the biologically active substance and exhibits zero order release, improved correlation between the rate of release and polymer degradation, and an induction period between introduction to the eroding environment and the initial release of the biologically active substance. The controlled drug release devices are stable for extended periods of time, flexible and durable and not subject to fracture and disintegration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 8 OF 51 USPATFULL
ACCESSION NUMBER: 89:92522 USPATFULL
TITLE: Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium salt-type redox carriers
INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4880816		19891114	<--
APPLICATION INFO.:	US 1987-116583		19871104 (7)	

DISCLAIMER DATE: 20020910
RELATED APPLN. INFO.: Division of Ser. No. US 1985-733463, filed on 13 May 1985, now patented, Pat. No. US 4727079 which is a continuation-in-part of Ser. No. US 1984-665940, filed on 29 Oct 1984 Ser. No. Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564 And Ser. No. US 1983-461543, filed on 27 Jan 1983 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 , said Ser. No. 665940 And Ser. No. 516382 , each

which is a continuation-in-part of Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 Ser. No. Ser. No. 461543 And Ser. No. 379316 , said Ser. No. 665940 which is a continuation-in-part of Ser. No. 516382

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1983-428192	19830516

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Baumeister, Mary Katherine, Clarke, Dennis P.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1,18
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2099
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 9 OF 51 USPATFULL
ACCESSION NUMBER: 89:71833 USPATFULL
TITLE: Composition using salt form of organic acid derivative of alpha-tocopheral
INVENTOR(S): Janoff, Andrew S., Yardley, PA, United States
Bolcsak, Lois E., Lawrenceville, NJ, United States
Weiner, Alan L., Lawrenceville, NJ, United States
Tremblay, Paul A., Hamilton, NJ, United States
Bergamini, Michael V. W., Easton, PA, United States
Suddith, Robert L., Robbinsville, NJ, United States
PATENT ASSIGNEE(S): The Liposome Company, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4861580		19890829	
APPLICATION INFO.:	US 1986-911138		19860924 (6)	<--
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1985-786740, filed on 15 Oct 1985, now abandoned			

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Bloom, Allen, Kurtz, Catherine L.
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions are described for the preparation of alpha-tocopherol vesicles, the bilayers of which comprise a salt form of an organic acid derivative of alpha-tocopherol such as the Tris salt form of alpha-tocopherol hemisuccinate. The method is rapid and

efficient and does not require the use of **organic solvents**. The alpha-tocopherol vesicles may be used to entrap compounds which are insoluble in aqueous solutions. Such preparations are especially useful for entrapping bioactive agents of limited solubility, thus enabling administration in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 10 OF 51 USPATFULL
ACCESSION NUMBER: 89:64934 USPATFULL
TITLE: Device comprising means for protecting and dispensing fluid sensitive medicament
INVENTOR(S): Eckenhoff, James B., Los Altos, CA, United States
Magruder, Judy A., Mt. View, CA, United States
Cortese, Richard, Cupertino, CA, United States
Peery, John R., Palo Alto, CA, United States
Wright, Jeremy C., Los Altos, CA, United States
PATENT ASSIGNEE(S): ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4855141		19890808	
APPLICATION INFO.:	US 1988-173209		19880325 (7)	<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Page, Thurman K.			
ASSISTANT EXAMINER:	Horne, Leon R.			
LEGAL REPRESENTATIVE:	Sabatine, Paul L., Mandell, Edward L., Stone, Steven F.			
NUMBER OF CLAIMS:	8			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 4 Drawing Page(s)			
LINE COUNT:	939			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A delivery device is disclosed for delivering a beneficial agent to an animal. The device comprises a wall housing an internal space, a beneficial agent in the space, expandable means in the space for causing the beneficial agent to be delivered from the device and means in the space for shielding the beneficial agent from fluid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 11 OF 51 USPATFULL
ACCESSION NUMBER: 89:51976 USPATFULL
TITLE: Product and process for isolating RNA
INVENTOR(S): Chomczynski, Piotr, 727 Martin Luther King Dr., Cincinnati, OH, United States 45220

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4843155		19890627	
APPLICATION INFO.:	US 1987-123107		19871119 (7)	<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Griffin, Ronald W.			
ASSISTANT EXAMINER:	Crane, L. Eric			
LEGAL REPRESENTATIVE:	Wood, Herron & Evans			
NUMBER OF CLAIMS:	7			
EXEMPLARY CLAIM:	1,7			
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)			
LINE COUNT:	309			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses a novel method for isolating RNA from biological tissue samples and a novel solvent adapted for use in the disclosed method. The method employs a single extraction using the

solvent containing guanidinium and phenol. The solvent is stable for about one month at room temperature without any appreciable phenol oxidation or decomposition. Application of the disclosed method and solvent to a biological tissue sample results in the isolation of a high yield of RNA in a substantially pure and undegraded form. The whole procedure can be completed in three hours, much more quickly than other procedures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 12 OF 51 USPATFULL
ACCESSION NUMBER: 89:47675 USPATFULL
TITLE: Liposomes with enhanced retention on mucosal tissue
INVENTOR(S): Guo, Luke S. S., Lafayette, CA, United States
Redemann, Carl T., Walnut Creek, CA, United States
Radhakrishnan, Ramachandran, Palo Alto, CA, United States
Yau-Young, Annie, Los Altos, CA, United States
PATENT ASSIGNEE(S): Liposome Technology, Inc., Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4839175		19890613	<--
APPLICATION INFO.:	US 1986-890815		19860728	(6)

DISCLAIMER DATE: 20060214
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Dehlinger, Peter J.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A liposome composition designed for enhanced binding to mucosal tissue, The liposomes contain about 10-40 mole percent of an amine-derivatized lipid component in which a charged amine group is spaced from a lipid polar head region by a carbon-containing spacer arm at least 3 atoms in length. The liposomes preferably have a close packed lipid structure produced by inclusion of between 20-50 mole percent of cholesterol or an amine-derivatized cholesterol, and/or phospholipids with predominantly saturated acyl chain moieties. For ophthalmic use, the liposomes may be suspended in an aqueous medium containing a high-viscosity polymer, to enhance further the retention of liposomes on a corneal surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 13 OF 51 USPATFULL
ACCESSION NUMBER: 89:12965 USPATFULL
TITLE: Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
INVENTOR(S): Kohn, Joachim, Brookline, MA, United States
Langer, Robert S., Somerville, MA, United States
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4806621		19890221	<--
APPLICATION INFO.:	US 1986-820351		19860121	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Anderson, Harold D.
LEGAL REPRESENTATIVE: Cook, Paul J.

NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 680
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel series of articles useful as medical devices, implants and protheses are provided which utilize poly(iminocarbonate) polymeric matrices. These articles are biocompatible, have excellent mechanical properties and degrade into non-toxic residues after introduction in vivo. The articles may be formed in any desired dimensions and configuration and may take specific shape as biodegradable sutures or as orthopedic appliances such as bone plates and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 14 OF 51 USPATFULL
ACCESSION NUMBER: 88:53792 USPATFULL
TITLE: Solubilization of proteins for pharmaceutical compositions using polymer conjugation
INVENTOR(S): Katre, Nandini, El Cerrito, CA, United States
Knauf, Michael J., Oakland, CA, United States
PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4766106		19880823	<--
APPLICATION INFO.:	US 1988-148145		19880125	(7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1986-866459, filed on 21 May 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-749955, filed on 26 Jun 1985, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hazel, Blondel
LEGAL REPRESENTATIVE: Halluin, Albert P., Hasak, Janet E.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not readily soluble in water at pH 6-8 without such solubilizing agent, is selectively conjugated to a water-soluble polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 15 OF 51 USPATFULL
ACCESSION NUMBER: 88:11520 USPATFULL
TITLE: Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides
INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4727079		19880223	<--
APPLICATION INFO.:	US 1985-733463		19850513	(6)

DISCLAIMER DATE: 20020910
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-461543, filed on 27 Jan 1983, now abandoned And a continuation-in-part of Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564 And a continuation-in-part of Ser. No. US 1984-665940, filed on 29 Oct 1984 , said Ser. No. 461543 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 , said Ser. No. 516382 which is a continuation-in-part of Ser. No. 379316 And a continuation-in-part of Ser. No. 461543 And a continuation-in-part of Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 , said Ser. No. 665940 which is a continuation-in-part of Ser. No. 379316 And a continuation-in-part of Ser. No. 461543 And a continuation-in-part of Ser. No. 475493 And a continuation-in-part of Ser. No. 516382
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Baumeister, Mary Katherine, Clarke, Dennis P.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1,29
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2124
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 16 OF 51 USPATFULL
ACCESSION NUMBER: 87:69949 USPATFULL
TITLE: Enzymatic reactions using magnetic particles
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4698302		19871006	<--
APPLICATION INFO.:	US 1985-744457		19850613	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fcelak, Morton
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Fennie & Edmonds
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 17 OF 51 USPATFULL
ACCESSION NUMBER: 87:68535 USPATFULL
TITLE: Process for the preparation of 2-bromo-.alpha.-ergocryptine
INVENTOR(S): Megyeri, Gabor, Budapest, Hungary
Keve, Tibor, Budapest, Hungary
Galambos, Janos, Budapest, Hungary
Kovacs, Jr., Lajos, Budapest, Hungary
Stefko, Bela, Budapest, Hungary
Bogsch, Erik, Budapest, Hungary
Trischler, Ferenc, Budapest, Hungary
PATENT ASSIGNEE(S): Richter Gedeon Vegyeszeti Gyar RT, Budapest, Hungary (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4697017		19870929	<--
APPLICATION INFO.:	US 1986-869203		19860530	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	HU 1985-2300	19850612

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Shen, Cecilia
LEGAL REPRESENTATIVE: Ross, Karl F., Dubno, Herbert
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a novel process for the preparation of 2-bromo-.alpha.-ergocryptine and its acid addition salt by brominating .alpha.-ergocryptine in such a way that the bromination is carried out at room temperature by using a dimethylsulphoxide-hydrogen bromide mixture containing no more 0.02% of water and, if desired, converting the thus-obtained 2-bromo-.alpha.-ergocryptine to an acid addition salt in a known manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 18 OF 51 USPATFULL
ACCESSION NUMBER: 87:66802 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
Whitehead, Roy A., Hingham, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4695393		19870922	<--
APPLICATION INFO.:	US 1985-744435		19850613 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fdelak, Morton
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1514
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 19 OF 51 USPATFULL
ACCESSION NUMBER: 87:66801 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4695392		19870922	<--
APPLICATION INFO.:	US 1985-744434		19850613 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1459
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 20 OF 51 USPATFULL
ACCESSION NUMBER: 87:41600 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Josephson, Lee, Arlington, MA, United States

PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4672040		19870609	<--
APPLICATION INFO.:	US 1985-749692		19850628	(6)

DISCLAIMER DATE: 20021119
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088 And Ser. No. US 1985-744351, filed on 13 Jun 1985, now patented, Pat. No. US 4628037 And Ser. No. US 1985-744435, filed on 13 Jun 1985 And Ser. No. US 1985-744434, filed on 13 Jun 1985 And Ser. No. US 1985-744457, filed on 13 Jun 1985
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Wieder, Stephen C.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for the use of magnetically responsive particles in systems in which the separation of certain molecules, macromolecules and cells from the surrounding medium is desirable. The magnetically responsive particles may be coupled to a wide variety of molecules. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 21 OF 51 USPATFULL
ACCESSION NUMBER: 87:8090 USPATFULL
TITLE: Insecticidally, acaricidally, and nematocidally 2-amino-1,3-dithiane derivatives and pesticidal compositions therefor
INVENTOR(S): Mitsudera, Hiroyuki, Osaka, Japan
Konishi, Kazuo, Osaka, Japan
Sato, Yasuo, Kyoto, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4640929		19870203	<--
APPLICATION INFO.:	US 1983-525635		19830823	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-149633	19820827

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Mullins, J. G.
LEGAL REPRESENTATIVE: Wegner & Bretschneider
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1,10
LINE COUNT: 1096
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel 1,3-dithiane of the formula ##STR1## wherein R.sup.1 is a

di-substituted amino group; R.sup.2 and R.sup.3 are such that one of them is an electron-withdrawing group with the other being a hydrogen atom, a hydrocarbon group or heterocyclic group of the class consisting of thienyl, triazolyl, and pyridyl, which may optionally be substituted or that R.sup.2 and R.sup.3 taken together with the adjacent carbon atom form a spiro ring provided that at least one of R.sup.2 and R.sup.3 is a carbonyl group; X.sup.1 and X.sup.2 each is a sulfur atom and at least one of X.sup.1 and X.sup.2 may be oxidized, or a salt thereof, possesses very useful pesticidal actions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 22 OF 51 USPATFULL
ACCESSION NUMBER: 86:69734 USPATFULL
TITLE: Binding assays employing magnetic particles
INVENTOR(S): Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
Whitehead, Roy A., Hingham, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4628037		19861209	<--
APPLICATION INFO.:	US 1985-744351		19850613 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554488
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Wieder, Stephen C.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 23 OF 51 USPATFULL
ACCESSION NUMBER: 85:68137 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4554088		19851119	<--
APPLICATION INFO.:	US 1983-493991		19830512 (6)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Demers, Arthur P.

LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 24 OF 51 USPATFULL
ACCESSION NUMBER: 85:46189 USPATFULL
TITLE: Analgesic dipeptide amides and method of use and compositions thereof
INVENTOR(S): Morgan, Barry A., Albany, NY, United States
PATENT ASSIGNEE(S): Sterling Drug Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4533655		19850806	<--
APPLICATION INFO.:	US 1982-423138		19820924 (6)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1981-286672, filed on 24 Jul 1981, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Miller, Theodore C., Dupont, Paul E., Wyatt, B. Woodrow
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A genus of dipeptide amides including as the preferred subgenus the dipeptide amides having the structural formula R.sub.1 TyrR.sub.2 D-AlaNHR.sub.4 wherein R.sub.1 and R.sub.2 are each hydrogen or alkyl provided that at least one of them is other than hydrogen and R.sub.4 is phenylalkyl or substituted-phenylalkyl are prepared by condensing the dipeptide with the amine or the amino acid with the amino acid amide and are useful as analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 25 OF 51 USPATFULL
ACCESSION NUMBER: 85:11772 USPATFULL
TITLE: Charge effects in enzyme immunoassays
INVENTOR(S): Gibbons, Ian, Menlo Park, CA, United States
Rowley, Gerald L., Cupertino, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4501692		19850226	<--
APPLICATION INFO.:	US 1982-259629		19820501 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1979-61099, filed on 26 Jul 1979, now patented, Pat. No. US 4287300
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Draper, Garnette D.
LEGAL REPRESENTATIVE: Rowland, Bertram I., Leitereg, Theodore J.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 1551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for determining a member of a specific binding pair-ligand and receptor (antiligand). Reagents employed include a first modified member which provides an electrical field due to the presence of a plurality of ionic charges and a second modified member labeled with a component of a signal producing system, which system may have one or more components. The average proximity in the assay medium of the first and second modified members is related to the amount of analyte, where the observed signal from the signal producing system is related to the effect of the electrical field on the signal producing system.

Also, compositions are provided, as well as reagents, in predetermined ratios for optimizing the signal response to variations in analyte concentration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 26 OF 51 USPATFULL
ACCESSION NUMBER: 84:64754 USPATFULL
TITLE: Process for producing a slow release composite
INVENTOR(S): Asano, Masaharu, Gunma, Japan
Yoshida, Masaru, Gunma, Japan
Kaetsu, Isao, Gunma, Japan
PATENT ASSIGNEE(S): Japan Atomic Energy Research Institute, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4483807		19841120	<--
APPLICATION INFO.:	US 1982-340989		19820120	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1981-10674	19810127
	JP 1981-12606	19810130
	JP 1981-79567	19810526

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lieberman, Paul
ASSISTANT EXAMINER: Thompson, W.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 440

AB A process is herein disclosed for producing a slow release composite comprising grinding and mixing mechanically in a frozen state one or more polypeptides, one or more proteins and one or more physiologically active substances shaping the blend into a desired form and compressing at a pressure of from 100 to 20,000 kg/cm.sup.2 to thereby produce a slow release composite having the physiologically active substances encapsulated therein.

L161 ANSWER 27 OF 51 USPATFULL
ACCESSION NUMBER: 84:54080 USPATFULL
TITLE: Method and immunochemical measurement
INVENTOR(S): Okazaki, Masaki, Kanagawa, Japan
Masuda, Nobuhito, Kanagawa, Japan

Kumano, Yoshiro, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4473652		19840925	<--
APPLICATION INFO.:	US 1983-506225		19830622	(6)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1981-298815, filed on 2 Sep 1981, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1980-120594	19800902
	JP 1980-120595	19800902

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marantz, Sidney
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 1118
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for immunochemical assay of an antigen or antibody by labelling the antigen or antibody with a specific cyanine or merocyanine dye containing a carboxy group followed by effecting an immune reaction and photochemical processing thereof is provided. The amount of the antigen or antibody is measured in term of optical density of developed silver halide which is brought into contact with either the antigen-antibody reaction product or the unreacted material.

This immunochemical assay method gives high detection sensitivity in a simple operation manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 28 OF 51 USPATFULL
ACCESSION NUMBER: 83:49319 USPATFULL
TITLE: Process for preparing a polymer composition
INVENTOR(S): Kaetsu, Isao, Takasaki, Japan
Yoshida, Masaru, Takasaki, Japan
Kumakura, Minoru, Takasaki, Japan
PATENT ASSIGNEE(S): Japan Atomic Energy Research Institute, Tokyo, Japan (non-U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4411754		19831025	<--
APPLICATION INFO.:	US 1981-234839		19810213	(6)

DISCLAIMER DATE: 19990323
RELATED APPLN. INFO.: Continuation of Ser. No. US 1979-18617, filed on 8 Mar 1979, now Defensive Publication No.

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-27109	19780309
	JP 1978-51239	19780428
	JP 1978-105306	19780829
	JP 1978-106097	19780830

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Briggs, Sr., Wilbert J.
LEGAL REPRESENTATIVE: Oblon, Fisher, Spivak, McClelland & Maier
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1

LINE COUNT: 929
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A polymer composition containing a physiologically active substance which can be released at a controlled rate is prepared by contacting one or more polymerizable monomers with the physiologically active substance, making the monomers into a specific shape and then irradiating the shaped article with light or an ionizing radiation at a low temperature below room temperature to polymerize the polymerizable monomers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 29 OF 51 USPATFULL
ACCESSION NUMBER: 83:15482 USPATFULL
TITLE: Hormonal plant growth regulator
INVENTOR(S): Szejtli, Jozsef, Budapest, Hungary
Budai, Zsuzsanna, Budapest, Hungary
Tetenyi nee Erdosi, Magda, Budapest, Hungary
Pap nee Imrenyi, Gabriella, Budapest, Hungary
PATENT ASSIGNEE(S): Chinoin Gyogyszer es Vegyeszeti Termekek Gyara R.T., Budapest, Hungary (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4380626		19830419	<--
APPLICATION INFO.:	US 1980-218206		19801219	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	HU 1979-CI2000	19791228

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Ross, Karl F., Dubno, Herbert
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new inclusion complexes of 2-chloro ethyl phosphonic acid formed with .alpha.-, .beta.- and/or .gamma.-cyclodextrin or a mixture thereof.

The new inclusion complexes contain preferably 10-30% of 2-chloro ethyl phosphonic acid.

The new complexes of the present invention are prepared by reacting 2-chloro ethyl phosphonic acid with .alpha.-, .beta.- and/or .gamma.-cyclodextrin or a mixture of one or more of the said cyclodextrins and linear dextrins and/or partially decomposed starch.

The new inclusion complexes of the present invention can be used for the preparation of plant growth regulating compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 30 OF 51 USPATFULL
ACCESSION NUMBER: 83:12151 USPATFULL
TITLE: Enzyme amplification compounds for assays for androgens
INVENTOR(S): Rubenstein, Kenneth E., Menlo Park, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 4376825 19830315 <--
APPLICATION INFO.: US 1980-221235 19801230 (6)
DISCLAIMER DATE: 19970304
RELATED APPLN. INFO.: Division of Ser. No. US 1979-36929, filed on 7 May 1979, now patented, Pat. No. US 4282325 which is a continuation-in-part of Ser. No. US 1977-857145, filed on 5 Dec 1977, now patented, Pat. No. US 4203302 which is a continuation-in-part of Ser. No. US 1977-802683, filed on 2 Jun 1977, now patented, Pat. No. US 4190496 which is a continuation of Ser. No. US 1977-760499, filed on 19 Jan 1977, now patented, Pat. No. US 4191613 which is a continuation-in-part of Ser. No. US 1976-722964, filed on 13 Sep 1976, now patented, Pat. No. US 4067774 which is a continuation of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned which is a division of Ser. No. US 1972-304157, filed on 6 Nov 1972, now patented, Pat. No. US 3852157 which is a continuation-in-part of Ser. No. US 1971-143609, filed on 14 May 1971, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tanenholtz, Alvin E.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 3486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as "ligands") and binding an enzyme to the ligand or ligand counterfeit to provide an "enzyme-bound-ligand", an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efficiencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 31 OF 51 USPATFULL
ACCESSION NUMBER: 83:9021 USPATFULL
TITLE: Macromolecular environment control in specific receptor assays
INVENTOR(S): Litman, David J., Palo Alto, CA, United States
Harel, Zvi, Stanford, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4374925		19830222	<--
APPLICATION INFO.:	US 1981-232777		19810209	(6)

DISCLAIMER DATE: 19980623
RELATED APPLN. INFO.: Division of Ser. No. US 1978-964099, filed on 24 Nov 1978, now patented, Pat. No. US 4275149, issued on 23 Jun 1981
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions are provided for performing protein binding assays involving a homologous pair consisting of ligand and receptor for the ligand. The method employs a label conjugated to a member of said homologous pair and a uniformly dispersed discontinuous phase of discrete particles in a continuous aqueous phase, where the discrete particles create microenvironments which allow for discrimination between the label associated with the particle--in a discontinuous phase--and the label in the continuous phase.

Various conjugates and particles are provided which find use in the subject method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 32 OF 51 USPATFULL
ACCESSION NUMBER: 82:56885 USPATFULL
TITLE: Process for the detection of antibodies
INVENTOR(S): Weltman, Joel K., 164 Summit Ave., Providence, RI, United States 02906

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4360592		19821123	<--
APPLICATION INFO.:	US 1980-208234		19801110	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1979-93607, filed on 13 Nov 1979, now patented, Pat. No. US 4251445, issued on 17 Feb 1981 which is a division of Ser. No. US 1978-889726, filed on 24 Mar 1978, now patented, Pat. No. US 4218539, issued on 19 Aug 1980
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shapiro, Lionel M.
LEGAL REPRESENTATIVE: Crowley, Richard P.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel enzyme conjugates useful in immunoassay methods are prepared with the use of a novel coupling reagent of N-succinimidyl (4-iodoacetyl) aminobenzoate by reacting the coupling reagent, firstly, with an amino-containing macromolecule, and, thereafter, with a sulfhydryl-containing enzyme, the enzyme conjugate prepared in a high yield and of high specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 33 OF 51 USPATFULL
ACCESSION NUMBER: 82:27696 USPATFULL
TITLE: Herbicidal 5-cyano-2,3-dihydro-benzofuran-2-ones
INVENTOR(S): Gates, Peter S., Cambridge, England
Baldwin, Derek, Cambridge, England
Wilson, Carol A., Saffron Walden, England
Gillon, John, Cambridge, England
PATENT ASSIGNEE(S): Fisons Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4333759		19820608	<--
APPLICATION INFO.:	US 1980-213151		19801204	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1979-62511, filed on 27 Jul 1979, now patented, Pat. No. US 4263037

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1978-31646	19780729
	GB 1978-41692	19781024

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1,6
LINE COUNT: 1919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides herbicidally-active 2,3-dihydro-5-cyanobenzofurans of the formula: ##STR1## (wherein: R.sup.1 and R.sup.2 together represent .dbd.O or R.sup.1 represents hydrogen and R.sup.2 represents hydrogen, hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, halogen, isothiocyanato, amino, alkylamino, dialkylamino, arylamino, acylamino, alkoxycarbonylamino, alkylthiocarbonylamino, N-bonded heterocyclyl, cyano or alkylthio; R.sup.3 and R.sup.4 together represent alkylene or each represent hydrogen or alkyl; and R.sup.5, R.sup.6 and R.sup.7, which may be the same or different, each represent hydrogen, halogen, alkyl, alkoxy, acyl or cyano), processes for their preparation and herbicidal compositions containing them. ,

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 34 OF 51 USPATFULL
ACCESSION NUMBER: 82:13589 USPATFULL
TITLE: Process for preparing a polymer composition
INVENTOR(S): Kaetsu, Isao, Takasaki, Japan
Yoshida, Masaru, Takasaki, Japan
Kumakura, Minoru, Takasaki, Japan
PATENT ASSIGNEE(S): Japan Atomic Energy Research Institute, Tokyo, Japan (non-U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4321117		19820323	<--
APPLICATION INFO.:	US 1979-18617		19790308	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-27109	19780309
	JP 1978-51239	19780428
	JP 1978-105306	19780829
	JP 1978-106097	19780830

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Briggs, Sr., Wilbert J.
LEGAL REPRESENTATIVE: Oblon, Fisher, Spivak, McClelland & Maier
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 970
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A polymer composition containing a physiologically active substance which can be released at a controlled rate is prepared by contacting one or more polymerizable monomers with the physiologically active substance, mking the monomers into a specific shape and then irradiating the shaped article with light or an ionizing radiation at a low temperature below room temperature to polymerize the polymerizable

monomers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 35 OF 51 USPATFULL
ACCESSION NUMBER: 81:47741 USPATFULL
TITLE: Charge effects in enzyme immunoassays
INVENTOR(S): Gibbons, Ian, Menlo Park, CA, United States
Rowley, Gerald L., Cupertino, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4287300		19810901	<--
APPLICATION INFO.:	US 1979-61099		19790726	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1,7
LINE COUNT: 1855
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for determining a member of a specific binding pair-ligand and receptor (antiligand). Reagents employed include a first modified member which provides an electrical field due to the presence of a plurality of ionic charges and a second modified member labeled with a component of a signal producing system, which system may have one or more components. The average proximity in the assay medium of the first and second modified members is related to the amount of analyte, where the observed signal from the signal producing system is related to the effect of the electrical field on the signal producing system.

Also, compositions are provided, as well as reagents, in predetermined ratios for optimizing the signal response to variations in analyte concentration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 36 OF 51 USPATFULL
ACCESSION NUMBER: 81:42278 USPATFULL
TITLE: Enzyme bound corticosteroids
INVENTOR(S): Rubenstein, Kenneth E., Menlo Park, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4282325		19810804	<--
APPLICATION INFO.:	US 1979-36929		19790507	(6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1977-857145, filed on 5 Dec 1977, now patented, Pat. No. US 4203802 which is a division of Ser. No. US 1976-722964, filed on 13 Sep 1976, now patented, Pat. No. US 4067774 which is a continuation of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned which is a division of Ser. No. US 1972-304157, filed on 6 Nov 1972, now patented, Pat. No. US 3852157 which is a continuation-in-part of Ser. No. US 1971-143609, filed on 14 May 1971, now abandoned And a continuation-in-part of Ser. No. US 1977-802683, filed on 2 Jun 1977, now patented, Pat. No. US 4190496 which is a continuation of Ser. No. US 1977-760499,

filed on 19 Jan 1977, now patented, Pat. No. US 4191613
which is a continuation-in-part of Ser. No. 722964
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tanenholtz, Alvin E.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 3495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as "ligands") and binding an enzyme to the ligand or ligand counterfeit to provide an "enzyme-bound-ligand", an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efficiencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 37 OF 51 USPATFULL
ACCESSION NUMBER: 81:40928 USPATFULL
TITLE: Double antibody for enhanced sensitivity in immunoassay
INVENTOR(S): Zuk, Robert F., San Francisco, CA, United States
Gibbons, Ian, Menlo Park, CA, United States
Rowley, Gerald L., Cupertino, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4281061		19810728	<--
APPLICATION INFO.:	US 1979-61542		19790727	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1497
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method and compositions are provided for performing homogeneous immunoassays. The method involves having a signal producing system, which provides a detectable signal, which system includes a macromolecular member. The determination of the analyte, which is a member of a specific binding pair consisting of a ligand and its homologous receptor, is performed by creating an extensive matrix in the assay medium by having in the assay medium in addition to the analyte, ligand labeled with one of the members of the signal producing system, antiligand either present as the analyte or added, a polyvalent receptor for antiligand, the macromolecular member of the signal producing system, and any additional members of the signal producing system. The labeled ligand, antiligand, and polyvalent receptor for the antiligand create a matrix which modulates, e.g. inhibits, the approach of the macromolecular member of the signal producing system to the labeled ligand. The extent and degree of formation of the matrix is dependent

upon the concentration of the analyte in the medium. By comparing the signal from an assay medium having an unknown amount of analyte, with a signal obtained from an assay medium having a known amount of analyte, the amount of analyte in the unknown sample may be determined qualitatively or quantitatively.

Kits are provided having predetermined amounts of the various reagents to allow for enhanced sensitivity of the method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 38 OF 51 USPATFULL
ACCESSION NUMBER: 81:40820 USPATFULL
TITLE: Glycosylated analogs of somatostatin
INVENTOR(S): Guillemin, Roger C. L., La Jolla, CA, United States
Lavielle, Solange, San Diego, CA, United States
Brazeau, Jr., Paul E., San Diego, CA, United States
Ling, Nicholas C., San Diego, CA, United States
Benoit, Robert A., San Diego, CA, United States
PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4280953		19810728	<--
APPLICATION INFO.:	US 1979-92647		19791108	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Fitch, Even, Tabin, Flannery & Welsh
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Somatostatin (SS) is modified to incorporate a carbohydrate moiety in the peptide chain by linkage to either Asn, Ser or Thr. The modified SS peptide analog may have the formula: ##STR1## wherein R.sub.1 is preferably a hexose or amino-hexose, such as glucose or N-acetylglucosamine. Alternatively, the carbohydrate can be linked to Ser or Thr by an ether bond. Such glycosomatostatins have an extended biological half-life compared to the parent peptide and substantially the same potency. Modifications and substitutions with respect to other amino acid residues in the chain can be made in the glycopeptides, for the purpose of increasing the effectiveness of SS analogs in other ways, and such increased effectiveness is a characteristic of the glycosomatostatin along with its longer-acting biological effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 39 OF 51 USPATFULL
ACCESSION NUMBER: 81:34595 USPATFULL
TITLE: Macromolecular environment control in specific receptor assays
INVENTOR(S): Litman, David J., Palo Alto, CA, United States
Harel, Zvi, Stanford, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4275149		19810623	<--
APPLICATION INFO.:	US 1978-964099		19781124	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1,19,46
LINE COUNT: 2543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions are provided for performing protein binding assays involving a homologous pair consisting of ligand and receptor for the ligand. The method employs a label conjugated to a member of said homologous pair and a uniformly dispersed discontinuous phase of discrete particles in a continuous aqueous phase, where the discrete particles create microenvironments which allow for discrimination between the label associated with the particle--in a discontinuous phase--and the label in the continuous phase.

Various conjugates and particles are provided which find use in the subject method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 40 OF 51 USPATFULL
ACCESSION NUMBER: 81:30260 USPATFULL
TITLE: Process for the manufacture of cystine-containing peptides
INVENTOR(S): Kamber, Bruno, Basel, Switzerland
Pittel, Werner, Basel, Switzerland
PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4271068		19810602	<--
APPLICATION INFO.:	US 1976-685857		19760513 (5)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 1972-296406, filed on 10 Oct 1972, now Defensive Publication No. which is a continuation-in-part of Ser. No. US 1969-818109, filed on 21 Apr 1969, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Almaula, Prabodh I.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns an improved process for the manufacture of cystine-containing peptides from cysteine-containing aminoacid sequences whose mercapto groups are protected by trityl groups, wherein the S-trityl cysteine-containing sequences are directly oxidized with iodine to yield the cystine disulfide bond.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 41 OF 51 USPATFULL
ACCESSION NUMBER: 81:24741 USPATFULL
TITLE: Piperazine derivatives
INVENTOR(S): Gootjes, Johan, Heerhugowaard, Netherlands
PATENT ASSIGNEE(S): Gist Brocades, N.V., Delft, Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4265894		19810505	<--
APPLICATION INFO.:	US 1979-90257		19791101 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1977-860460, filed on 14 Dec

1977, now patented, Pat. No. US 4202896

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1976-52223	19761214

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Turnipseed, James H.
LEGAL REPRESENTATIVE: Burns, Robert E., Lobato, Emmanuel J., Adams, Bruce L.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1,21
LINE COUNT: 643
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Piperazine derivatives of the general formula ##STR1## wherein R.sub.1 -R.sub.9 are the same or different and each represents a hydrogen or halogen atom or a lower alkyl or lower alkoxy group, n is 2 or 3 and X represents a group (CH.sub.2).sub.m (in which m is 1, 2, 3 or 4) or a group --CH.sub.2 --CH.dbd.CH--, having methylene linked to the piperazine group, and acid addition and quaternary ammonium salts thereof, are described.

The compounds exhibit a strong specific dopaminergic activity.

Also described are methods for their preparation and use as therapeutic agents in the form of therapeutic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 42 OF 51 USPATFULL
ACCESSION NUMBER: 81:21966 USPATFULL
TITLE: 3-Lower alkoxy-6-trichloromethylpyridazines and their use as fungicides
INVENTOR(S): Rothgery, Eugene F., North Branford, CT, United States
Schroeder, Hansjuergen A., Hamden, CT, United States
PATENT ASSIGNEE(S): Olin Corporation, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4263297		19810421	<--
APPLICATION INFO.:	US 1977-844003		19771020	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Robinson, Douglas W.
LEGAL REPRESENTATIVE: Simons, William A., O'Day, Thomas P.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 298
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 3-halo- and 3-lower alkoxy-6-trichloromethylpyridazine compounds are disclosed as fungicides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 43 OF 51 USPATFULL
ACCESSION NUMBER: 81:21707 USPATFULL
TITLE: 5-Cyano-2,3-dihydrobenzofurans useful as herbicides
INVENTOR(S): Gates, Peter S., Cambridge, England
Baldwin, Derek, Cambridge, England
Wilson, Carol A., Saffron Walden, England
Gillon, John, Cambridge, England
PATENT ASSIGNEE(S): Fisons Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4263037		19810421	<--
APPLICATION INFO.:	US 1979-62511		19790727	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1978-31646	19780729
	GB 1978-41982	19781024

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,5
LINE COUNT: 1994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides herbicidally-active 2,3-dihydro-5-cyanobenzofurans of the formula: ##STR1## (wherein: R.sup.1 and R.sup.2 together represent .dbd.O or R.sup.1 represents hydrogen and R.sup.2 represents hydrogen, hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, halogen, isothiocyanato, amino, alkylamino, dialkylamino, arylamino, acylamino, alkoxycarbonylamino, alkylthiocarbonylamino, N-bonded heterocyclyl, cyano or alkylthio; R.sup.3 and R.sup.4 together represent alkylene or each represent hydrogen or alkyl; and R.sup.5, R.sup.6 and R.sup.7, which may be the same or different, each represent hydrogen, halogen, alkyl, alkoxy, acyl or cyano), processes for their preparation and herbicidal compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 44 OF 51 USPATFULL
ACCESSION NUMBER: 81:20470 USPATFULL
TITLE: Novel somatostatin analogue
INVENTOR(S): Sakakibara, Shunpei, Suita, Japan
Shigeta, Yukio, Kobe, Japan
PATENT ASSIGNEE(S): Shiraimatsu Shingaku Co., Ltd., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4261885		19810414	<--
APPLICATION INFO.:	US 1979-83942		19791011	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-133055	19781028

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel somatostatin analogs exhibiting high activity in inhibiting insulin glucagon and **growth hormone** secretion are depicted by the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 45 OF 51 USPATFULL

ACCESSION NUMBER: 81:9349 USPATFULL
TITLE: N-succinimidyl haloacetyl aminobenzoates as coupling agents
INVENTOR(S): Weltman, Joel K., 164 Summit Ave., Providence, RI, United States 02906

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4251445		19810217	<--
APPLICATION INFO.:	US 1979-93607		19791113 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1978-889726, filed on 24 Mar 1978, now patented, Pat. No. US 4218539
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Eakin, M. C.
LEGAL REPRESENTATIVE: Crowley, Richard P.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel enzyme conjugates useful in immunoassay methods are prepared with the use of a novel coupling reagent of N-succinimidyl (4-iodoacetyl) aminobenzoate by reacting the coupling reagent, firstly, with an amino-containing macromolecule, and, thereafter, with a sulfhydryl-containing enzyme, the enzyme conjugate prepared in a high yield and of high specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 46 OF 51 USPATFULL
ACCESSION NUMBER: 80:45377 USPATFULL
TITLE: Certain herbicidal sulfonates and sulfamates
INVENTOR(S): Gates, Peter S., Cambridge, England
Baldwin, Derek, Cambridge, England
PATENT ASSIGNEE(S): Fisons Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4222767		19800916	<--
APPLICATION INFO.:	US 1979-22599		19790321 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1978-875189, filed on 3 Feb 1978, now patented, Pat. No. US 4162154

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1977-4847	19770205
	GB 1977-4848	19770205
	GB 1977-4849	19770205
	GB 1977-32839	19770805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1,11
LINE COUNT: 1238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides herbicidally-active sulphonates of the formula ##STR1## wherein X represents a group --CHR.sup.3 --OR.sup.4 and Y represents a group --OR.sup.5, or X and Y together represent a group --CHR.sup.3 --O-- or a group --CHR.sup.3 --O--Z--O--, the free oxygen atom of which is attached to the benzene ring; R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each represent hydrogen or

C 1 to 6 alkyl, or R.sup.1 and R.sup.2 together or R.sup.2 and R.sup.3 together form a C 3 to 6 alkylene chain; R.sup.4 and R.sup.5, which may be the same or different, each represent hydrogen, C 1 to 6 alkyl, C 2 to 6 alkenyl, C 2 to 6 alkynyl, phenyl, a group --C(.dbd.O)R.sup.10 or a group --SO.sub.2 R.sup.11 ; R.sup.6, R.sup.7 and R.sup.8, which may be the same or different, each represent hydrogen, C 1 to 6 alkyl, halogen, cyano, C 2 to 6 carboxylic acyl, or C 1 to 4 alkoxy; R.sup.9 represents C 1 to 6 alkyl, phenyl or C 7 to 10 phenylalkyl (each of which may be unsubstituted or substituted by one or more chlorine or bromine atoms, C 1 to 4 alkyl groups, C 1 to 4 alkoxy groups or nitro groups), C 5 to 7 cycloalkyl, C 1 to 4 alkylamino, or dialkylamino wherein each alkyl moiety has from 1 to 4 carbon atoms; R.sup.10 represents C 1 to 6 alkyl or alkoxy, C 2 to 6 alkenyl or alkenyloxy, C 2 to 6 alkynyl or alkynyloxy, phenyl, phenoxy, phenylamino, C 1 to 6 alkylamino or dialkylamino wherein each alkyl moiety has from 1 to 6 carbon atoms, each of the groups which R.sup.10 may represent being unsubstituted or substituted by one or more halogen atoms or C 1 to 4 alkoxy groups; R.sup.11 represents C 1 to 6 alkyl, phenyl, C 1 to 6 alkylamino or dialkylamino each of the alkyl moieties thereof having from 1 to 6 carbon atoms, each of the groups which R.sup.11 may represent being unsubstituted or substituted by one or more halogen atoms or C 1 to 4 alkoxy groups; Z represents a group of formula --S(.dbd.O)n, --CR.sup.12 R.sup.13 or --P(.dbd.Q)(OR.sup.14)--; n represents 1 or 2; R.sup.12 and R.sup.13, which may be the same or different, each present hydrogen, C 1 to 6 alkyl or alkoxy, C 2 to 6 alkenyl or alkynyl, phenyl, phenoxy, cyano or (C 1 to 6 alkoxy)carbonyl, or R.sup.12 and R.sup.13 together represent an oxygen atom, a sulphur atom, a C 3 to 6 alkylene chain or a C 1 to 6 alkylimino group or a phenylimino group; and R.sup.14 represents C 1 to 6 alkyl; and Q represents oxygen or sulphur, together with processes for their preparation and herbicidal compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 47 OF 51 USPATFULL
ACCESSION NUMBER: 80:40663 USPATFULL
TITLE: Enzyme conjugates and method of preparation and use
INVENTOR(S): Weltman, Joel K., 154 Summit Ave., Providence, RI, United States 02906

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4218539		19800819	<--
APPLICATION INFO.:	US 1978-889726		19780324	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shapiro, Lionel M.
LEGAL REPRESENTATIVE: Crowley, Richard P.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel enzyme conjugates useful in immunoassay methods are prepared with the use of a novel coupling reagent of N-succinimidyl (4-iodoacetyl) aminobenzoate by reacting the coupling reagent, firstly, with an amino-containing macromolecule, and, thereafter, with a sulfhydryl-containing enzyme, the enzyme conjugate prepared in a high yield and of high specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 48 OF 51 USPATFULL
ACCESSION NUMBER: 80:24329 USPATFULL
TITLE: Inhibitable enzyme amplification assay
INVENTOR(S): Rubenstein, Kenneth E., Menlo Park, CA, United States

	Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S):	Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4203802		19800520	<--
APPLICATION INFO.:	US 1977-857145		19771205	(5)

RELATED APPLN. INFO.: Division of Ser. No. US 1976-722964, filed on 13 Sep 1976, now patented, Pat. No. US 4067774 which is a continuation of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned which is a division of Ser. No. US 1972-304157, filed on 6 Nov 1972, now patented, Pat. No. US 3852157 which is a continuation-in-part of Ser. No. US 1971-143609, filed on 14 May 1971, now abandoned which is a continuation-in-part of Ser. No. US 1977-802683, filed on 2 Jun 1977, now patented, Pat. No. US 4190496 which is a continuation of Ser. No. US 1977-760499, filed on 19 Jan 1977, now Defensive Publication No. which is a continuation of Ser. No. US 1976-722964, filed on 13 Sep 1976, now Defensive Publication No.

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Tanenholtz, Alvin E.
LEGAL REPRESENTATIVE:	Rowland, Bertram I.
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
LINE COUNT:	3436

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as "ligands") and binding an enzyme to the ligand or ligand counterfeit to provide an "enzyme-bound-ligand", an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efficiencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 49 OF 51 USPATFULL

ACCESSION NUMBER:	80:23357 USPATFULL
TITLE:	N-Benzhydryloxyethyl-N-phenylpropyl-piperazines
INVENTOR(S):	Gootjes, Johan, Heerhugowaard, Netherlands
PATENT ASSIGNEE(S):	Gist-Brocades N.V., Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4202896		19800513	<--
APPLICATION INFO.:	US 1977-860460		19771214	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1976-52223	19761214

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Tovar, Jose

LEGAL REPRESENTATIVE: Burns, Robert E., Lobato, Emmanuel J., Adams, Bruce L.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1,10
LINE COUNT: 611
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Piperazine derivatives of the general formula ##STR1## wherein R.sub.1 -R.sub.9 are the same or different and each represents a hydrogen or halogen atom or a lower alkyl or lower alkoxy group, n is 2 or 3 and X represents a group (CH.sub.2).sub.m (in which m is 1, 2, 3 or 4) or a group --CH.sub.2 --CH.dbd.CH--, having methylene linked to the piperazine group, and acid addition and quaternary ammonium salts thereof, are described.

The compounds exhibit a strong specific dopaminergic activity.

Also described are methods for their preparation and use as therapeutic agents in the form of therapeutic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 50 OF 51 USPATFULL
ACCESSION NUMBER: 80:13908 USPATFULL
TITLE: Labeled liposome particle compositions and immunoassays therewith
INVENTOR(S): Ullman, Edwin F., Atherton, CA, United States
Brinkley, John M., Oakland, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4193983		19800318	<--
APPLICATION INFO.:	US 1978-906514		19780516	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fagelson, Anna P.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1469
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention concerns novel compositions for use in immunoassays, as well as immunoassays employing such novel compositions. The compositions comprise discrete charged colloidal particles comprised of small molecules which particles are capable of retaining their discrete character in an aqueous medium and composed of aggregates of lipophilic and/or amphiphilic organic molecules to which are bound non-covalently a label capable of producing a detectible signal and a ligand or an analog of the ligand capable of competing with a ligand for a ligand receptor. The discrete colloidal particle serves as a hub or nucleus for retaining the ligand or its analog and the label within a limited locus.

The compositions are prepared by individually covalently bonding the ligand and the label, when not naturally lipophilic, to a lipophilic (includes amphiphilic) compound, normally a phospholipid. Depending upon the nature of the particle, the amphiphilic conjugated ligand and label are combined with the particle or alternatively may be combined with the compounds employed for preparing the particle under particle forming conditions. Particles are then obtained having the analog of the ligand and the label bound to the particle.

The compositions find use in immunoassays where an interaction between the label and receptor provides a means for modulating a detectible signal. The interaction can be as a result of quenching or modification

of fluorescence, where the label is a fluorescer, steric inhibition of the approach of a signal modifier to the label, such as a label receptor or with an enzyme label, an antienzyme or enzyme inhibitor, the inhibition of cleavage of an enzyme labile bond or the cooperative interaction of two labels, such as two enzymes, where the product of one enzyme is a substrate of another enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L161 ANSWER 51 OF 51 USPATFULL
ACCESSION NUMBER: 80:10223 USPATFULL
TITLE: Homogeneous enzyme assay for antibodies
INVENTOR(S): Rubenstein, Kenneth E., Menlo Park, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4190496		19800226	<--
APPLICATION INFO.:	US 1977-802683		19770602	(5)
DISCLAIMER DATE:	19910618			

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1977-760499, filed on 19 Jan 1977, now Defensive Publication No. which is a continuation-in-part of Ser. No. US 1976-722964, filed on 13 Sep 1976, now patented, Pat. No. US 4067774 which is a continuation of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned And a continuation-in-part of Ser. No. US 1976-689234, filed on 24 May 1976, now patented, Pat. No. US 4046636 which is a continuation-in-part of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned which is a division of Ser. No. US 1972-304157, filed on 6 Nov 1972, now patented, Pat. No. US 3852157 which is a continuation-in-part of Ser. No. US 1971-143609, filed on 14 May 1971, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tanenholtz, Alvin E.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 3567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as "ligands") and binding an enzyme to the ligand or ligand counterfeit to provide an "enzyme-bound-ligand", an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efficiencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

The subject method may also be used for determining receptors, employing the same procedure, except for not including receptor as a reagent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

=> d 1440 1-146 ibib abs

L440 ANSWER 1 OF 146 USPATFULL
ACCESSION NUMBER: 1998:87247 USPATFULL
TITLE: Delivery systems for pharmacological agents encapsulated with proteinoids
INVENTOR(S): Steiner, Solomon, Mt. Kisco, NY, United States
Rosen, Robert, Rochester, NY, United States(4)
PATENT ASSIGNEE(S): Emisphere Technologies, Inc., Hawthorne, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 35862		19980728	
	US 4925673		19900515	(Original)
	WO 8801213		19880225	<--
APPLICATION INFO.:	US 1994-252979		19940602	(8)
	US 1987-98027		19870814	(Original)
	WO 1987-US2025		19870814	
			19870908	PCT 371 date
			19870908	PCT 102(e) date

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-883562, filed on 15 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1986-897361, filed on 18 Aug 1986, now abandoned
DOCUMENT TYPE: Reissue
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phelan, D. Gabrielle
LEGAL REPRESENTATIVE: Darby & Darby
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 24
LINE COUNT: 1135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are described for targeting the release of an active pharmacological agent in an animal by administering that agent encapsulated in proteinoid microspheres which are stable to the environment encountered from the point of introduction until they migrate to the targeted body organs, fluids or cells and are there unstable. Orally administered delivery systems for insulin, heparin and physostigmine utilize encapsulating microspheres which are predominantly of less than about 10 microns in diameter and pass readily through the gastrointestinal mucosa and which are made of an acidic proteinoid that is stable and unaffected by stomach enzymes and acid, but which releases the microencapsulated agent in pharmacologically active form in the near neutral blood stream. Basic proteinoid microspheres encapsulating a dopamine redox carrier system are administered in the weakly basic, where they are stable, and then enter the blood stream, where the encapsulated agent is similarly released.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 2 OF 146 USPATFULL
ACCESSION NUMBER: 92:81595 USPATFULL
TITLE: Sialic acid derivatives having active carbonyl group
INVENTOR(S): Yoshimura, Shoji, Iruma, Japan
Shibayama, Shohei, Tokorozawa, Japan
Numata, Masaaki, Kawagoe, Japan
Ito, Masayoshi, Kunitachi, Japan
Shitori, Yoshiyasu, Tokyo, Japan
Ogawa, Tomoya, Musashino, Japan
PATENT ASSIGNEE(S): MECT Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 34091		19921006

	US 4918177	19900417	(Original)<--
APPLICATION INFO.:	US 1991-779874	19911021	(7)
	US 1987-136144	19871221	(Original)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1986-310181	19861229
	JP 1987-295641	19871124

DOCUMENT TYPE: Reissue
FILE SEGMENT: Granted
PRIMARY EXAMINER: Brown, Johnnie R.
ASSISTANT EXAMINER: White, Everett
LEGAL REPRESENTATIVE: Rodman & Rodman
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 9,16
LINE COUNT: 831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sialic acid derivative having an active carbonyl group represented by the formula [I]: ##STR1## wherein R.sup.1 represents hydrogen or acetyl group; R.sup.2 represents hydrogen, a metal or a lower alkyl group; R.sup.3 represents hydrogen, hydroxyl gorup, or a residue removed hydrogen from an alcohol portion of an active ester; Ac represents acetyl group; and n is 1 to 20, respectively. This sialic acid derivative [I] can be utilized as a starting material for various complex having a sialic acid in the molecule since it has an active carbonyl group in the molecules so that it shows high reactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 3 OF 146 USPATFULL
ACCESSION NUMBER: 90:98729 USPATFULL
TITLE: Biodegradable absorption enhancers
INVENTOR(S): Wong, Ooi, Lawrence, KS, United States
Nishiahta, Toshiaki, Wadai Tukuba Ibaraki, Japan
Rytting, Joseph H., Lawrence, KS, United States
PATENT ASSIGNEE(S): Odontex, Inc., Lawrence, KS, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4980378		19901225	<--
APPLICATION INFO.:	US 1988-201029		19880601	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shippen, Michael L.
LEGAL REPRESENTATIVE: Zarley, McKee, Thomte, Voorhees & Sease
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 843
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biodegradable absorption enhancers, especially useful in pharmaceutical formulations, are compounds having the formula ##STR1## wherein R is hydrogen, C.sub.1 -C.sub.7 alkyl, benzyl or 4-hydroxybenzyl; n is a whole number from 4 to 18 inclusive; R.sub.1 and R.sub.2 are independently selected from hydrogen and C.sub.1 -C.sub.7 alkyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached are combined to form a substituted or unsubstituted heterocycloalkyl radical having a total of 5 to 7 ring atoms, optionally including a hetero ring atom selected from oxygen, sulfur and nitrogen in addition to the indicated nitrogen atom, the substituents when present being one to three C.sub.1 -C.sub.7 alkyl radicals, which may be the same or different; and R.sub.3 and R.sub.4 are independently selected from hydrogen, methyl and ethyl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 4 OF 146 USPATFULL
ACCESSION NUMBER: 90:94902 USPATFULL
TITLE: Anhydrous delivery systems for pharmacological agents
INVENTOR(S): Steiner, Solomon S., Mt. Kisco, NY, United States
PATENT ASSIGNEE(S): Clinical Technologies Associates, Inc., Elmsford, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4976968		19901211	<--
APPLICATION INFO.:	US 1989-315440		19890224	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
LEGAL REPRESENTATIVE: Kilpatrick & Cody
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substantially anhydrous pharmacological agents microencapsulated within protective hollow proteinoid microspheres are produced by contacting an aqueous mixture of such agent with an insoluble proteinoid and lyophilizing the resulting microspheres. Such encapsulation and dehydration results in a free flowing powder that has a long shelf life under naturally occurring temperature conditions and that quickly reabsorbs water without damage to the capsular wall. Gastrointestinally labile or poorly absorbed agents, such as insulin, heparin or dopamine redox carrier system, which are so microencapsulated in protective microspheres are rapidly rehydrated by body fluids in the gastrointestinal tract. Those microspheres having a diameter of about 10 microns or less penetrate the gastrointestinal mucosa and release the agent into the bloodstream in physiologically active form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 5 OF 146 USPATFULL
ACCESSION NUMBER: 90:78358 USPATFULL
TITLE: Aspartic acid derivatives
INVENTOR(S): Okada, Yoshio, Akashi, Japan
Kawasaki, Koichi, Kobe, Japan
Iguchi, Shin, Kobe, Japan
PATENT ASSIGNEE(S): Watanabe, Hidehiko, Hiroshima, Japan (non-U.S. individual)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4962225		19901009	<--
APPLICATION INFO.:	US 1988-176597		19880401	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shippen, Michael L.
LEGAL REPRESENTATIVE: Flehr, Hohbach, Test, Albritton & Herbert
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New aspartic acid derivatives include N-.alpha.-t-butoxycarbonyl-aspartic acid-.beta.-2-adamantyl ester-.alpha.-benzyl ester, N-.alpha.-t-butoxycarbonyl-aspartic acid-.beta.-2-adamantyl ester and benzyloxycarbonyl-aspartic acid-.beta.-2-adamantyl ester-.alpha.-benzyl ester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 6 OF 146 USPATFULL
ACCESSION NUMBER: 90:75092 USPATFULL
TITLE: Drug administration
INVENTOR(S): Carey, Martin C., Wellesley, MA, United States
Moses, Alan C., Waban, MA, United States
Flier, Jeffrey S., West Newton, MA, United States
PATENT ASSIGNEE(S): Beth Israel Hospital Assn., Boston, MA, United States (U.S. corporation)
The Brigham and Womens Hospital, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4959358		19900925	<--
APPLICATION INFO.:	US 1988-197729		19880523	(7)

DISCLAIMER DATE: 20021022
RELATED APPLN. INFO.: Continuation of Ser. No. US 1984-614115, filed on 25 May 1984, now patented, Pat. No. US 4746508 which is a continuation-in-part of Ser. No. US 1983-501187, filed on 6 Jun 1983, now patented, Pat. No. US 4548922
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schenkman, Leonard
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of the human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 7 OF 146 USPATFULL
ACCESSION NUMBER: 90:74953 USPATFULL
TITLE: Method for delivering somatotropin to an animal
INVENTOR(S): Eckenhoff, James B., Los Altos, CA, United States
Magruder, Judy A., Mt. View, CA, United States
Cortese, Richard, Cupertino, CA, United States
Peery, John R., Palo Alto, CA, United States
Wright, Jeremy C., Los Altos, CA, United States
PATENT ASSIGNEE(S): Alza Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4959218		19900925	<--
APPLICATION INFO.:	US 1988-291930		19881228	(7)

DISCLAIMER DATE: 20060808
RELATED APPLN. INFO.: Division of Ser. No. US 1988-173209, filed on 25 Mar 1988, now patented, Pat. No. US 4855141, issued on 8 Aug 1989
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Horne, Leon R.

LEGAL REPRESENTATIVE: Mandell, Edward L., Sabatine, Paul L., Stone, Steven F.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 904
AB A delivery device is disclosed for delivering a beneficial agent to an animal. The device comprises a wall housing an internal space, a beneficial agent in the space, expandable means in the space for causing the beneficial agent to be delivered from the device and means in the space for shielding the beneficial agent from fluid.

L440 ANSWER 8 OF 146 USPATFULL
ACCESSION NUMBER: 90:69386 USPATFULL
TITLE: 2,3-methanoproline
INVENTOR(S): Stammer, Charles H., Athens, GA, United States
PATENT ASSIGNEE(S): University of Georgia Research Foundation, Inc., Athens, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4954158		19900904	<--
APPLICATION INFO.:	US 1988-285542		19881215	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1987-41642, filed on 22 Apr 1987 which is a continuation of Ser. No. US 1986-879842, filed on 26 Jun 1986 which is a continuation of Ser. No. US 1984-636091, filed on 3 Aug 1984 which is a continuation-in-part of Ser. No. US 1983-523080, filed on 16 Aug 1983
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Tsung, Frederick F.
LEGAL REPRESENTATIVE: Kilpatrick & Cody
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,7
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is 2,3-methanoproline, derivatives thereof, and biologically active molecules incorporating 2,3-methanoproline. These compounds are useful as inhibitors of ethylene production in plant material, and as synthetic analogs of biologically active molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 9 OF 146 USPATFULL
ACCESSION NUMBER: 90:61337 USPATFULL
TITLE: Single polypeptide chain binding molecules
INVENTOR(S): Ladner, Robert C., Ijamsville, MD, United States
Bird, Robert E., Rockville, MD, United States
Hardman, Karl, Chevy Chase, MD, United States
PATENT ASSIGNEE(S): Genex Corporation, Gaithersburg, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4946778		19900807	<--
APPLICATION INFO.:	US 1989-299617		19890119	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1987-92110, filed on 3 Sep 1987, now abandoned And a continuation-in-part of Ser. No. US 1986-902971, filed on 2 Sep 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Teskin, Robin L.
ASSISTANT EXAMINER: Marks, Michelle S.
LEGAL REPRESENTATIVE: Saidman, Sterne, Kessler & Goldstein
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 14
NUMBER OF DRAWINGS: 47 Drawing Figure(s); 45 Drawing Page(s)
LINE COUNT: 2408
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody, to genetic sequences coding therefor, and to recombinant DNA methods of producing such molecule and uses for such molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 10 OF 146 USPATFULL
ACCESSION NUMBER: 90:44565 USPATFULL
TITLE: Immobilized artificial membranes
INVENTOR(S): Pidgeon, Charles, West Lafayette, IN, United States
PATENT ASSIGNEE(S): Purdue Research Foundation, West Lafayette, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4931498		19900605	<--
APPLICATION INFO.:	US 1988-160196		19880225	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, III, John
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Barnes & Thornburg
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and materials are described for the preparation of novel immobilized membrane compositions. The described compositions are useful for evaluating membrane association charcteristics of chemical compounds, and as a chromatographic support material for separation/purification of biomolecules and particularly those expressed by genetically transformed cells as novel hybrid proteins having covalently bound membrane-binding peptides. Novel phospholipid carboxylates are useful intermediates for the preparation of chromatography supports having surfaces formed as covalently bound artificial membranes which simulate natural cellular membranes. The immobilized membrane compositions are adapted for use in chromatographic systems to study interactions of biologically active substances with membranes in vitro. The immobilized membranes are expected to find use for vaccine production, protein purification, chiral separations/synthesis, as a combination reverse phase/normal phase HPLC support material, and for drug screening.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 11 OF 146 USPATFULL
ACCESSION NUMBER: 90:38246 USPATFULL
TITLE: Delivery systems for pharmacological agents encapsulated with proteinoids
INVENTOR(S): Steiner, Solomon, Mt. Kisco, NY, United States
Rosen, Robert, Rochester, NY, United States
PATENT ASSIGNEE(S): Clinical Technologies Associates, Inc., Elmsford, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4925673		19900515	<--
	WO 8801213		19880225	<--
APPLICATION INFO.:	US 1987-98027		19870908	(7)
	WO 1987-US2025		19870814	
			19870908	PCT 371 date
			19870908	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-897361, filed on 18 Aug 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
LEGAL REPRESENTATIVE: Kilpatrick & Cody
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are described for targeting the release of an active pharmacological agent in an animal by administering that agent encapsulated in proteinoid microspheres which are stable to the environment encountered from the point of introduction until they migrate to the targeted body organs, fluids or cells and are there unstable. Orally administered delivery systems for insulin, heparin and physostigmine utilize encapsulating microspheres which are predominantly of less than about 10 microns in diameter and pass readily through the gastrointestinal mucosa and which are made of an acidic proteinoid that is stable and unaffected by stomach enzymes and acid, but which releases the microencapsulated agent in pharmacologically active form in the near neutral blood stream. Basic proteinoid microspheres encapsulating a dopamine redox carrier system are administered in the weakly basic, where they are stable, and then enter the blood stream, where the encapsulated agent is similarly released.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 12 OF 146 USPATFULL
ACCESSION NUMBER: 90:32290 USPATFULL
TITLE: Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
INVENTOR(S): Tang, Reginald T., Warren, NJ, United States
Mares, Frank, Whippany, NJ, United States
Boyle, Jr., William J., Parsippany, NJ, United States
Chiu, Tin-Ho, Millburn, NJ, United States
Patel, Kundabhai M., Landing, NJ, United States
PATENT ASSIGNEE(S): Allied-Signal Inc., Morris Township, Morris County, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4920203		19900424	<--
APPLICATION INFO.:	US 1988-227386		19880802	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1987-134290, filed on 17 Dec 1987 And a continuation-in-part of Ser. No. US 1987-134301, filed on 17 Dec 1987, now patented, Pat. No. US 4891263 And a continuation-in-part of Ser. No. US 1987-134339, filed on 17 Dec 1987
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Pertilla, Theodore E.
LEGAL REPRESENTATIVE: Stewart, Richard C., Fuchs, Gerhard H.
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
LINE COUNT: 2334

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to medical devices formed totally or in part from homopolymers or copolymers comprising recurring carbonate moieties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 13 OF 146 USPATFULL
ACCESSION NUMBER: 90:30118 USPATFULL
TITLE: Sialic acid derivatives having active carbonyl group
INVENTOR(S): Yoshimura, Shoji, Iruma, Japan
Shibayama, Shohei, Tokorozawa, Japan
Numata, Masaaki, Kawagoe, Japan
Ito, Masayoshi, Kunitachi, Japan
Shitori, Yoshiyasu, Tokyo, Japan
Ogawa, Tomoya, Musashino, Japan
PATENT ASSIGNEE(S): Mect Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4918177		19900417	<--
APPLICATION INFO.:	US 1987-136144		19871221	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
ASSISTANT EXAMINER: White, Everett
LEGAL REPRESENTATIVE: Rodman & Rodman
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A sialic acid derivative having an active carbonyl group represented by the formula [I]: ##STR1## wherein R.sup.1 represents hydrogen or acetyl group; R.sup.2 represents hydrogen, a metal or a lower alkyl group; R.sup.3 represents hydrogen, hydroxyl group, or a residue removed hydrogen from an alcohol portion of an active ester; Ac represents acetyl group; and n is 1 to 20, respectively. This sialic acid derivative [I] can be utilized as a starting material for various complex having a sialic acid in the molecule since it has an active carbonyl group in the molecules so that it shows high reactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 14 OF 146 USPATFULL
ACCESSION NUMBER: 90:29840 USPATFULL
TITLE: Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
INVENTOR(S): Katre, Nandini, El Cerrito, CA, United States
Knauf, Michael J., Oakland, CA, United States
PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4917883		19900417	<--
APPLICATION INFO.:	US 1987-131901		19871211	(7)

RELATED APPLN. INFO.: Division of Ser. No. US 1986-866459, filed on 21 May 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-749955, filed on 26 Jun 1985, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hazel, Blondel
LEGAL REPRESENTATIVE: Hasak, Janet E., McGarrigle, Philip L., Halluin, Albert P.
NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not readily soluble in water at pH 6-8 without such solubilizing agent, is selectively conjugated to a water-soluble polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 15 OF 146 USPATFULL
ACCESSION NUMBER: 90:29654 USPATFULL
TITLE: Bone replacement material on the basis of carbonate and alkali containing calciumphosphate apatites
INVENTOR(S): Scheicher, Hans, Rondell Neuwittelsbach 4, 8000 Munchen 19, Germany, Federal Republic of
Wendler, Eberhard, Sedelhofstr. 3, 8000 Munchen 60, Germany, Federal Republic of

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4917702		19900417	<--
APPLICATION INFO.:	US 1988-153885		19880209	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-866199, filed on 9 May 1986, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1984-3433210	19840910

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cannon, Alan W.
LEGAL REPRESENTATIVE: Millen, White & Zelano
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1181
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention sets forth an agent for filling bone and tooth defects, for building up bone, for bone-contact layers and for the replacement of bones and the roots of teeth, which contains calcium phosphate apatite having carbonate and alkali portions, all ions being definedly integrated in the **crystal** lattice; use is optionally made together with additives and/or diluents both tolerated by the body. Furthermore, it sets forth the use of this apatite for filling bone and tooth defects, for building up bone, for bone-contact layers, as a replacement for bones and the roots of teeth and as an implant article consisting completely or partially of this apatite or consisting of a material known for implant articles and being coated completely or partially with a layer of this apatite.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 16 OF 146 USPATFULL
ACCESSION NUMBER: 90:19315 USPATFULL
TITLE: Silicon semiconductor wafer for analyzing micronic biological samples
INVENTOR(S): Pace, Salvatore J., Wilmington, DE, United States
PATENT ASSIGNEE(S): E. I. Du Pont De Nemours & Co., Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4908112		19900313	<--
APPLICATION INFO.:	US 1988-207535		19880616	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Niebling, John F.
ASSISTANT EXAMINER: Rodriguez, Isabelle
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 763
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An analytical separation device in which a capillary sized conduit is formed by a channel in a semiconductor device and the channel is closed by a glass plate. Electrodes are positioned in the channel and to activate the motion of liquids through the conduit by electroosmosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 17 OF 146 USPATFULL
ACCESSION NUMBER: 90:13251 USPATFULL
TITLE: Polylactide compositions
INVENTOR(S): Loomis, Gary L., Drexel Hill, PA, United States
Murdoch, Joseph R., Wilmington, DE, United States
PATENT ASSIGNEE(S): E. I. DuPont De Nemours and Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4902515		19900220	<--
APPLICATION INFO.:	US 1988-256471		19881012	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1988-187350, filed on 28 Apr 1988, now patented, Pat. No. US 4800219 which is a division of Ser. No. US 1987-108531, filed on 15 Oct 1987, now patented, Pat. No. US 4766182 which is a division of Ser. No. US 1986-944588, filed on 22 Dec 1986, now patented, Pat. No. US 4719246
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Foelak, Morton
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1043
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Systems for delivery of biologically active materials employing novel polylactide composition containing segments of poly(R-lactide) interlocked with segments of poly(S-lactide) as the carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 18 OF 146 USPATFULL
ACCESSION NUMBER: 89:100700 USPATFULL
TITLE: Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4888427		19891219	<--
APPLICATION INFO.:	US 1987-35648		19870407	(7)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Fan, Jane T.
LEGAL REPRESENTATIVE: Baumeister, Mary K., Clarke, Dennis P.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel amino acids and peptides containing them which comprise a dihydropyridine.revreaction.pyridinium salt-type redox system and which provide site-specific and sustained delivery of pharmacologically active peptides to the brain. These new amino acids contain a redox system appended directly or via an alkylene bridge to the carbon atom adjacent to the carboxyl carbon and may be incorporated into a peptide chain at a variety of positions, including non-terminal positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 19 OF 146 USPATFULL
ACCESSION NUMBER: 89:100450 USPATFULL
TITLE: Controlled drug delivery high molecular weight polyanhydrides
INVENTOR(S): Langer, Robert S., Sommerville, MA, United States
Domb, Abraham J., Brookline, MA, United States
Laurencin, Cato T., Cambridge, MA, United States
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4888176		19891219	<--
APPLICATION INFO.:	US 1987-61294		19870612	(7)

DISCLAIMER DATE: 20050712
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1984-613001, filed on 21 May 1984 And a continuation-in-part of Ser. No. US 1987-49988, filed on 15 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-892809, filed on 1 Aug 1986 , said Ser. No. 613001 which is a continuation of Ser. No. US 1983-477710, filed on 22 Mar 1983, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schofer, Joseph L.
ASSISTANT EXAMINER: Kulkosky, Peter F.
LEGAL REPRESENTATIVE: Kilpatrick & Cody
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1023
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A bioerodible controlled drug release device is produced as a homogeneous polymeric matrix from a high molecular weight polyanhydride and a suitable biologically active substance. The high molecular weight polyanhydride is defined by a molecular weight greater than 20,000 and an intrinsic viscosity greater than 0.3 dl/g. The controlled drug release device is preferrably formed by solvent casting with the biologically active substance and exhibits zero order release, improved correlation between the rate of release and polymer degradation, and an induction period between introduction to the eroding environment and the initial release of the biologically active substance. The controlled drug release devices are stable for extended periods of time, flexible and durable and not subject to fracture and disintegration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 20 OF 146 USPATFULL
ACCESSION NUMBER: 89:97222 USPATFULL
TITLE: Aqueous protein solutions stable to denaturation
INVENTOR(S): Thurow, Horst, Taunus, Germany, Federal Republic of
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4885164		19891205	<--
APPLICATION INFO.:	US 1987-136673		19871222	(7)
DISCLAIMER DATE:	20040129			

RELATED APPLN. INFO.: Continuation of Ser. No. US 1983-564346, filed on 21 Dec 1983, now patented, Pat. No. US 4783441 which is a continuation of Ser. No. US 1981-263720, filed on 14 May 1981, now abandoned which is a continuation-in-part of Ser. No. US 1980-144040, filed on 28 Apr 1980, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1979-2917535	19790430
	DE 1979-2952119	19791222

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Waddell, Frederick E.
LEGAL REPRESENTATIVE: Curtis, Morris & Safford
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 555
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB What are disclosed are a method for preventing the denaturation of proteins such as insulin in aqueous solution at interfaces by the addition to the solution of a surface-active substance comprising a chain of alternating weakly hydrophobic and weakly hydrophilic zones, protein solutions containing such a surface-active substance, methods of purifying proteins contained in such solutions, and methods of treating surfaces with such a surface-active material to prevent the denaturation of proteins thereon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 21 OF 146 USPATFULL
ACCESSION NUMBER: 89:92522 USPATFULL
TITLE: Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium salt-type redox carriers
INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4880816		19891114	<--
APPLICATION INFO.:	US 1987-116583		19871104	(7)
DISCLAIMER DATE:	20020910			

RELATED APPLN. INFO.: Division of Ser. No. US 1985-733463, filed on 13 May 1985, now patented, Pat. No. US 4727079 which is a continuation-in-part of Ser. No. US 1984-665940, filed on 29 Oct 1984 Ser. No. Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564 And Ser. No. US 1983-461543, filed on 27 Jan 1983 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 , said Ser. No. 665940 And Ser. No. 516382 , each which is a continuation-in-part of Ser. No. US

1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 Ser. No. Ser. No. 461543 And Ser. No. 379316 , said Ser. No. 665940 which is a continuation-in-part of Ser. No. 516382

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1983-428192	19830516

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Baumeister, Mary Katherine, Clarke, Dennis P.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1,18
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2099
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 22 OF 146 USPATFULL
ACCESSION NUMBER: 89:90821 USPATFULL
TITLE: Linker compounds, linker-compound-ligands and linker-compound-receptors
INVENTOR(S): Baldwin, Thomas O., 801 Delma Dr., Bryan, TX, United States 77801
Holzman, Thomas F., 807 D Nauidad, Bryan, TX, United States 77801
Satoh, Paul S., 1424 Surrey, Portage, MI, United States 49081
Yein, Frederick S., 907 Boswell La., Kalamazoo, MI, United States 49007

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4879249		19891107	<--
APPLICATION INFO.:	US 1986-840187		19860317	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1983-469852, filed on 25 Feb 1983, now patented, Pat. No. US 4614712, issued on 30 Sep 1986
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marantz, Sidney
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 2
LINE COUNT: 1062
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel immunoassay which utilizes an enzyme linked ligand or receptor wherein the enzyme is bacterial luciferase; mercantile kit useful in performing said immunoassay; and compounds utilized in performing said assay.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 23 OF 146 USPATFULL
ACCESSION NUMBER: 89:80775 USPATFULL
TITLE: Dehydration of hydrous matter with anhydrous maltose
INVENTOR(S): Mitsuhashi, Masakazu, Okayama, Japan
Sakai, Shuzo, Okayama, Japan
Miyake, Toshio, Okayama, Japan
PATENT ASSIGNEE(S): Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4870059		19890926	<--
APPLICATION INFO.:	US 1986-870132		19860603	(6)

DISCLAIMER DATE: 20060328

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1985-266559	19851127
	JP 1985-278634	19851211

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are disclosed a novel desiccant containing anhydrous maltose and dehydration of hydrous matters, e.g. food, pharmaceutical and cosmetic, therewith. Such hydrous matters are dehydrated without causing alteration or deterioration by incorporating anhydrous maltose into the hydrous matters to convert the anhydrous maltose into crystalline beta-maltose hydrate. The anhydrous maltoses usable in the invention are anhydrous crystalline alpha-maltose, anhydrous crystalline beta-maltose and anhydrous amorphous beta-maltose, specifically, those in pulverulent form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 24 OF 146 USPATFULL
ACCESSION NUMBER: 89:76387 USPATFULL
TITLE: Bacterial methionine N-terminal peptidase
INVENTOR(S): Ben-Bassat, Arie, Concord, CA, United States
Bauer, Keith A., Oakland, CA, United States
Chang, Shing, Oakland, CA, United States
Chang, Sheng-Yung, Oakland, CA, United States
PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4865974		19890912	<--
APPLICATION INFO.:	US 1986-860330		19860506	(6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1985-778414, filed on 20 Sep 1985
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
ASSISTANT EXAMINER: Carson, Pat
LEGAL REPRESENTATIVE: Murashige, Kate H., Halluin, Albert P.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)

LINE COUNT: 1025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for obtaining N-terminal methionine-free proteins involve a novel E. coli methionine amino peptidase. The method is capable of in vitro or in vivo application. For in vivo application, a plasmid-borne DNA encoding the peptide is expressed in a bacterial host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 25 OF 146 USPATFULL
ACCESSION NUMBER: 89:76121 USPATFULL
TITLE: Capillary gel electrophoresis columns
INVENTOR(S): Karger, Barry L., Newton, MA, United States
Cohen, Aharon S., Brookline, MA, United States
PATENT ASSIGNEE(S): Northeastern University, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4865707		19890912	<--
APPLICATION INFO.:	US 1988-143442		19880112	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-921311, filed on 21 Oct 1986
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Niebling, John F.
ASSISTANT EXAMINER: Starsiak, Jr., John S.
LEGAL REPRESENTATIVE: Weingarten, Schurgin, Gagnebin & Hayes
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 39
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 970
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved microcapillary column for high performance electrophoresis includes a microcapillary, a hydrophilic polymer within a gel of crosslinked polyacrylamide polymerized in the tube, and preferably, a thin layer of connecting material covalently bonded to the inner surface of the microcapillary wall and to the polymeric gel. The microcapillary is prepared by first covalently bonding a suitable bifunctional reagent to the inner surface of the microcapillary wall, and then causing a mixture of the hydrophilic polymer, monomer, crosslinking agent, and polymerization catalyst to react in the bore of the microcapillary to form a hydrophilic polymer-containing gel matrix which is covalently bonded to the microcapillary wall via the bifunctional reagent. In electrophoresis, this improved gel-containing microcapillary can provide peak efficiencies in excess of 100,000 theoretical plates within separation times of less than thirty minutes, permits trace level determinations of molecular weights, and permits electrophoretic operation at fields of 1000 V/cm or higher, resulting in extremely high resolution separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 26 OF 146 USPATFULL
ACCESSION NUMBER: 89:71848 USPATFULL
TITLE: Cellular encapsulation of biologicals for animal and human use
INVENTOR(S): Barnes, Andrew C., San Diego, CA, United States
Edwards, David L., San Diego, CA, United States
PATENT ASSIGNEE(S): Mycogen Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4861595		19890829	<--

APPLICATION INFO.: US 1987-95749 19870911 (7)
DISCLAIMER DATE: 20040922
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1985-750369, filed on 28 Jun 1985, now patented, Pat. No. US 4695462
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dixon, Jr., William R.
ASSISTANT EXAMINER: Brunsman, David M.
LEGAL REPRESENTATIVE: Saliwanchik, Roman, Saliwanchik, David R.
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 35
LINE COUNT: 470
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A biological delivery system particularly suited for delivery of protein compounds to animals and humans is disclosed. The system uses a producing microbe itself after suitable treatment by chemical and/or physical means. The product being delivered is contained within the treated microbial cell; it is produced intracellularly by a homologous (native) gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 27 OF 146 USPATFULL
ACCESSION NUMBER: 89:71833 USPATFULL
TITLE: Composition using salt form of organic acid derivative of alpha-tocopheral
INVENTOR(S): Janoff, Andrew S., Yardley, PA, United States
Bolcsak, Lois E., Lawrenceville, NJ, United States
Weiner, Alan L., Lawrenceville, NJ, United States
Tremblay, Paul A., Hamilton, NJ, United States
Bergamini, Michael V. W., Easton, PA, United States
Suddith, Robert L., Robbinsville, NJ, United States
PATENT ASSIGNEE(S): The Liposome Company, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4861580		19890829	<--
APPLICATION INFO.:	US 1986-911138		19860924 (6)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1985-786740, filed on 15 Oct 1985, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Bloom, Allen, Kurtz, Catherine L.
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions are described for the preparation of alpha-tocopherol vesicles, the bilayers of which comprise a salt form of an organic acid derivative of alpha-tocopherol such as the Tris salt form of alpha-tocopherol hemisuccinate. The method is rapid and efficient and does not require the use of organic solvents. The alpha-tocopherol vesicles may be used to entrap compounds which are insoluble in aqueous solutions. Such preparations are especially useful for entrapping bioactive agents of limited solubility, thus enabling administration in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 28 OF 146 USPATFULL
ACCESSION NUMBER: 89:64934 USPATFULL
TITLE: Device comprising means for protecting and dispensing

fluid sensitive medicament

INVENTOR(S): Eckenhoff, James B., Los Altos, CA, United States
Magruder, Judy A., Mt. View, CA, United States
Cortese, Richard, Cupertino, CA, United States
Peery, John R., Palo Alto, CA, United States
Wright, Jeremy C., Los Altos, CA, United States

PATENT ASSIGNEE(S): ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4855141		19890808	<--
APPLICATION INFO.:	US 1988-173209		19880325	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Horne, Leon R.
LEGAL REPRESENTATIVE: Sabatine, Paul L., Mandell, Edward L., Stone, Steven F.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A delivery device is disclosed for delivering a beneficial agent to an animal. The device comprises a wall housing an internal space, a beneficial agent in the space, expandable means in the space for causing the beneficial agent to be delivered from the device and means in the space for shielding the beneficial agent from fluid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 29 OF 146 USPATFULL
ACCESSION NUMBER: 89:51976 USPATFULL
TITLE: Product and process for isolating RNA
INVENTOR(S): Chomczynski, Piotr, 727 Martin Luther King Dr., Cincinnati, OH, United States 45220

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4843155		19890627	<--
APPLICATION INFO.:	US 1987-123107		19871119	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
ASSISTANT EXAMINER: Crane, L. Eric
LEGAL REPRESENTATIVE: Wood, Herron & Evans
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,7
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses a novel method for isolating RNA from biological tissue samples and a novel solvent adapted for use in the disclosed method. The method employs a single extraction using the solvent containing guanidinium and phenol. The solvent is stable for about one month at room temperature without any appreciable phenol oxidation or decomposition. Application of the disclosed method and solvent to a biological tissue sample results in the isolation of a high yield of RNA in a substantially pure and undegraded form. The whole procedure can be completed in three hours, much more quickly than other procedures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 30 OF 146 USPATFULL

ACCESSION NUMBER: 89:47675 USPATFULL
TITLE: Liposomes with enhanced retention on mucosal tissue
INVENTOR(S): Guo, Luke S. S., Lafayette, CA, United States
Redemann, Carl T., Walnut Creek, CA, United States
Radhakrishnan, Ramachandran, Palo Alto, CA, United States
Yau-Young, Annie, Los Altos, CA, United States
PATENT ASSIGNEE(S): Liposome Technology, Inc., Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4839175		19890613	<--
APPLICATION INFO.:	US 1986-890815		19860728	(6)

DISCLAIMER DATE: 20060214
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Dehlinger, Peter J.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A liposome composition designed for enhanced binding to mucosal tissue, The liposomes contain about 10-40 mole percent of an amine-derivatized lipid component in which a charged amine group is spaced from a lipid polar head region by a carbon-containing spacer arm at least 3 atoms in length. The liposomes preferably have a close packed lipid structure produced by inclusion of between 20-50 mole percent of cholesterol or an amine-derivatized cholesterol, and/or phospholipids with predominantly saturated acyl chain moieties. For ophthalmic use, the liposomes may be suspended in an aqueous medium containing a high-viscosity polymer, to enhance further the retention of liposomes on a corneal surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 31 OF 146 USPATFULL
ACCESSION NUMBER: 89:43432 USPATFULL
TITLE: Luminescent cyclic hydrazides for analytical assays
INVENTOR(S): Belanger, Alain, Cap-Rouge, Canada
Brassard, Paul, Ste-Foy, Canada
PATENT ASSIGNEE(S): Universite Laval, Quebec, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4835268		19890530	<--
APPLICATION INFO.:	US 1987-46869		19870507	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1986-508758	19860508

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Robert J.
ASSISTANT EXAMINER: Benson, Robert
LEGAL REPRESENTATIVE: Swabey, Mitchell, Houle, Marcoux & Sher
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are derivatives of 5-(lower alkyl)-7-amino-2,3-dihydro-1,4-phthalazinedione having substituents on the amino group. The derivatives have luminescent properties which render them useful as analytical tools in clinical chemistry. Adaptation of the derivatives

for luminescent immunoassay provides valuable reagents and assays with outstanding sensitivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 32 OF 146 USPATFULL
ACCESSION NUMBER: 89:19165 USPATFULL
TITLE: Dehydration of hydrous matter using anhydrous glycosylfructose
INVENTOR(S): Mitsuhashi, Masakazu, Okayama, Japan
Sakai, Shuzo, Okayama, Japan
Miyake, Toshio, Okayama, Japan
PATENT ASSIGNEE(S): Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4812444		19890314	<--
APPLICATION INFO.:	US 1986-942421		19861216	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1985-292297	19851226

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel dehydration method using anhydrous glycosylfructose as the desiccant is disclosed. Anhydrous glycosylfructose is converted to the crystalline hydrate and acts as the desiccant when incorporated into a hydrous matter. Natural saccharides such as palatinose, raffinose, erlose, and melezitose can be used. The dehydration is applicable to hydrous matters, such as those of foods, pharmaceuticals, cosmetics, and their materials and intermediates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 33 OF 146 USPATFULL
ACCESSION NUMBER: 89:19032 USPATFULL
TITLE: Kit for use in the treatment of osteoporosis
INVENTOR(S): Uchtman, Vernon A., Cincinnati, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4812311		19890314	<--
APPLICATION INFO.:	US 1986-906859		19860912	(6)

DISCLAIMER DATE: 20060314
RELATED APPLN. INFO.: Continuation of Ser. No. US 1984-684560, filed on 21 Dec 1984, now abandoned which is a continuation-in-part of Ser. No. US 1984-605540, filed on 30 Apr 1984, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schenkman, Leonard
LEGAL REPRESENTATIVE: Graff, IV, Milton B., Goldstein, Steven J., Schaeffer, Jack D.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 773

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A kit for use in the treatment of osteoporosis is disclosed. The kit comprises a bone cell activating compound, a bone resorption inhibiting polyphosphonate, and a nutrient supplement or placebo, for sequential administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 34 OF 146 USPATFULL
ACCESSION NUMBER: 89:17428 USPATFULL
TITLE: Dehydration of hydrous matter using anhydrous aldohexose
INVENTOR(S): Mitsuhashi, Masakazu, Okayama, Japan
Sakai, Shuzo, Okayama, Japan
Miyake, Toshio, Okayama, Japan
PATENT ASSIGNEE(S): Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4810827		19890307	<--
APPLICATION INFO.:	US 1986-942423		19861216	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1985-292295	19851226

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 645
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel dehydration process using anhydrous aldohexose as the desiccant is disclosed. Anhydrous aldohexose is converted to crystalline hydrate and acts as the desiccant when it is incorporated into a hydrous substance. Natural saccharides such as glucose, galactose, and mannose are suitable for the aldohexose. The dehydration is applicable to hydrous matters, such as those of foods, pharmaceuticals, cosmetics, and their materials and intermediates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 35 OF 146 USPATFULL
ACCESSION NUMBER: 89:12965 USPATFULL
TITLE: Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
INVENTOR(S): Kohn, Joachim, Brookline, MA, United States
Langer, Robert S., Somerville, MA, United States
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4806621		19890221	<--
APPLICATION INFO.:	US 1986-820351		19860121	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Anderson, Harold D.
LEGAL REPRESENTATIVE: Cook, Paul J.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 680
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel series of articles useful as medical devices, implants and protheses are provided which utilize poly(iminocarbonate) polymeric matrices. These articles are biocompatible, have excellent mechanical properties and degrade into non-toxic residues after introduction in vivo. The articles may be formed in any desired dimensions and configuration and may take specific shape as biodegradable sutures or as orthopedic appliances such as bone plates and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 36 OF 146 USPATFULL
ACCESSION NUMBER: 89:7657 USPATFULL
TITLE: Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
INVENTOR(S): Auer, Henry E., Skokie, IL, United States
PATENT ASSIGNEE(S): International Minerals & Chemical Corp., Terre Haute, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4801691		19890131	<--
APPLICATION INFO.:	US 1987-50146		19870515 (7)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Guffey, Wendell R., Farquer, Thomas L.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Guanidine hydrochloride (GCl) is used to remove excess sodium dodecyl sulfate (SDS) from SDS-solubilized protein solutions, and particularly from SDS-solubilized inclusion body solutions, GCl is added to the solution containing SDS to induce the formation of a GCl-SDS complex (GDS) which, when allowed to precipitate, can easily be removed by centrifugation, filtration, or other suitable means.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 37 OF 146 USPATFULL
ACCESSION NUMBER: 89:1121 USPATFULL
TITLE: Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
INVENTOR(S): Kashdan, David S., Kingsport, TN, United States 37663
PATENT ASSIGNEE(S): Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4795641		19890103	<--
APPLICATION INFO.:	US 1987-87566		19870820 (7)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dixon, Jr., William R.
ASSISTANT EXAMINER: Brunsman, David M.
LEGAL REPRESENTATIVE: Savitsky, Thomas R., Heath, Jr., William P.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1081
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are polymer blends containing a minor amount of cellulose acetate and a major amount of cellulose acetate phthalate, cellulose acetate trimellitate or cellulose acetate succinate. The blends have

reverse phase morphology, that is, the minor component forms a continuous phase. The blends are useful for zero-order controlled delivery of bioactive agents such as pharmaceutical and agricultural chemicals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 38 OF 146 USPATFULL
ACCESSION NUMBER: 88:72388 USPATFULL
TITLE: Aqueous protein solutions stable to denaturation
INVENTOR(S): Thurow, Horst, Kelkheim, Germany, Federal Republic of
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4783441		19881108	<--
APPLICATION INFO.:	US 1983-564346		19831221	(6)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1981-263720, filed on 14 Jun 1981, now abandoned which is a continuation-in-part of Ser. No. US 1980-144040, filed on 28 Apr 1980, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1979-2917535	19790430
	DE 1979-2952119	19791222

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Waddell, Frederick E.
LEGAL REPRESENTATIVE: Curtis, Morris & Safford
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB What are disclosed are a method for preventing the denaturation of proteins such as insulin in aqueous solution at interfaces by the addition to the solution of a surface-active substance comprising a chain of alternating weakly hydrophobic and weakly hydropholic zones, protein solutions containing such a surface-active substance, methods of purifying proteins contained in such solutions, and methods of treating surfaces with such a surface-active material to prevent the denaturation of proteins thereon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 39 OF 146 USPATFULL
ACCESSION NUMBER: 88:53792 USPATFULL
TITLE: Solubilization of proteins for pharmaceutical compositions using polymer conjugation
INVENTOR(S): Katre, Nandini, El Cerrito, CA, United States
Knauf, Michael J., Oakland, CA, United States
PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4766106		19880823	<--
APPLICATION INFO.:	US 1988-148145		19880125	(7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1986-866459, filed on 21 May 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-749955, filed on 26 Jun 1985, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Hazel, Blondel
LEGAL REPRESENTATIVE: Halluin, Albert P., Hasak, Janet E.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not readily soluble in water at pH 6-8 without such solubilizing agent, is selectively conjugated to a water-soluble polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 40 OF 146 USPATFULL
ACCESSION NUMBER: 88:48754 USPATFULL
TITLE: Regimen for treating osteoporosis
INVENTOR(S): Flora, Lawrence, Fairfield, OH, United States
Floyd, Benjamin F., Cincinnati, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4761406		19880802	<--
APPLICATION INFO.:	US 1985-741976		19850606	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, Stanley J.
LEGAL REPRESENTATIVE: Graff, IV, Milton B., Goldstein, Steven J., Schaeffer, Jack D.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating or preventing osteoporosis utilizing a cyclic regimen comprising alternating for two or more cycles the administration of a bone resorption inhibiting polyphosphonate and a no treatment (rest) period. Further disclosed is a kit for use in implementing this method of treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 41 OF 146 USPATFULL
ACCESSION NUMBER: 88:32579 USPATFULL
TITLE: Drug administration
INVENTOR(S): Carey, Martin C., Wellesley, MA, United States
Moses, Alan C., Waban, MA, United States
Flier, Jeffrey S., West Newton, MA, United States
PATENT ASSIGNEE(S): Beth Israel Hospital Assn., Boston, MA, United States (U.S. corporation)
The Brigham and Womens Hospital, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4746508		19880524	<--
APPLICATION INFO.:	US 1984-614115		19840525	(6)

DISCLAIMER DATE: 20021022
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-501187, filed on 6 Jun 1983, now patented, Pat. No. US 4548922

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schenkman, Leonard
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
LINE COUNT: 1309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of a human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 42 OF 146 USPATFULL
ACCESSION NUMBER: 88:11520 USPATFULL
TITLE: Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides
INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4727079		19880223	<--
APPLICATION INFO.:	US 1985-733463		19850513	(6)

DISCLAIMER DATE: 20000910
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-461543, filed on 27 Jan 1983, now abandoned And a continuation-in-part of Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564 And a continuation-in-part of Ser. No. US 1984-665940, filed on 29 Oct 1984 , said Ser. No. 461543 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 , said Ser. No. 516382 which is a continuation-in-part of Ser. No. 379316 And a continuation-in-part of Ser. No. 461543 And a continuation-in-part of Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 , said Ser. No. 665940 which is a continuation-in-part of Ser. No. 379316 And a continuation-in-part of Ser. No. 461543 And a continuation-in-part of Ser. No. 475493 And a continuation-in-part of Ser. No. 516382
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Baumeister, Mary Katherine, Clarke, Dennis P.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1,29
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 3124
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a

dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 43 OF 146 USPATFULL
ACCESSION NUMBER: 87:74973 USPATFULL
TITLE: Expression vector carrying a gene coding for a phosphate-binding protein, a method for preparing the same and a method for preparing the same and a method for producing a polypeptide using the same
INVENTOR(S): Nakata, Atsuo, Toyonaka, Japan
Shinagawa, Hideo, Minoo, Japan
PATENT ASSIGNEE(S): The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4703005		19871027	<--
APPLICATION INFO.:	US 1983-501559		19830606	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-96775	19820604

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
ASSISTANT EXAMINER: Maurey, Karen
LEGAL REPRESENTATIVE: Armstrong, Nikaido, Marmelstein & Kubovcik
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An expression vector carrying a gene coding for a phosphate-binding protein has been found to have a strong gene expression. The expression vector can be produced by transforming a bacterium belonging to Enterobacteriaceae with a recombinant vector carrying a DNA fragment containing a gene coding for a phosphate-binding protein to form transformants, selecting the transformants containing the desired recombinant vector from said transformants, and isolating the desired recombinant vector from the selected transformants. The expression vector is useful for producing polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 44 OF 146 USPATFULL
ACCESSION NUMBER: 87:69949 USPATFULL
TITLE: Enzymatic reactions using magnetic particles
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4698302		19871006	<--
APPLICATION INFO.:	US 1985-744457		19850613	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Foelak, Morton
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 45 OF 146 USPATFULL
ACCESSION NUMBER: 87:68535 USPATFULL
TITLE: Process for the preparation of 2-bromo-.alpha.-ergocryptine
INVENTOR(S): Megyeri, Gabor, Budapest, Hungary
Keve, Tibor, Budapest, Hungary
Galambos, Janos, Budapest, Hungary
Kovacs, Jr., Lajos, Budapest, Hungary
Stefko, Bela, Budapest, Hungary
Bogsch, Erik, Budapest, Hungary
Trischler, Ferenc, Budapest, Hungary
PATENT ASSIGNEE(S): Richter Gedeon Vegyeszeti Gyar RT, Budapest, Hungary (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4697017		19870929	<--
APPLICATION INFO.:	US 1986-869203		19860530	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	HU 1985-2300	19850612

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Shen, Cecilia
LEGAL REPRESENTATIVE: Ross, Karl F., Dubno, Herbert
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a novel process for the preparation of 2-bromo-.alpha.-ergocryptine and its acid addition salt by brominating .alpha.-ergocryptine in such a way that the bromination is carried out at room temperature by using a dimethylsulphoxide-hydrogen bromide mixture containing no more 0.02% of water and, if desired, converting the thus-obtained 2-bromo-.alpha.-ergocryptine to an acid addition salt in a known manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 46 OF 146 USPATFULL
ACCESSION NUMBER: 87:66802 USPATFULL

TITLE: Magnetic particles for use in separations
INVENTOR(S): Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
Whitehead, Roy A., Hingham, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4695393		19870922	<--
APPLICATION INFO.:	US 1985-744435		19850613 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Foelak, Morton
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1514
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 47 OF 146 USPATFULL
ACCESSION NUMBER: 87:66801 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4695392		19870922	<--
APPLICATION INFO.:	US 1985-744434		19850613 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1459
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be

redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 48 OF 146 USPATFULL
ACCESSION NUMBER: 87:41600 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4672040		19870609	<--
APPLICATION INFO.:	US 1985-749692		19850628	(6)

DISCLAIMER DATE: 20021119
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088 And Ser. No. US 1985-744351, filed on 13 Jun 1985, now patented, Pat. No. US 4628037 And Ser. No. US 1985-744435, filed on 13 Jun 1985 And Ser. No. US 1985-744434, filed on 13 Jun 1985 And Ser. No. US 1985-744457, filed on 13 Jun 1985
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Wieder, Stephen C.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for the use of magnetically responsive particles in systems in which the separation of certain molecules, macromolecules and cells from the surrounding medium is desirable. The magnetically responsive particles may be coupled to a wide variety of molecules. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 49 OF 146 USPATFULL
ACCESSION NUMBER: 87:36197 USPATFULL
TITLE: Method for producing an active protein
INVENTOR(S): Ishida, Torao, Nagareyama, Japan
PATENT ASSIGNEE(S): Asahi Kasei Kogyo Kabushiki Kaisha, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4667017		19870519	<--
APPLICATION INFO.:	US 1984-640819		19840815	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1983-148026	19830815

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1
LINE COUNT: 1917
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An active protein can be easily, safely produced by a method comprising providing a first peptide fragment having a first amino acid sequence corresponding to part of an active protein and a second peptide fragment having a second amino acid sequence corresponding to the remaining part of the active protein, at least one of said first peptide fragment and said second peptide fragment being one which has been obtained by recombinant DNA technique or has been obtained by a method comprising producing a predetermined peptide fragment by recombinant DNA technique and deleting from or adding to said predetermined peptide fragment at its N-terminus at least one amino acid residue; and linking said first peptide fragment at its C-terminus to said second peptide fragment at its N-terminus. The method of the present invention may be practiced, with further advantages, by predetermining said first peptide fragment and said second peptide fragment so that a first occurring methionine residue subsequent to the N-terminal amino acid residue of the active protein constitutes the N-terminal amino acid of the amino acid sequence of said second peptide fragment, or so that an amino acid residue positioned near the first occurring methionine residue subsequent to the N-terminal amino acid residue of the desired protein on the side of the N-terminus of the desired protein constitutes the N-terminal amino acid residue of said second peptide fragment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 50 OF 146 USPATFULL
ACCESSION NUMBER: 87:11393 USPATFULL
TITLE: Production of HCG
INVENTOR(S): Livingston-Wheeler, Virginia, 8441 Whale Watch Way, LaJolla, CA, United States 92037
Majnarich, John J., 8541 Southeast 80th St., Mercer Island, WA, United States 98040

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4643970		19870217	<--
APPLICATION INFO.:	US 1983-469004		19830223	(6)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1980-171280, filed on 23 Jul 1980, now abandoned which is a continuation of Ser. No. US 1979-27516, filed on 5 Apr 1979, now abandoned which is a continuation-in-part of Ser. No. US 1978-957206, filed on 3 Nov 1978, now abandoned Ser. No. Ser. No. US 1978-878483, filed on 16 Feb 1978, now abandoned Ser. No. Ser. No. US 1976-686896, filed on 17 May 1976, now abandoned Ser. No. Ser. No. US 1976-672965, filed on 2 Apr 1976, now abandoned And Ser. No. US 1972-295720, filed on 6 Oct 1972, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shapiro, Lionel M.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for the production of chorionic gonadotropin (CG) with properties similar to those of human CG (HCG) from a microorganism or mutant thereof isolated by natural or hybridization procedure from the body or body extract carrier of a malignant tumor carrier and having the capacity to synthesize the polypeptide hormone known as human chorionic gonadotropin in its total form or in its sub-units (.alpha. & .beta.) which comprises:

(a) culturing the microorganism or mutant thereof in a culture media;

(b) incubating the culture of the microorganism or mutant thereof, whereby the microorganism or mutant thereof in vivo produces a crude material containing chorionic gonadotropin and/or its sub-units (.alpha. & .beta.);

(c) separating the crude material containing chorionic gonadotropin and/or its sub-units (.alpha. & .beta.) from the culture media and the microorganism or mutant thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 51 OF 146 USPATFULL
ACCESSION NUMBER: 87:8090 USPATFULL
TITLE: Insecticidally, acaricidally, and nematocidally 2-amino-1,3-dithiane derivatives and pesticidal compositions therefor
INVENTOR(S): Mitsudera, Hiroyuki, Osaka, Japan
Konishi, Kazuo, Osaka, Japan
Sato, Yasuo, Kyoto, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4640929		19870203	<--
APPLICATION INFO.:	US 1983-525635		19830823	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-149633	19820827

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Mullins, J. G.
LEGAL REPRESENTATIVE: Wegner & Bretschneider
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1,10
LINE COUNT: 1096
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel 1,3-dithiane of the formula ##STR1## wherein R.sup.1 is a di-substituted amino group; R.sup.2 and R.sup.3 are such that one of them is an electron-withdrawing group with the other being a hydrogen atom, a hydrocarbon group or heterocyclic group of the class consisting of thienyl, triazolyl, and pyridyl, which may optionally be substituted or that R.sup.2 and R.sup.3 taken together with the adjacent carbon atom form a spiro ring provided that at least one of R.sup.2 and R.sup.3 is a carbonyl group; X.sup.1 and X.sup.2 each is a sulfur atom and at least one of X.sup.1 and X.sup.2 may be oxidized, or a salt thereof, possesses very useful pesticidal actions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 52 OF 146 USPATFULL
ACCESSION NUMBER: 86:69734 USPATFULL
TITLE: Binding assays employing magnetic particles
INVENTOR(S): Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
Whitehead, Roy A., Hingham, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4628037		19861209	<--
APPLICATION INFO.:	US 1985-744351		19850613 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554488
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Wieder, Stephen C.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 53 OF 146 USPATFULL
ACCESSION NUMBER: 86:64777 USPATFULL
TITLE: Process for peptide synthesis
INVENTOR(S): Carpino, Louis A., Amherst, MA, United States
Cohen, Beri, Tarrytown, NY, United States
PATENT ASSIGNEE(S): Research Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4623484		19861118	<--
APPLICATION INFO.:	US 1985-805483		19851205 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1984-614344, filed on 24 May 1984, now patented, Pat. No. US 4575541
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Henderson, Christopher A.
LEGAL REPRESENTATIVE: Scully, Scott Murphy & Presser
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 394
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polymers of the formula ##STR1## wherein Z is polystyrene, or a copolymer comprising styrene and a comonomer or comonomers.

Y is selected from the group comprising nitro, acyl, carboxyl, formyl, cyano, carbalkoxy, sulfone, carboxyamide, or halogen; and

P is hydroxy, aryloxy, alkoxy, halogen, formyloxy, acyloxy, cyano, amino, substituted amino, carboxyamine, thiol, alkylthio, arylthio, aralkylthio or acylthio, useful in peptide synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 54 OF 146 USPATFULL
ACCESSION NUMBER: 86:55087 USPATFULL
TITLE: Immunoassays with luciferase labeled ligands or receptors
INVENTOR(S): Baldwin, Thomas O., Bryan, TX, United States

Holzman, Thomas F., Bryan, TX, United States
Satoh, Paul S., Portage, MI, United States
Yein, Frederick S., Kalamazoo, MI, United States
PATENT ASSIGNEE(S): The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
Texas A&M University System, College Station, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4614712		19860930	<--
APPLICATION INFO.:	US 1983-469852		19830225	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marantz, Sidney
LEGAL REPRESENTATIVE: Hattan, L. Ruth
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1,3,22
LINE COUNT: 1204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immunoassays which utilize an enzyme linked ligand or receptor wherein the enzyme is bacterial luciferase; mercantile kit useful in performing said immunoassay; and compounds utilized in performing said assay.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 55 OF 146 USPATFULL
ACCESSION NUMBER: 86:14025 USPATFULL
TITLE: Polymer with sulfone-benzene appendage
INVENTOR(S): Carpino, Louis A., Amherst, MA, United States
Cohen, Beri, Tarrytown, NY, United States
PATENT ASSIGNEE(S): Research Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4575541		19860311	<--
APPLICATION INFO.:	US 1984-614344		19840524	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Henderson, Christopher A.
LEGAL REPRESENTATIVE: Scully, Scott, Murphy & Presser
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to polymers of the formula ##STR1## wherein Z is polystyrene, or a copolymer comprising styrene and a comonomer or comonomers.

Y is selected from the group comprising nitro, acyl, carboxyl, formyl, cyano, carbalkoxy, sulfone, carboxyamide, or halogen; and

P is hydroxy, aryloxy, alkoxy, halogen, formyloxy, acyloxy, cyano, amino, substituted amino, carboxyamine, thiol, alkylthio, arylthio, aralkylthio or acylthio, useful in peptide synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 56 OF 146 USPATFULL
ACCESSION NUMBER: 86:11100 USPATFULL
TITLE: Soft buccal
INVENTOR(S): Kigasawa, Kazuo, Tokyo, Japan
Shimizu, Hiroaki, Tokyo, Japan
Hayashi, Toshihiro, Chiba, Japan

Watabe, Kazuo, Kanagawa, Japan
Tanizaki, Akira, Tokyo, Japan
Koyama, Osamu, Tokyo, Japan
Wakisaka, Kikuo, Tokyo, Japan
Ogawa, Yasuaki, Osaka, Japan
PATENT ASSIGNEE(S): Grelan Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4572832		19860225	<--
APPLICATION INFO.:	US 1983-540161		19831007	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-175352	19821007
	JP 1983-172245	19830920

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Wegner & Bretschneider
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A soft buccal containing (1) a medicament to be absorbed through the oral mucosa, (2) a water-soluble protein, (3) a polyhydric alcohol, and (4) a fatty acid ester or/and a carboxyvinyl polymer, has various advantages such as good feeling in use, good retainability within the mouth, slow release, improved absorbability of drug through the mucosa, improved bioavailability, etc., and therefore can be used an excellent pharmaceutical preparation for administration to the mucous membrane of the mouth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 57 OF 146 USPATFULL
ACCESSION NUMBER: 85:68137 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4554088		19851119	<--
APPLICATION INFO.:	US 1983-493991		19830512	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Demers, Arthur P.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be

redispersed and reused. The magnetic particles are useful in biological systems involving separations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 58 OF 146 USPATFULL
ACCESSION NUMBER: 85:62606 USPATFULL
TITLE: Drug administration
INVENTOR(S): Carey, Martin C., Wellesley, MA, United States
Moses, Alan C., Waban, MA, United States
Flier, Jeffrey S., Newton, MA, United States
PATENT ASSIGNEE(S): Beth Israel Hospital, Boston, MA, United States (U.S. corporation)
The Brigham & Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4548922		19851022	<--
APPLICATION INFO.:	US 1983-501187		19830606	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1,2
LINE COUNT: 553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition useful for the treatment of an animal suffering from a predetermined medical disorder including, in admixture, a medically effective amount of a drug, other than an antibiotic, effective against the medical disorder, and a biocompatible, water-soluble, amphiphilic steroid, other than a bile salt, which is capable of increasing the permeability to the drug of a surface of the animal across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 59 OF 146 USPATFULL
ACCESSION NUMBER: 85:46189 USPATFULL
TITLE: Analgesic dipeptide amides and method of use and compositions thereof
INVENTOR(S): Morgan, Barry A., Albany, NY, United States
PATENT ASSIGNEE(S): Sterling Drug Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4533655		19850806	<--
APPLICATION INFO.:	US 1982-423138		19820924	(6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1981-286672, filed on 24 Jul 1981, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Miller, Theodore C., Dupont, Paul E., Wyatt, B. Woodrow
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A genus of dipeptide amides including as the preferred subgenus the dipeptide amides having the structural formula R.sub.1 TyrR.sub.2 D-AlaNHR.sub.4 wherein R.sub.1 and R.sub.2 are each hydrogen or alkyl provided that at least one of them is other than hydrogen and R.sub.4 is

phenylalkyl or substituted-phenylalkyl are prepared by condensing the dipeptide with the amine or the amino acid with the amino acid amide and are useful as analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 60 OF 146 USPATFULL
ACCESSION NUMBER: 85:35849 USPATFULL
TITLE: Microcellular polyurethane foams having integral skin
INVENTOR(S): Hostettler, Fritz, R.F.D. 3, Box 318E, Stillhouse Rd., Freehold, NJ, United States 07728

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4524102		19850618	<--
APPLICATION INFO.:	US 1984-580434		19840215	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cockeram, Herbert S.
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1,2,33
LINE COUNT: 2456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are provided a wide range of polyurethane products, e.g., cellular, dense elastomer, and integral skin microcellular products, obtained by the reaction of (a) a polyisocyanate compound, (b) a polyol, (c) optionally a chain extender and/or blowing agent with/without other known additives, (d) in the presence of a non-hydroxyl flow modifier characterized by carbon and hydrogen atoms, at least one and, generally, a plurality of oxyalkylene groups, and at least one urethane, ##STR1## group. Several of the polyurethane products exhibit unique properties, e.g., foamed articles with capability to conduct static electricity, soft elastomers characterized by improved coefficient of friction, etc. Several classes of the flow modifiers are novel per se. The polyurethane products can be synthesized via the one shot or prepolymer process. Multipackage systems, in particular, two and three component systems are useful in molding operations, e.g., manufacture of shoe soles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 61 OF 146 USPATFULL
ACCESSION NUMBER: 85:31449 USPATFULL
TITLE: Bacteriolytic proteins
INVENTOR(S): Hultmark, Dan, Nacka, Sweden
Steiner, Hakan, Vallenhuna, Sweden
Rasmuson, Torgny, Ume.ang., Sweden
Boman, Hans G., Stockholm, Sweden
PATENT ASSIGNEE(S): KabiGen AB, Stockholm, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4520016		19850528	<--
APPLICATION INFO.:	US 1982-404119		19820802	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1980-160393, filed on 17 Jun 1980, now patented, Pat. No. US 4355104
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hazel, Blondel
ASSISTANT EXAMINER: Teskin, Robin Lyn
LEGAL REPRESENTATIVE: Gottlieb, Rackman & Reisman
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A non-lysozyme highly active bacteriolytic protein which is heat stable and has a relatively low molecular weight. The protein may be produced by immunizing an insect against E. coli and recovering the protein from the insect. The protein is useful for extracting proteins from genetically engineered bacteria and as a pharmaceutical for inhibiting certain bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 62 OF 146 USPATFULL
ACCESSION NUMBER: 85:28512 USPATFULL
TITLE: Method for enzyme immunoassay and peptide-enzyme conjugate and antibody therefor
INVENTOR(S): Iwasa, Susumu, Tsuzuki, Japan
Yoshida, Isamu, Takatsuki, Japan
Kondo, Koichi, Osaka, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4517290		19850514	<--
APPLICATION INFO.:	US 1983-533619		19830919	(6)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1981-244323, filed on 16 Mar 1981, now abandoned			

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1980-42484	19800331
	JP 1980-80467	19800613
	JP 1981-4507	19810114

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shapiro, Lionel M.
ASSISTANT EXAMINER: Tarcza, John E.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 2206
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In an enzyme immunoassay, when a specific antibody produced by contacting a peptide essential to the formation of a specific antibody to a peptide antigen, a freeze-dried material of .beta.-D-galactosidase-enzyme conjugate or a peptide-enzyme conjugate prepared by coupling a labeling enzyme with a peptide of the general formula:

H-R.sub.1 -Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln-OH

wherein R.sub.1 is a peptide fragment consisting of 1 to 14 amino acid residues including Gly in the 14-position of the peptide Ala.sup.1 -Pro.sup.2 -Pro.sup.3 -Pro.sup.4 -Ser.sup.5 -Leu.sup.6 -Pro.sup.7 -Ser.sup.8 -Pro.sup.9 -Ser.sup.10 -Arg.sup.11 -Leu.sup.12 -Pro.sup.13 -Gly.sup.14 is used, a high reproducibility of the result of the enzyme immunoassay is obtained.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 63 OF 146 USPATFULL
ACCESSION NUMBER: 95:11772 USPATFULL
TITLE: Charge effects in enzyme immunoassays
INVENTOR(S): Gibbons, Ian, Menlo Park, CA, United States
Rowley, Gerald L., Cupertino, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S.

corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4501692		19850226	<--
APPLICATION INFO.:	US 1982-259629		19820501	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1979-61099, filed on 26 Jul 1979, now patented, Pat. No. US 4287300
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Draper, Garnette D.
LEGAL REPRESENTATIVE: Rowland, Bertram I., Leitereg, Theodore J.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 1551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for determining a member of a specific binding pair-ligand and receptor (antiligand). Reagents employed include a first modified member which provides an electrical field due to the presence of a plurality of ionic charges and a second modified member labeled with a component of a signal producing system, which system may have one or more components. The average proximity in the assay medium of the first and second modified members is related to the amount of analyte, where the observed signal from the signal producing system is related to the effect of the electrical field on the signal producing system.

Also, compositions are provided, as well as reagents, in predetermined ratios for optimizing the signal response to variations in analyte concentration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 64 OF 146 USPATFULL
ACCESSION NUMBER: 84:64754 USPATFULL
TITLE: Process for producing a slow release composite
INVENTOR(S): Asano, Masaharu, Gunma, Japan
Yoshida, Masaru, Gunma, Japan
Kaetsu, Isao, Gunma, Japan
PATENT ASSIGNEE(S): Japan Atomic Energy Research Institute, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4483807		19841120	<--
APPLICATION INFO.:	US 1982-340989		19820120	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1981-10674	19810127
	JP 1981-12606	19810130
	JP 1981-79567	19810526

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lieberman, Paul
ASSISTANT EXAMINER: Thompson, W.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 440

AB A process is herein disclosed for producing a slow release composite comprising grinding and mixing mechanically in a frozen state one or more polypeptides, one or more proteins and one or more physiologically active substances shaping the blend into a desired form and compressing

at a pressure of from 100 to 20,000 kg/cm.sup.2 to thereby produce a slow release composite having the physiologically active substances encapsulated therein.

L440 ANSWER 65 OF 146 USPATFULL
ACCESSION NUMBER: 84:54080 USPATFULL
TITLE: Method and immunochemical measurement
INVENTOR(S): Okazaki, Masaki, Kanagawa, Japan
Masuda, Nobuhito, Kanagawa, Japan
Kumano, Yoshiro, Kanagawa, Japan
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4473653		19840925	<--
APPLICATION INFO.:	US 1983-506225		19830622	(6)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1981-298815, filed on 2 Sep 1981, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1980-120594	19800902
	JP 1980-120595	19800902

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marantz, Sidney
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 1118
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for immunochemical assay of an antigen or antibody by labelling the antigen or antibody with a specific cyanine or merocyanine dye containing a carboxy group followed by effecting an immune reaction and photochemical processing thereof is provided. The amount of the antigen or antibody is measured in term of optical density of developed silver halide which is brought into contact with either the antigen-antibody reaction product or the unreacted material.

This immunochemical assay method gives high detection sensitivity in a simple operation manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 66 OF 146 USPATFULL
ACCESSION NUMBER: 84:31589 USPATFULL
TITLE: Cholesterol matrix delivery system for sustained release of macromolecules
INVENTOR(S): Kent, John S., Palo Alto, CA, United States
PATENT ASSIGNEE(S): Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4450775		19840605	<--
APPLICATION INFO.:	US 1982-446749		19821203	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Buckles, Ellen J., Moran, Tom M., Krubiner, Alan M.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 780

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Delivery systems for releasing macromolecular active agents to a body site at a controlled rate for a prolonged period of time, comprising a cholesteric matrix permeable to passage of the macromolecular active agent by diffusion, are disclosed. The cholesteric matrix comprises cholesterol powder and cholesterol prills optionally in combination with a binding agent and a lubricating agent. The macromolecular active agent is dispersed throughout the matrix; macromolecules suitable for release from this delivery system have molecular weights of about 1300 to about 75,000 and are at least very slightly soluble in water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 67 OF 146 USPATFULL

ACCESSION NUMBER: 84:28761 USPATFULL

TITLE: Biodegradable, implantable drug delivery depots, and method for preparing and using the same

INVENTOR(S): Sidman, Kenneth R., Wayland, MA, United States

PATENT ASSIGNEE(S): Arthur D. Little, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4450150		19840522	<--
APPLICATION INFO.:	US 1981-262149		19810511	(6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1978-896552, filed on 14 Apr 1978, now abandoned which is a continuation-in-part of Ser. No. US 1975-596444, filed on 16 Jul 1975 which is a continuation-in-part of Ser. No. US 1983-361182, filed on 17 May 1983, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1974-199552	19740510
	GB 1974-21361	19740514
	CH 1974-6744	19740516
	DE 1974-2424169	19740517
	JP 1974-54595	19740517
	FR 1974-34307	19741110

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Padgett, Benjamin R.

ASSISTANT EXAMINER: Moskowitz, M.

LEGAL REPRESENTATIVE: Hammond, Richard J.

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1,2,5

NUMBER OF DRAWINGS: 19 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT: 1169

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An implantable drug deliver depot comprising a hydrophilic poly(glutamic acid-co-ethyl glutamate) structure having one or more substances, e.g., drugs and/or diagnostic agents physically contained therein. The drug or diagnostic agent is released by its permeation of and diffusion through the copolymer structure. The depot may be designed to release the substance or substances at predetermined rates and in predetermined sequence. The copolymer structure ultimately biodegrades to glutamic acid. Among the preferred configurations for the depots are rods and closed-end capsules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 68 OF 146 USPATFULL

ACCESSION NUMBER: 84:16982 USPATFULL

TITLE: Polyol-hormone mixture for use in chronic parenteral hormone administration

INVENTOR(S): Blackshear, Perry J., Cambridge, MA, United States
Palmer, John L., Watertown, MA, United States
Rohde, Thomas D., Minneapolis, MN, United States
PATENT ASSIGNEE(S): Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4439181		19840327	<--
APPLICATION INFO.:	US 1981-228097		19810126	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rosenbaum, C. Fred
ASSISTANT EXAMINER: Wallen, T. J.
LEGAL REPRESENTATIVE: Burd, Bartz & Gutenkauf
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 296

AB A method of preventing the precipitation of proteins, such as hormone preparations, within drug delivery systems that depend on the fluidity of the infusate for proper function. A polyol, such as glycerol, is mixed with the protein solution prior to the introduction of the solution into the drug delivery system. The polyol is added in amount sufficient to prevent precipitation of the protein during long-term storage in the drug delivery device. According to one form of usage, the protein-polyol solution is injected to the pressurized drug storage reservoir of an implanted infusion pump by injection through the patient's skin. As the solution is discharged from the delivery device by the constant pressure exerted upon the storage chamber, its low rate of flow is controlled by a restricted fluid passage. The solution is conveyed to an infusion site and diluted by the blood stream.

L440 ANSWER 69 OF 146 USPATFULL
ACCESSION NUMBER: 84:14430 USPATFULL
TITLE: Tagged immunoassay
INVENTOR(S): Wang, Chia-Gee, Millwood, NY, United States
PATENT ASSIGNEE(S): Wang Associates, Millwood, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4436826		19840313	<--
APPLICATION INFO.:	US 1981-313711		19811021	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Turk, Arnold
LEGAL REPRESENTATIVE: Ladas & Parry
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An immunoassay method for measurement of the content of a target antigen or antibody in a fluid or tissue specimen comprises reacting the target with reagent antibody or antigen which forms a complex with the target and is tagged with tagging elements which are unassociated chemically with said reagent and are protected against reaction with the target and the biological and chemical environment of the assay. Preferably the reagent antibody or antigen is carried by small, tagged mobile units, such as latex particles of a size smaller than 0.8 .mu.m, having tagging elements embedded therein. The tagged complexes which are formed may be measured by X-ray fluorescence or by detection of radioactive decay. Different target antigens or antibodies can be assayed simultaneously by employing different tagged mobile units, and the mobile units with the

tagging elements can be recovered for disposal or for reuse.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 70 OF 146 USPATFULL
ACCESSION NUMBER: 83:49319 USPATFULL
TITLE: Process for preparing a polymer composition
INVENTOR(S): Kaetsu, Isao, Takasaki, Japan
Yoshida, Masaru, Takasaki, Japan
Kumakura, Minoru, Takasaki, Japan
PATENT ASSIGNEE(S): Japan Atomic Energy Research Institute, Tokyo, Japan (non-U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4411754		19831025	<--
APPLICATION INFO.:	US 1981-234839		19810213	(6)

DISCLAIMER DATE: 19990323
RELATED APPLN. INFO.: Continuation of Ser. No. US 1979-18617, filed on 8 Mar 1979, now Defensive Publication No.

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-27109	19780309
	JP 1978-51239	19780428
	JP 1978-105306	19780829
	JP 1978-106097	19780830

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Briggs, Sr., Wilbert J.
LEGAL REPRESENTATIVE: Oblon, Fisher, Spivak, McClelland & Maier
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 929
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A polymer composition containing a physiologically active substance which can be released at a controlled rate is prepared by contacting one or more polymerizable monomers with the physiologically active substance, making the monomers into a specific shape and then irradiating the shaped article with light or an ionizing radiation at a low temperature below room temperature to polymerize the polymerizable monomers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 71 OF 146 USPATFULL
ACCESSION NUMBER: 83:41304 USPATFULL
TITLE: Beta-galactosyl-umbelliferone-labeled hapten conjugates
INVENTOR(S): Boguslaski, Robert C., Elkhart, IN, United States
Burd, John F., Elkhart, IN, United States
Carrico, Robert J., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4404366		19830913	<--
APPLICATION INFO.:	US 1981-284137		19810716	(6)

DISCLAIMER DATE: 19971007
RELATED APPLN. INFO.: Division of Ser. No. US 1980-147339, filed on 6 May 1980, now patented, Pat. No. US 4331590 which is a division of Ser. No. US 1979-87819, filed on 23 Oct 1979, now patented, Pat. No. US 4279992 which is a continuation-in-part of Ser. No. US 1978-886094, filed on 13 Mar 1978, now patented, Pat. No. US 4226978

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Brown, Johnnie R.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 9
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1854
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved specific binding assay method and reagent for determining a ligand in a liquid medium employing, as an enzyme-cleavable substrate label, a residue having the formula:

G--D--R

wherein G is a glycone, D is a dye indicator moiety, and R is a linking group through which the label residue is covalently bound to a binding component of a conventional binding assay system, such as the ligand, an analog thereof, or a specific binding partner thereof. The monitored characteristic of the label is the release of a detectable product, usually a fluorogen or chromogen, upon enzymatic cleavage of the glycosidic linkage between the glycone and the dye indicator moiety. The assay method may follow a homogeneous or heterogeneous format. The preferred glycone is a .beta.-galactosyl group and the preferred dye indicator moiety is an umbelliferone residue. The improved assay is particularly suited to the determination of haptens, such as drugs, and antigenic proteins and polypeptides, including antibodies, following a homogeneous competitive binding assay format.

CROSS-REFERENCE TO RELATED APPLICATION

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 72 OF 146 USPATFULL
ACCESSION NUMBER: 83:15482 USPATFULL
TITLE: Hormonal plant growth regulator
INVENTOR(S): Szejtli, Jozsef, Budapest, Hungary
Budai, Zsuzsanna, Budapest, Hungary
Tetenyi nee Erdosi, Magda, Budapest, Hungary
Pap nee Imrenyi, Gabriella, Budapest, Hungary
PATENT ASSIGNEE(S): Chinoin Gyogyszer es Vegyeszeti Termekek Gyara R.T., Budapest, Hungary (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4380626		19830419	<--
APPLICATION INFO.:	US 1980-218206		19801219	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	HU 1979-CI2000	19791228

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Ross, Karl F., Dubno, Herbert
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to new inclusion complexes of 2-chloro ethyl phosphonic acid formed with .alpha.-, .beta.- and/or .gamma.-cyclodextrin or a mixture thereof.

The new inclusion complexes contain preferably 10-30% of 2-chloro ethyl phosphonic acid.

The new complexes of the present invention are prepared by reacting 2-chloro ethyl phosphonic acid with .alpha.-, .beta.- and/or .gamma.-cyclodextrin or a mixture of one or more of the said cyclodextrins and linear dextrins and/or partially decomposed starch.

The new inclusion complexes of the present invention can be used for the preparation of plant growth regulating compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 73 OF 146 USPATFULL
ACCESSION NUMBER: 83:12151 USPATFULL
TITLE: Enzyme amplification compounds for assays for androgens
INVENTOR(S): Rubenstein, Kenneth E., Menlo Park, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4376825		19830315	<--
APPLICATION INFO.:	US 1980-221235		19801230	(6)
DISCLAIMER DATE:	19970304			

RELATED APPLN. INFO.: Division of Ser. No. US 1979-36929, filed on 7 May 1979, now patented, Pat. No. US 4282325 which is a continuation-in-part of Ser. No. US 1977-857145, filed on 5 Dec 1977, now patented, Pat. No. US 4203802 which is a continuation-in-part of Ser. No. US 1977-802683, filed on 2 Jun 1977, now patented, Pat. No. US 4190496 which is a continuation of Ser. No. US 1977-760499, filed on 19 Jan 1977, now patented, Pat. No. US 4191613 which is a continuation-in-part of Ser. No. US 1976-722964, filed on 13 Sep 1976, now patented, Pat. No. US 4067774 which is a continuation of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned which is a division of Ser. No. US 1972-304157, filed on 6 Nov 1972, now patented, Pat. No. US 3852157 which is a continuation-in-part of Ser. No. US 1971-143609, filed on 14 May 1971, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tanenholtz, Alvin E.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 3486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as "ligands") and binding an enzyme to the ligand or ligand counterfeit to provide an "enzyme-bound-ligand", an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efficiencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 74 OF 146 USPATFULL
ACCESSION NUMBER: 83:9021 USPATFULL
TITLE: Macromolecular environment control in specific receptor assays
INVENTOR(S): Litman, David J., Palo Alto, CA, United States
Harel, Zvi, Stanford, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4374925		19830222	<--
APPLICATION INFO.:	US 1981-232777		19810209	(6)

DISCLAIMER DATE: 19980623
RELATED APPLN. INFO.: Division of Ser. No. US 1978-964099, filed on 24 Nov 1978, now patented, Pat. No. US 4275149, issued on 23 Jun 1981
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions are provided for performing protein binding assays involving a homologous pair consisting of ligand and receptor for the ligand. The method employs a label conjugated to a member of said homologous pair and a uniformly dispersed discontinuous phase of discrete particles in a continuous aqueous phase, where the discrete particles create microenvironments which allow for discrimination between the label associated with the particle--in a discontinuous phase--and the label in the continuous phase.

Various conjugates and particles are provided which find use in the subject method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 75 OF 146 USPATFULL
ACCESSION NUMBER: 82:60307 USPATFULL
TITLE: Chemiluminescent-labeled haptens and antigens
INVENTOR(S): Boguslaski, Robert C., Elkhart, IN, United States
Carrico, Robert J., Elkhart, IN, United States
Christner, James E., Birmingham, AL, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4363759		19821214	<--
APPLICATION INFO.:	US 1978-927622		19780724	(5)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1978-894836, filed on 10 Apr 1978, now Defensive Publication No. which is a continuation of Ser. No. US 1976-667996, filed on 18 Mar 1976, now abandoned which is a continuation-in-part of Ser. No. US 1975-572008, filed on 28 Apr 1975, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Waddell, Frederick E.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 3

EXEMPLARY CLAIM: 1
LINE COUNT: 1178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chemiluminescent-labeled conjugates of the formula: ##STR1## wherein one of R.sup.1 and R.sup.2 is hydrogen and the other is -NR.sup.3 R.sup.4 ; R.sup.3 is hydrogen or straight chain alkyl containing 1-4 carbon atoms and R.sup.4 is ##STR2## wherein n=1-3 and L(CO-- is the ligand or analog bound through an amide bond. Intermediates produced in the synthesis of such conjugates are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 76 OF 146 USPATFULL
ACCESSION NUMBER: 82:56885 USPATFULL
TITLE: Process for the detection of antibodies
INVENTOR(S): Weltman, Joel K., 164 Summit Ave., Providence, RI, United States 02906

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4360592		19821123	<--
APPLICATION INFO.:	US 1980-208234		19801110	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1979-93607, filed on 13 Nov 1979, now patented, Pat. No. US 4251445, issued on 17 Feb 1981 which is a division of Ser. No. US 1978-889726, filed on 24 Mar 1978, now patented, Pat. No. US 4218539, issued on 19 Aug 1980
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shapiro, Lionel M.
LEGAL REPRESENTATIVE: Crowley, Richard P.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel enzyme conjugates useful in immunoassay methods are prepared with the use of a novel coupling reagent of N-succinimidyl (4-iodoacetyl) aminobenzoate by reacting the coupling reagent, firstly, with an amino-containing macromolecule, and, thereafter, with a sulfhydryl-containing enzyme, the enzyme conjugate prepared in a high yield and of high specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 77 OF 146 USPATFULL
ACCESSION NUMBER: 82:54535 USPATFULL
TITLE: Polypeptide and its production and use
INVENTOR(S): Fujino, Masahiko, Takarazuka, Japan
Wakimasu, Mitsuhiro, Suita, Japan
Kitada, Chieko, Sakai, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4358440		19821109	<--
APPLICATION INFO.:	US 1981-286600		19810121	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1980-11868	19800102

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Hubbell, Cohen, Stiefel & Gross

NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polypeptide of the formula:

H-Tyr-Gly-Gly-Phe-Met-Lys-Pro-Tyr-Thr-Lys-Gln-Ser-His-Lys-Pro-Leu-Ile-Thr-Leu-Leu-Lys-His-Ile-Thr-Leu-Lys-Asn-Glu-Gln-OH is useful as an analgesic agent. Methods of its preparation are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 78 OF 146 USPATFULL
ACCESSION NUMBER: 82:50954 USPATFULL
TITLE: Amino-functionalized phthalhydrazide intermediates
INVENTOR(S): Boguslaski, Robert C., Elkhart, IN, United States
Carrico, Robert J., Elkhart, IN, United States
Christner, James E., Birmingham, AL, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4355165		19821019	<--
APPLICATION INFO.:	US 1980-131881		19800320	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1978-927622, filed on 24 Jul 1978, now Defensive Publication No. which is a continuation-in-part of Ser. No. US 1978-894836, filed on 10 Apr 1978, now Defensive Publication No. which is a continuation of Ser. No. US 1976-667996, filed on 18 Mar 1976, now abandoned which is a continuation-in-part of Ser. No. US 1975-572008, filed on 28 Apr 1975, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rizzo, Nicholas S.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 1180
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Amino-functionalized phthalhydrazide intermediates of the formula: ##STR1## wherein one of R.sup.5 and R.sup.6 is hydrogen and the other is --NR.sup.7 R.sup.8 ; R.sup.7 is hydrogen or straight chain alkyl containing 1-4 carbon atoms and R.sup.8 is ##STR2## wherein n=1-3. The compounds are intermediates in the synthesis of chemiluminescent-labeled conjugates which are useful as reagents in specific binding assays for determining ligands or their specific binding partners in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 79 OF 146 USPATFULL
ACCESSION NUMBER: 82:50893 USPATFULL
TITLE: Bacteriolytic proteins
INVENTOR(S): Hultmark, Dan, Nacka, Sweden
Steiner, Hakan, Vallentuna, Sweden
Rasmuson, Torgny, Umea, Sweden
Boman, Hans G., Stockholm, Sweden
PATENT ASSIGNEE(S): Kabigen AB, Stockholm, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4355104		19821019	<--
APPLICATION INFO.:	US 1980-160393		19800617	(6)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Tarcza, John E.
LEGAL REPRESENTATIVE: Gottlieb, Rackman & Reisman
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1,2
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A non-lysozyme highly active bacteriolytic protein which is heat stable and has a relatively low molecular weight. The protein may be produced by immunizing an insect against E. coli and recovering the protein from the insect. The protein is useful for extracting proteins from genetically engineered bacteria and as a pharmaceutical.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 80 OF 146 USPATFULL
ACCESSION NUMBER: 82:41282 USPATFULL
TITLE: Plant growth promoting brassinosteroids
INVENTOR(S): Thompson, Malcolm J., Baltimore, MD, United States
Mandava, Nagabhushanam, Silver Spring, MD, United States
Worley, deceased, Joseph F., late of Rockville, MD, United States by Anita S. Worley, a personal representative
Dutky, Samson R., Silver Spring, MD, United States
Robbins, William E., Silver Spring, MD, United States
Flippen-Anderson, Judith L., Annandale, VA, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the department of Agriculture, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4346226		19820824	<--
APPLICATION INFO.:	US 1980-182210		19800828	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fan, Jane T.
LEGAL REPRESENTATIVE: Silverstein, M. Howard, Scott, William E., McConnell, David G.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 467
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic polyhydroxylated steroidal lactones are found to be highly effective plant growth promoting substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 81 OF 146 USPATFULL
ACCESSION NUMBER: 82:28006 USPATFULL
TITLE: Chemiluminescent phthalhydrazide-labeled hapten conjugates
INVENTOR(S): Buckler, Robert T., Edwardsburg, MI, United States
Schroeder, Hartmut R., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4334069		19820608	<--
APPLICATION INFO.:	US 1978-927621		19780724	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Sutto, Anton H.
ASSISTANT EXAMINER: Turnipseed, James H.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chemiluminescent-labeled conjugates of the formula: ##STR1## wherein one of R.sup.1 and R.sup.2 is hydrogen and the other is --NR.sup.3 R.sup.4 ; R.sup.3 is hydrogen or straight chain alkyl containing 1-4 carbon atoms and R.sup.4 is

L(CO--HN--CH.sub.2).sub.n

wherein n=2-8 and L(CO)-- is a hapten bound through an amide bond. The labeled conjugates are useful as reagents in specific binding assays for determining haptens or their specific binding partners in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 82 OF 146 USPATFULL
ACCESSION NUMBER: 82:27696 USPATFULL
TITLE: Herbicidal 5-cyano-2,3-dihydro-benzofuran-2-ones
INVENTOR(S): Gates, Peter S., Cambridge, England
Baldwin, Derek, Cambridge, England
Wilson, Carol A., Saffron Walden, England
Gillon, John, Cambridge, England
PATENT ASSIGNEE(S): Fisons Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4333759		19820608	<--
APPLICATION INFO.:	US 1980-213151		19801204 (6)	
RELATED APPLN. INFO.:	Division of Ser. No. US 1979-62511, filed on 27 Jul 1979, now patented, Pat. No. US 4263037			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1978-31646	19780729
	GB 1978-41692	19781004

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1,6
LINE COUNT: 1919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides herbicidally-active 2,3-dihydro-5-cyanobenzofurans of the formula: ##STR1## (wherein: R.sup.1 and R.sup.2 together represent .dbd.O or R.sup.1 represents hydrogen and R.sup.2 represents hydrogen, hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, halogen, isothiocyanato, amino, alkylamino, dialkylamino, arylamino, acylamino, alkoxycarbonylamino, alkylthiocarbonylamino, N-bonded heterocyclyl, cyano or alkylthio; R.sup.3 and R.sup.4 together represent alkylene or each represent hydrogen or alkyl; and R.sup.5, R.sup.6 and R.sup.7, which may be the same or different, each represent hydrogen, halogen, alkyl, alkoxy, acyl or cyano), processes for their preparation and herbicidal compositions containing them. ,

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 83 OF 146 USPATFULL
ACCESSION NUMBER: 82:25472 USPATFULL
TITLE: Chemiluminescent naphthalene-1,2-dicarboxylic acid hydrazide-labeled haptens
INVENTOR(S): Buckler, Robert T., Edwardsburg, MI, United States
Schroeder, Hartmut R., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4331808		19820525	<--
APPLICATION INFO.:	US 1979-82109		19791005 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1978-927286, filed on 24 Jul 1978, now patented, Pat. No. US 4225485
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fagelson, Anna P.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chemiluminescent-labeled conjugates of the formula: ##STR1## wherein R is hydrogen or straight chain alkyl containing 1-4 carbon atoms, n=2-6 and L(CO-- is a specifically bindable ligand, such as an antigenic protein or polypeptide, a hapten or an antibody, or a binding analog thereof, bound through an amide bond; and intermediates produced in the synthesis of such conjugates. The labeled conjugates are useful as reagents in specific binding assays for determining ligands or their specific binding partners in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 84 OF 146 USPATFULL
ACCESSION NUMBER: 82:25254 USPATFULL
TITLE: .beta.-Galactosyl-umbelliferone-labeled protein and polypeptide conjugates
INVENTOR(S): Bocuslaski, Robert C., Elkhart, IN, United States
Burd, John F., Elkhart, IN, United States
Carrico, Robert J., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4331590		19820525	<--
APPLICATION INFO.:	US 1980-147339		19800506 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1978-87819, filed on 23 Oct 1978, now patented, Pat. No. US 4279992 which is a continuation-in-part of Ser. No. US 1978-886094, filed on 13 Mar 1978, now patented, Pat. No. US 4226978
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved specific binding assay method and reagent for determining a ligand in a liquid medium employing, as an enzyme-cleavable substrate label, a residue having the formula:

G-D-R

wherein G is a glycone, D is a dye indicator moiety, and R is a linking group through which the label residue is covalently bound to a binding component of a conventional binding assay system, such as the ligand, an analog thereof, or a specific binding partner thereof. The monitored characteristic of the label is the release of a detectable product, usually a fluorogen or chromogen, upon enzymatic cleavage of the glycosidic linkage between the glycone and the dye indicator moiety. The assay method may follow a homogeneous or heterogeneous format. The preferred glycone is a .beta.-galactosyl group and the preferred dye indicator moiety is an umbelliferone residue. The improved assay is particularly suited to the determination of haptens, such as drugs, and antigenic proteins and polypeptides, including antibodies, following a homogeneous competitive binding assay format.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 85 OF 146 USPATFULL
ACCESSION NUMBER: 82:24555 USPATFULL
TITLE: Element for implantation in body tissue, particularly bone tissue
INVENTOR(S): Branemark, Per I., S-431 39, Molndal, Sweden
Thuresson af Ekenstam, Bo, S-412 53, Goteborg, Sweden

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4330891		19820525	<--
APPLICATION INFO.:	US 1980-125654		19800228	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1979-2035	19790307

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Frinks, Ronald L.
LEGAL REPRESENTATIVE: Ostrolenk, Faber, Gerb & Soffen
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 408

AB In an element for implantation in body tissue, particularly bone tissue, consisting of a biologically flawless material with a micro-pitted surface, the pores in the surface have a diameter many times smaller than has been previously known in order to permit the occurrence of such a tight and extensive boundary zone around the implanted element that this achieves reinforced and inextricable anchoring in the tissue. The pore diameter may be as little as about 10 nm and as large as a few multiples of the normal diameter of the cells in the tissue, preferably no larger than the cell diameter, i.e. about 1000 nm. Optimal results are obtained with pore diameters equal to or smaller than about 300 nm and a finely pored rutile layer has been found to give a particularly strong and durable joint with the growing tissue. Preferably at least one deposit of an agent facilitating and/or accelerating the growing-together process is arranged on or in the element. The element may be shaped with grooves, corrugations, channels etc. and be provided with an opening for tissue to grow through. The element is extremely suitable as anchoring device for a prosthesis or partial prosthesis and may be made integral therewith.

L440 ANSWER 86 OF 146 USPATFULL
ACCESSION NUMBER: 82:13589 USPATFULL
TITLE: Process for preparing a polymer composition
INVENTOR(S): Kaetsu, Isao, Takasaki, Japan

Yoshida, Masaru, Takasaki, Japan
Kumakura, Minoru, Takasaki, Japan
PATENT ASSIGNEE(S): Japan Atomic Energy Research Institute, Tokyo, Japan (non-U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4321117		19820323	<--
APPLICATION INFO.:	US 1979-18617		19790308	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-27109	19780309
	JP 1978-51239	19780428
	JP 1978-105306	19780829
	JP 1978-106097	19780830

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Briggs, Sr., Wilbert J.
LEGAL REPRESENTATIVE: Oblon, Fisher, Spivak, McClelland & Maier
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 970
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A polymer composition containing a physiologically active substance which can be released at a controlled rate is prepared by contacting one or more polymerizable monomers with the physiologically active substance, mking the monomers into a specific shape and then irradiating the shaped article with light or an ionizing radiation at a low temperature below room temperature to polymerize the polymerizable monomers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 87 OF 146 USPATFULL
ACCESSION NUMBER: 81:68951 USPATFULL
TITLE: Method of maintaining the fluidity of hormone solutions for parenteral administration
INVENTOR(S): Dorman, Frank D., Minneapolis, MN, United States
Rohde, Thomas D., Minneapolis, MN, United States
Rublein, Thomas G., Minneapolis, MN, United States
PATENT ASSIGNEE(S): The Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4306553		19811222	<--
APPLICATION INFO.:	US 1980-171091		19800722	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Michell, Robert W.
ASSISTANT EXAMINER: Wallen, T. J.
LEGAL REPRESENTATIVE: Burd, Bartz & Gutenkauf
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 8
LINE COUNT: 406
AB A method of preventing the precipitation of hormone preparations within drug delivery systems that depend on the fluidity of the infusate for proper function. A non-toxic water soluble detergent is dissolved in the hormone solution prior to the introduction of the solution into the drug delivery system. The detergent is added in amount sufficient to prevent precipitation of the hormone during long-term storage in the drug delivery device. According to one form of usage, the hormone-detergent solution is charged to the pressurized drug storage chamber of an implanted infusion pump by injection through the patient's skin. As the

solution is discharged from the delivery device by the constant pressure exerted upon the storage chamber, its low rate of flow is controlled by a restricted fluid passage. The solution is conveyed to an infusion site and diluted by the blood stream.

L440 ANSWER 88 OF 146 USPATFULL
ACCESSION NUMBER: 81:66934 USPATFULL
TITLE: Enkephalin analogues
INVENTOR(S): Hudson, Derek, 23A Elm Rd., Wembley, Middlesex, England
Sharpe, Robert, 99 King House, Ducane Rd., London, W12, England
Szelke, Michael, 10 North Dr., Ruislip, Middlesex, England

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4304715		19811208	<--
APPLICATION INFO.:	US 1980-112122		19800114 (6)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1978-923478, filed on 10 Jul 1978, now patented, Pat. No. US 4198398

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1979-20124	19790608

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Larson and Taylor
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds corresponding in structure to enkephalin or polypeptide analogues thereof, wherein one or more peptide links of the enkephalin or analogue is represented by a group or groups the same or different selected from dimethylene, hydroxydimethylene, methylene-imino and ketomethylene groups and/or wherein adjacent peptide bond nitrogen atoms are linked by a carbonyl or thiocarbonyl group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 89 OF 146 USPATFULL
ACCESSION NUMBER: 81:58776 USPATFULL
TITLE: Chemiluminescent phthalhydrazide-labeled protein and polypeptide conjugates
INVENTOR(S): Buckler, Robert T., Edwardsburg, MI, United States
Schroeder, Hartmut R., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4297273		19811027	<--
APPLICATION INFO.:	US 1980-111809		19800114 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1978-927621, filed on 24 Jul 1978, now Defensive Publication No.
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 605
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chemiluminescent-labeled conjugates of the formula: ##STR1## wherein one of R.sup.1 and R.sup.2 is hydrogen and the other is --NR.sup.3 R.sup.4 ; R.sup.3 is hydrogen or straight chain alkyl containing 1-4 carbon atoms and R.sup.4 is

L(CO)--HN--(CH.sub.2).sub.n

wherein n=2-8 and L(CO)-- is an antigenic protein or polypeptide bound through an amide bond. The labeled conjugates are useful as reagents in specific binding assays for determining antigenic proteins or polypeptides, or their binding partners, in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 90 OF 146 USPATFULL
ACCESSION NUMBER: 81:47741 USPATFULL
TITLE: Charge effects in enzyme immunoassays
INVENTOR(S): Gibbons, Ian, Menlo Park, CA, United States
Rowley, Gerald L., Cupertino, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4287300		19810901	<--
APPLICATION INFO.:	US 1979-61099		19790726	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1,7
LINE COUNT: 1855
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for determining a member of a specific binding pair-ligand and receptor (antiligand). Reagents employed include a first modified member which provides an electrical field due to the presence of a plurality of ionic charges and a second modified member labeled with a component of a signal producing system, which system may have one or more components. The average proximity in the assay medium of the first and second modified members is related to the amount of analyte, where the observed signal from the signal producing system is related to the effect of the electrical field on the signal producing system.

Also, compositions are provided, as well as reagents, in predetermined ratios for optimizing the signal response to variations in analyte concentration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 91 OF 146 USPATFULL
ACCESSION NUMBER: 81:46773 USPATFULL
TITLE: Enkephalin analogues
INVENTOR(S): Hudson, Derek, 23A Elm Rd., Wembley, Middlesex, England
Sharpe, Robert, 99 King House, Ducane Rd., London W12 OHS, England
Szelke, Michael, 10 North Dr., Ruislip, Middlesex, England

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 30731		19810901	<--
	US 4198398		19800415	(Original)
APPLICATION INFO.:	US 1980-178345		19800814	(6)

US 1978-923478 19780710 (Original)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1977-29207	19770712
	GB 1977-51159	19771208

DOCUMENT TYPE: Reissue
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Larson and Taylor
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds corresponding in structure to enkephalin or polypeptide analogues thereof, wherein one or more peptide links of the enkephalin or analogue is represented by a group or groups the same or different selected from dimethylene, methylene-imino and keto-methylene groups.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 92 OF 146 USPATFULL
ACCESSION NUMBER: 81:42278 USPATFULL
TITLE: Enzyme bound corticosteroids
INVENTOR(S): Rubenstein, Kenneth E., Menlo Park, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4282325		19810804	<--
APPLICATION INFO.:	US 1979-36929		19790507	(6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1977-857145, filed on 5 Dec 1977, now patented, Pat. No. US 4203802 which is a division of Ser. No. US 1976-722964, filed on 13 Sep 1976, now patented, Pat. No. US 4067774 which is a continuation of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned which is a division of Ser. No. US 1972-304157, filed on 6 Nov 1972, now patented, Pat. No. US 3852157 which is a continuation-in-part of Ser. No. US 1971-143609, filed on 14 May 1971, now abandoned And a continuation-in-part of Ser. No. US 1977-802683, filed on 2 Jun 1977, now patented, Pat. No. US 4190496 which is a continuation of Ser. No. US 1977-760499, filed on 19 Jan 1977, now patented, Pat. No. US 4191613 which is a continuation-in-part of Ser. No. 722964
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tanenholtz, Alvin E.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 3495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as "ligands") and binding an enzyme to the ligand or ligand counterfeit to provide an "enzyme-bound-ligand", an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efficiencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 93 OF 146 USPATFULL
ACCESSION NUMBER: 81:40928 USPATFULL
TITLE: Double antibody for enhanced sensitivity in immunoassay
INVENTOR(S): Zuk, Robert F., San Francisco, CA, United States
Gibbons, Ian, Menlo Park, CA, United States
Rowley, Gerald L., Cupertino, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4281061		19810728	<--
APPLICATION INFO.:	US 1979-61542		19790727	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1497
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions are provided for performing homogeneous immunoassays. The method involves having a signal producing system, which provides a detectable signal, which system includes a macromolecular member. The determination of the analyte, which is a member of a specific binding pair consisting of a ligand and its homologous receptor, is performed by creating an extensive matrix in the assay medium by having in the assay medium in addition to the analyte, ligand labeled with one of the members of the signal producing system, antiligand either present as the analyte or added, a polyvalent receptor for antiligand, the macromolecular member of the signal producing system, and any additional members of the signal producing system. The labeled ligand, antiligand, and polyvalent receptor for the antiligand create a matrix which modulates, e.g. inhibits, the approach of the macromolecular member of the signal producing system to the labeled ligand. The extent and degree of formation of the matrix is dependent upon the concentration of the analyte in the medium. By comparing the signal from an assay medium having an unknown amount of analyte, with a signal obtained from an assay medium having a known amount of analyte, the amount of analyte in the unknown sample may be determined qualitatively or quantitatively.

Kits are provided having predetermined amounts of the various reagents to allow for enhanced sensitivity of the method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 94 OF 146 USPATFULL
ACCESSION NUMBER: 81:40820 USPATFULL
TITLE: Glycosylated analogs of somatostatin
INVENTOR(S): Guillemin, Roger C. L., La Jolla, CA, United States
Lavielle, Solange, San Diego, CA, United States
Brazeau, Jr., Paul E., San Diego, CA, United States
Ling, Nicholas C., San Diego, CA, United States
Benoit, Robert A., San Diego, CA, United States
PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, San Diego,

CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4280953		19810728	<--
APPLICATION INFO.:	US 1979-92647		19791108	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Fitch, Even, Tabin, Flannery & Welsh
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Somatostatin (SS) is modified to incorporate a carbohydrate moiety in the peptide chain by linkage to either Asn, Ser or Thr. The modified SS peptide analog may have the formula: ##STR1## wherein R.sub.1 is preferably a hexose or amino-hexose, such as glucose or N-acetylglucosamine. Alternatively, the carbohydrate can be linked to Ser or Thr by an ether bond. Such glycosomatostatins have an extended biological half-life compared to the parent peptide and substantially the same potency. Modifications and substitutions with respect to other amino acid residues in the chain can be made in the glycopeptides, for the purpose of increasing the effectiveness of SS analogs in other ways, and such increased effectiveness is a characteristic of the glycosomatostatin along with its longer-acting biological effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 95 OF 146 USPATFULL
ACCESSION NUMBER: 81:39777 USPATFULL
TITLE: Specific binding assay employing an enzyme-cleavable substrate as label
INVENTOR(S): Boguslaski, Robert C., Elkhart, IN, United States
Burd, John F., Elkhart, IN, United States
Carrico, Robert J., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4279992		19810721	<--
APPLICATION INFO.:	US 1979-87819		19791023	(6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1978-886094, filed on 13 Mar 1978, now patented, Pat. No. US 4226978
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2039
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved specific binding assay method and reagent for determining a ligand in a liquid medium employing, as an enzyme-cleavable substrate label, a residue having the formula:

G--D--R

wherein G is a glycone, D is a dye indicator moiety, and R is a linking group through which the label residue is covalently bound to a binding component of a conventional binding assay system, such as the ligand, an analog thereof, or a specific binding partner thereof. The monitored characteristic of the label is the release of a detectable product,

usually a fluorogen or chromogen, upon enzymatic cleavage of the glycosidic linkage between the glycone and the dye indicator moiety. The assay method may follow a homogeneous or heterogeneous format. The preferred glycone is a .beta.-galactosyl group and the preferred dye indicator moiety is an umbelliferone residue. The improved assay is particularly suited to the determination of haptens, such as drugs, and antigenic proteins and polypeptides, including antibodies, following a homogeneous competitive binding assay format.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 96 OF 146 USPATFULL
ACCESSION NUMBER: 81:37013 USPATFULL
TITLE: Tetrapeptidehydrazide derivatives
INVENTOR(S): Fujino, Masahiko, Hyogo, Japan
Shinagawa, Susumu, Osaka, Japan
Kawai, Kiyohisa, Kyoto, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4277394		19810707	<--
APPLICATION INFO.:	US 1979-90021		19791031	(6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1979-32503, filed on 23 Apr 1979, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
ASSISTANT EXAMINER: Hazel, Blondel
LEGAL REPRESENTATIVE: Wegner & Bretschneider
NUMBER OF CLAIMS: 90
EXEMPLARY CLAIM: 1
LINE COUNT: 2552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel tetrapeptidehydrazide derivatives, inclusive of a pharmacologically acceptable acid addition salt thereof, which has the general formula (I): ##STR1## [wherein R.sub.1 is hydrogen or lower alkyl; R.sub.2 is hydrogen or the side chain of a D-.alpha.-amino acid; R.sub.3 is hydrogen or lower alkyl; R.sub.4 is hydrogen, or a saturated or unsaturated and straight or branched lower aliphatic acyl group which may optionally be substituted by hydroxy, amino, lower alkoxy, halogen, oxo, lower alkylthio or lower alkylthiooxide], are useful as analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 97 OF 146 USPATFULL
ACCESSION NUMBER: 81:34595 USPATFULL
TITLE: Macromolecular environment control in specific receptor assays
INVENTOR(S): Litman, David J., Palo Alto, CA, United States
Harel, Zvi, Stanford, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4275149		19810623	<--
APPLICATION INFO.:	US 1978-964099		19781124	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wiseman, Thomas G.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 46

EXEMPLARY CLAIM: 1,19,46
LINE COUNT: 2543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions are provided for performing protein binding assays involving a homologous pair consisting of ligand and receptor for the ligand. The method employs a label conjugated to a member of said homologous pair and a uniformly dispersed discontinuous phase of discrete particles in a continuous aqueous phase, where the discrete particles create microenvironments which allow for discrimination between the label associated with the particle--in a discontinuous phase--and the label in the continuous phase.

Various conjugates and particles are provided which find use in the subject method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 98 OF 146 USPATFULL
ACCESSION NUMBER: 81:30260 USPATFULL
TITLE: Process for the manufacture of cystine-containing peptides
INVENTOR(S): Kamber, Bruno, Basel, Switzerland
Rittel, Werner, Basel, Switzerland
PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4271068		19810602	<--
APPLICATION INFO.:	US 1976-685857		19760513 (5)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 1972-296406, filed on 10 Oct 1972, now Defensive Publication No. which is a continuation-in-part of Ser. No. US 1969-818109, filed on 21 Apr 1969, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Almaula, Prabodh I.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns an improved process for the manufacture of cystine-containing peptides from cysteine-containing aminoacid sequences whose mercapto groups are protected by trityl groups, wherein the S-trityl cysteine-containing sequences are directly oxidized with iodine to yield the cystine disulfide bond.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 99 OF 146 USPATFULL
ACCESSION NUMBER: 81:24741 USPATFULL
TITLE: Piperazine derivatives
INVENTOR(S): Gootjes, Johan, Heerhugowaard, Netherlands
PATENT ASSIGNEE(S): Gist Brocades, N.V., Delft, Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4265894		19810505	<--
APPLICATION INFO.:	US 1979-90257		19791101 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1977-860460, filed on 14 Dec 1977, now patented, Pat. No. US 4202896

	NUMBER	DATE

PRIORITY INFORMATION:	GB 1976-52223	19761214
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Daus, Donald G.	
ASSISTANT EXAMINER:	Turnipseed, James H.	
LEGAL REPRESENTATIVE:	Burns, Robert E., Lobato, Emmanuel J., Adams, Bruce L.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1,21	
LINE COUNT:	643	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Piperazine derivatives of the general formula ##STR1## wherein R.sub.1 -R.sub.9 are the same or different and each represents a hydrogen or halogen atom or a lower alkyl or lower alkoxy group, n is 2 or 3 and X represents a group (CH.sub.2).sub.m (in which m is 1, 2, 3 or 4) or a group --CH.sub.2 --CH.dbd.CH--, having methylene linked to the piperazine group, and acid addition and quaternary ammonium salts thereof, are described.

The compounds exhibit a strong specific dopaminergic activity.

Also described are methods for their preparation and use as therapeutic agents in the form of therapeutic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 100 OF 146 USPATFULL

ACCESSION NUMBER:	81:21966 USPATFULL	
TITLE:	3-Lower alkoxy-6-trichloromethylpyridazines and their use as fungicides	
INVENTOR(S):	Rothgery, Eugene F., North Branford, CT, United States Schroeder, Hansjuergen A., Hamden, CT, United States	
PATENT ASSIGNEE(S):	Olin Corporation, New Haven, CT, United States (U.S. corporation)	

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4263297		19810421	<--
APPLICATION INFO.:	US 1977-844003		19771020	(5)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Robinson, Douglas W.
LEGAL REPRESENTATIVE:	Simons, William A., O'Day, Thomas P.
NUMBER OF CLAIMS:	2
EXEMPLARY CLAIM:	1
LINE COUNT:	298

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 3-halo- and 3-lower alkoxy-6-trichloromethylpyridazine compounds are disclosed as fungicides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 101 OF 146 USPATFULL

ACCESSION NUMBER:	81:21707 USPATFULL	
TITLE:	5-Cyano-2,3-dihydrobenzofurans useful as herbicides	
INVENTOR(S):	Gates, Peter S., Cambridge, England Baldwin, Derek, Cambridge, England Wilson, Carol A., Saffron Walden, England Gillon, John, Cambridge, England	
PATENT ASSIGNEE(S):	Fisons Limited, London, England (non-U.S. corporation)	

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4263037		19810421	<--
APPLICATION INFO.:	US 1979-62511		19790727	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1978-31646	19780729
	GB 1978-41982	19781024

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,5
LINE COUNT: 1994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides herbicidally-active 2,3-dihydro-5-cyanobenzofurans of the formula: ##STR1## (wherein: R.sup.1 and R.sup.2 together represent .dbd.O or R.sup.1 represents hydrogen and R.sup.2 represents hydrogen, hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, halogen, isothiocyanato, amino, alkylamino, dialkylamino, arylamino, acylamino, alkoxycarbonylamino, alkylthiocarbonylamino, N-bonded heterocyclyl, cyano or alkylthio; R.sup.3 and R.sup.4 together represent alkylene or each represent hydrogen or alkyl; and R.sup.5, R.sup.6 and R.sup.7, which may be the same or different, each represent hydrogen, halogen, alkyl, alkoxy, acyl or cyano), processes for their preparation and herbicidal compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 102 OF 146 USPATFULL
ACCESSION NUMBER: 81:20478 USPATFULL
TITLE: Bis-phthalimide intermediates
INVENTOR(S): Boguslaski, Robert C., Elkhart, IN, United States
Carrico, Robert J., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4261893		19810414	<--
APPLICATION INFO.:	US 1979-67801		19790820	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1978-927622, filed on 24 Jul 1978, now Defensive Publication No. which is a continuation-in-part of Ser. No. US 1978-894836, filed on 10 Apr 1978, now Defensive Publication No. which is a continuation of Ser. No. US 1976-667996, filed on 18 Mar 1976, now abandoned which is a continuation-in-part of Ser. No. US 1975-572008, filed on 28 Apr 1975, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Eakin, M. C.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 1184
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bis-phthalimide intermediates of the formula: ##STR1## wherein one of R.sup.9 and R.sup.10 is hydrogen and the other is --NR.sup.11 R.sup.12 ; R.sup.11 is hydrogen or straight stain alkyl containing 1-4 carbon atoms and R.sup.12 is ##STR2## wherein n=1-3. The compounds are intermediates in the synthesis of chemiluminescent-labeled conjugates which are useful as reagents in specific binding assays for determining ligands or their specific binding partners in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 103 OF 146 USPATFULL
ACCESSION NUMBER: 81:20470 USPATFULL
TITLE: Novel somatostatin analogue
INVENTOR(S): Sakakibara, Shunpei, Suita, Japan
Shigeta, Yukio, Kobe, Japan
PATENT ASSIGNEE(S): Shiraimatsu Shingaku Co., Ltd., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4261885		19810414	<--
APPLICATION INFO.:	US 1979-83942		19791011	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-133055	19781028

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel somatostatin analogs exhibiting high activity in inhibiting insulin glucagon and **growth hormone** secretion are depicted by the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 104 OF 146 USPATFULL
ACCESSION NUMBER: 81:16521 USPATFULL
TITLE: Disulfide derivatives having S--S exchange reactivity
INVENTOR(S): Fujii, Tadashiro, Mishima, Japan
Nakagawa, Nobuaki, Shizuoka, Japan
Kotani, Kikuo, Shizuoka, Japan
PATENT ASSIGNEE(S): Toyo Jozo Kabushiki Kaisha, Shizuoka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4258193		19810324	<--
APPLICATION INFO.:	US 1979-57503		19790713	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-85900	19780713

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Whittenbaugh, Robert C.
LEGAL REPRESENTATIVE: Young & Thompson
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 515
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A disulfide derivative, having S--S exchange reactivity, of the formula

R.sub.1 --S--S--R.sub.2 --CO--R.sub.3).sub.n R.sub.4 [I]

wherein R.sub.1 is 2-benzothiazolyl or 2-pyridyl-N-oxide, R.sub.2 is alkylene having optionally free or protected functional groups, R.sub.3 is the carboxyl residue of an amino acid or lower polypeptide, R.sub.4 is carboxyl or a reactive derivative thereof or protected carboxyl or imidate, and n is 0 or 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 105 OF 146 USPATFULL
ACCESSION NUMBER: 81:9349 USPATFULL
TITLE: N-succinimidyl haloacetyl aminobenzoates as coupling agents
INVENTOR(S): Weltman, Joel K., 164 Summit Ave., Providence, RI, United States 02906

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4251445		19810217	<--
APPLICATION INFO.:	US 1979-93607		19791113	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1978-889726, filed on 24 Mar 1978, now patented, Pat. No. US 4218539
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Eakin, M. C.
LEGAL REPRESENTATIVE: Crowley, Richard P.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel enzyme conjugates useful in immunoassay methods are prepared with the use of a novel coupling reagent of N-succinimidyl (4-iodoacetyl) aminobenzoate by reacting the coupling reagent, firstly, with an amino-containing macromolecule, and, thereafter, with a sulfhydryl-containing enzyme, the enzyme conjugate prepared in a high yield and of high specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 106 OF 146 USPATFULL
ACCESSION NUMBER: 81:6694 USPATFULL
TITLE: Immunochemical process of measuring physiologically active substances
INVENTOR(S): Mochida, Ei, Tokyo, Japan
Ogawa, Nobuhisa, Omiya, Japan
Shinkai, Hiroyuki, Kawagoe, Japan
Hashimoto, Masakatsu, Tokyo, Japan
PATENT ASSIGNEE(S): Mochida Seiyaku Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4248965		19810203	<--
APPLICATION INFO.:	US 1977-838947		19771003	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1976-120621	19761007
	JP 1976-120622	19761007

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shapiro, Lionel M.
LEGAL REPRESENTATIVE: Brisebois & Kruger
NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immunochemical measurement by either (1) the reaction of the measurement substance with the insolubilized substance and then the reaction of the reaction product of the first procedure with the labeled substance or (2) the reaction of the measurement substance with the labelled substance and then the reaction of the resulting reaction product with the insolubilized substance, or (3) the simultaneous reaction of the three substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 107 OF 146 USPATFULL
ACCESSION NUMBER: 80:61933 USPATFULL
TITLE: 5,6-Benzo analogues of prostaglandin
INVENTOR(S): Buckler, Robert T., Edwardsburg, MI, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4238623		19801209	<--
APPLICATION INFO.:	US 1976-671423		19760329	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Killos, Paul J.
LEGAL REPRESENTATIVE: Davidson, Louis E.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1386
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are prostaglandin analogues having the structural formula, ##STR1## in which: T is selected from the group consisting of carboxyl, alkoxycarbonyl or cyano;

M is selected from the group consisting of carbonyl, R-hydroxymethylene or S-hydroxymethylene;

L is selected from the group consisting of methylene or methine, provided L is methine only if J is methine;

J is selected from the group consisting of methylene, ethylene, R-hydroxymethylene, S-hydroxymethylene or methine, provided J is methine only if L is methine;

W is selected from the group consisting of ##STR2## T.sub.1 and T.sub.2 are attached to adjacent carbon atoms; T.sub.1 is selected from the group consisting of hydrogen or phenyl, provided T.sub.1 is phenyl only if T.sub.2 is lower alkyl;

T.sub.2 is selected from the group consisting of n-pentyl or lower alkyl, provided T.sub.2 is lower alkyl only if T.sub.1 is phenyl; or

T.sub.1 and T.sub.2 are joined together to form an alkylene group of 4 or 6 carbon atoms. Also disclosed are methods for preparing such prostaglandin analogues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 108 OF 146 USPATFULL
ACCESSION NUMBER: 80:61791 USPATFULL
TITLE: Novel cyclopeptides
INVENTOR(S): Rink, Hans, Riehen, Switzerland

Kamber, Bruno, Arlesheim, Switzerland
Sieber, Peter, Reinach, Switzerland
PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4238481		19801209	<--
APPLICATION INFO.:	US 1978-942565		19780915	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	LU 1977-78191	19770928

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Maitner, John J., Almaula, Prabodh I.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 2151
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sulphur-free cyclopeptides with somatostatin-analogous aminoacid partial sequences, of the formula ##STR1## in which R is Asn, Ala or de-R, trp is D-Trp or L-Trp, which can be substituted in the benzene ring by halogen atoms or nitro groups, W is a free or etherified hydroxyl group or halogen atom present as a substituent on the benzene ring of the L-phenylalanine radical, or is hydrogen, X is the radical of an .omega.-amino-lower alkane-(mono or di)-carboxylic acid or de-X and Y is the radical of an .omega.-amino-lower alkane-(mono or di)-carboxylic acid or de-Y, and also acid addition salts and complexes thereof have biological properties similar to those of somatostatin and can be used, especially in the form of pharmaceutical preparations, for the treatment of excessive secretion of somatotropin, insulin and/or glucagon. The compounds according to the invention are obtained by cyclising a corresponding linear peptide compound in which the .epsilon.-amino group of the lysine radical and, if desired, also the hydroxyl group of the threonine radical are protected and detaching the protective groups which are present.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 109 OF 146 USPATFULL
ACCESSION NUMBER: 80:61705 USPATFULL
TITLE: Dimethyl 7-[.omega.-N-(phthalimido)alkyl]aminonaphthalene-1,2-dicarboxylates
INVENTOR(S): Buckler, Robert T., Edwardsburg, MI, United States
Schroeder, Hartmut R., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4238395		19801209	<--
APPLICATION INFO.:	US 1979-82040		19791005	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1978-927286, filed on 24 Jul 1978, now Defensive Publication No.
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Eakin, M. C.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 556
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB -Dimethyl 7-[.omega.-N-(phthalimido)alkyl]aminonaphthalene -1,2-dicarboxylates of the formula: ##STR1## wherein R is hydrogen or straight chain alkyl containing 1-4 carbon atoms and n=2-6. The compounds are intermediates in the synthesis of chemiluminescent naphthalene-1,2-dicarboxylic acid hydrazide-labeled conjugates which are useful as reagents in specific binding assays for determining ligands or their specific binding partners in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 110 OF 146 USPATFULL
ACCESSION NUMBER: 80:49955 USPATFULL
TITLE: Amino-functionalized phthalhydrazides
INVENTOR(S): Buckler, Robert T., Edwardsburg, MI, United States
Schroeder, Hartmut R., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4226993		19801007	<--
APPLICATION INFO.:	US 1979-34250		19790430 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1978-927621, filed on 24 Jul 1978, now Defensive Publication No.
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Turnipseed, James H.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 587
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Amino-functionalized phthalhydrazides of the formula: ##STR1## wherein one of R.sup.5 and R.sup.6 is hydrogen and the other is --NR.sup.7 R.sup.8 ; R.sup.7 is hydrogen or straight chain alkyl containing 1-4 carbon atoms and R.sup.8 is

H.sub.2 N--CH.sub.2).sub.n

wherein n=2-8. The compounds are intermediates in the synthesis of chemiluminescent phthalhydrazide-labeled conjugates which are useful as reagents in specific binding assays for determining ligands or their specific binding partners in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 111 OF 146 USPATFULL
ACCESSION NUMBER: 80:48328 USPATFULL
TITLE: Chemiluminescent naphthalene-1,2-dicarboxylic acid hydrazide-labeled polypeptides and proteins
INVENTOR(S): Buckler, Robert T., Edwardsburg, MI, United States
Schroeder, Hartmut R., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4225485		19800930	<--
APPLICATION INFO.:	US 1978-927286		19780724 (5)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1
LINE COUNT: 598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chemiluminescent-labeled conjugates of the formula: ##STR1## wherein R is hydrogen or straight chain alkyl containing 1-4 carbon atoms, n=2-6 and L(CO-- is a specifically bindable ligand, such as an antigenic protein or polypeptide, a hapten or an antibody, or a binding analog thereof, bound through an amide bond; and intermediates produced in the synthesis of such conjugates. The labeled conjugates are useful as reagents in specific binding assays for determining ligands or their specific binding partners in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 112 OF 146 USPATFULL
ACCESSION NUMBER: 80:45377 USPATFULL
TITLE: Certain herbicidal sulfonates and sulfamates
INVENTOR(S): Gates, Peter S., Cambridge, England
Baldwin, Derek, Cambridge, England
PATENT ASSIGNEE(S): Fisons Limited, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4222767		19800916	<--
APPLICATION INFO.:	US 1979-22599		19790321	(6)
RELATED APPLN. INFO.:	Division of Ser. No. US 1978-875189, filed on 3 Feb 1978, now patented, Pat. No. US 4162154			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1977-4847	19770205
	GB 1977-4848	19770205
	GB 1977-4849	19770205
	GB 1977-32839	19770805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1,11
LINE COUNT: 1238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides herbicidally-active sulphonates of the formula ##STR1## wherein X represents a group --CHR.sup.3 --OR.sup.4 and Y represents a group --OR.sup.5, or X and Y together represent a group --CHR.sup.3 --O-- or a group --CHR.sup.3 --O--Z--O--, the free oxygen atom of which is attached to the benzene ring; R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each represent hydrogen or C 1 to 6 alkyl, or R.sup.1 and R.sup.2 together or R.sup.2 and R.sup.3 together form a C 3 to 6 alkylene chain; R.sup.4 and R.sup.5, which may be the same or different, each represent hydrogen, C 1 to 6 alkyl, C 2 to 6 alkenyl, C 2 to 6 alkynyl, phenyl, a group --C(.dbd.O)R.sup.10 or a group --SO.sub.2 R.sup.11 ; R.sup.6, R.sup.7 and R.sup.8, which may be the same or different, each represent hydrogen, C 1 to 6 alkyl, halogen, cyano, C 2 to 6 carboxylic acyl, or C 1 to 4 alkoxy; R.sup.9 represents C 1 to 6 alkyl, phenyl or C 7 to 10 phenylalkyl (each of which may be unsubstituted or substituted by one or more chlorine or bromine atoms, C 1 to 4 alkyl groups, C 1 to 4 alkoxy groups or nitro groups), C 5 to 7 cycloalkyl, C 1 to 4 alkylamino, or dialkylamino wherein each alkyl moiety has from 1 to 4 carbon atoms; R.sup.10 represents C 1 to 6 alkyl or alkoxy, C 2 to 6 alkenyl or alkenyloxy, C 2 to 6 alkynyl or alkynyloxy, phenyl, phenoxy, phenylamino, C 1 to 6 alkylamino or dialkylamino wherein each alkyl moiety has from 1 to 6 carbon atoms, each of the groups which R.sup.10 may represent being unsubstituted or

substituted by one or more halogen atoms or C 1 to 4 alkoxy groups; R.sup.11 represents C 1 to 6 alkyl, phenyl, C 1 to 6 alkylamino or dialkylamino each of the alkyl moieties thereof having from 1 to 6 carbon atoms, each of the groups which R.sup.11 may represent being unsubstituted or substituted by one or more halogen atoms or C 1 to 4 alkoxy groups; Z represents a group of formula --S(.dbd.O)n, --CR.sup.12 R.sup.13 or --P(.dbd.Q)(OR.sup.14)--; n represents 1 or 2; R.sup.12 and R.sup.13, which may be the same or different, each present hydrogen, C 1 to 6 alkyl or alkoxy, C 2 to 6 alkenyl or alkynyl, phenyl, phenoxy, cyano or (C 1 to 6 alkoxy)carbonyl, or R.sup.12 and R.sup.13 together represent an oxygen atom, a sulphur atom, a C 3 to 6 alkylene chain or a C 1 to 6 alkylimino group or a phenylimino group; and R.sup.14 represents C 1 to 6 alkyl; and Q represents oxygen or sulphur, together with processes for their preparation and herbicidal compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 113 OF 146 USPATFULL
ACCESSION NUMBER: 80:40663 USPATFULL
TITLE: Enzyme conjugates and method of preparation and use
INVENTOR(S): Weltman, Joel K., 164 Summit Ave., Providence, RI, United States 02906

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4218539		19800819	<--
APPLICATION INFO.:	US 1978-899726		19780324 (5)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shapiro, Lionel M.
LEGAL REPRESENTATIVE: Crowley, Richard P.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel enzyme conjugates useful in immunoassay methods are prepared with the use of a novel coupling reagent of N-succinimidyl (4-iodoacetyl) aminobenzoate by reacting the coupling reagent, firstly, with an amino-containing macromolecule, and, thereafter, with a sulfhydryl-containing enzyme, the enzyme conjugate prepared in a high yield and of high specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 114 OF 146 USPATFULL
ACCESSION NUMBER: 80:34316 USPATFULL
TITLE: Bis-phthalimides
INVENTOR(S): Buckler, Robert T., Edwardsburg, MI, United States
Schroeder, Hartmut R., Elkhart, IN, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4212805		19800715	<--
APPLICATION INFO.:	US 1979-34249		19790430 (6)	

RELATED APPLN. INFO.: Division of Ser. No. US 1978-927621, filed on 24 Jul 1978, now Defensive Publication No.
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Eakin, M. C.
LEGAL REPRESENTATIVE: Klawitter, Andrew L.
NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 586
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Bis-phthalimides of the formula: ##STR1## wherein one of R.sup.9 and R.sup.10 is hydrogen and the other is--NR.sup.11 R.sup.12 ; R.sup.11 is hydrogen or straight chain alkyl containing 1-4 carbon atoms and R.sup.12 is ##STR2## wherein n=2-8. The compounds are intermediates in the synthesis of chemiluminescent phthalhydrazide-labeled conjugates which are useful as reagents in specific binding assays for determining ligands or their specific binding partners in liquid media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 115 OF 146 USPATFULL
ACCESSION NUMBER: 80:24329 USPATFULL
TITLE: Inhibitable enzyme amplification assay
INVENTOR(S): Rubenstein, Kenneth E., Menlo Park, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4203802		19800520	<--
APPLICATION INFO.:	US 1977-857145		19771205 (5)	

RELATED APPLN. INFO.: Division of Ser. No. US 1976-722964, filed on 13 Sep 1976, now patented, Pat. No. US 4067774 which is a continuation of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned which is a division of Ser. No. US 1972-304157, filed on 6 Nov 1972, now patented, Pat. No. US 3852157 which is a continuation-in-part of Ser. No. US 1971-143609, filed on 14 May 1971, now abandoned which is a continuation-in-part of Ser. No. US 1977-802683, filed on 2 Jun 1977, now patented, Pat. No. US 4190496 which is a continuation of Ser. No. US 1977-760499, filed on 19 Jan 1977, now Defensive Publication No. which is a continuation of Ser. No. US 1976-722964, filed on 13 Sep 1976, now Defensive Publication No.
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tanenholtz, Alvin E.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 3436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as "ligands") and binding an enzyme to the ligand or ligand counterfeit to provide an "enzyme-bound-ligand", an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efficiencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 116 OF 146 USPATFULL
ACCESSION NUMBER: 80:23357 USPATFULL
TITLE: N-Benzhydryloxyethyl-N-phenylpropyl-piperazines
INVENTOR(S): Gootjes, Johan, Heerhugowaard, Netherlands
PATENT ASSIGNEE(S): Gist-Brocades N.V., Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4202896		19800513	<--
APPLICATION INFO.:	US 1977-860460		19771214	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1976-52223	19761214

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tovar, Jose
LEGAL REPRESENTATIVE: Burns, Robert E., Lobato, Emmanuel J., Adams, Bruce L.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1,10
LINE COUNT: 611
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Piperazine derivatives of the general formula ##STR1## wherein R.sub.1 -R.sub.9 are the same or different and each represents a hydrogen or halogen atom or a lower alkyl or lower alkoxy group, n is 2 or 3 and X represents a group (CH.sub.2).sub.m (in which m is 1, 2, 3 or 4) or a group --CH.sub.2 --CH.dbd.CH--, having methylene linked to the piperazine group, and acid addition and quaternary ammonium salts thereof, are described.

The compounds exhibit a strong specific dopaminergic activity.

Also described are methods for their preparation and use as therapeutic agents in the form of therapeutic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 117 OF 146 USPATFULL
ACCESSION NUMBER: 80:20760 USPATFULL
TITLE: Immunochemical measuring process
INVENTOR(S): Mochida, Ei, Tokyo, Japan
Ogawa, Nobuhisa, Omiya, Japan
Shinkai, Hiroyuki, Kawagoe, Japan
Hashimoto, Masakatsu, Tokyo, Japan
PATENT ASSIGNEE(S): Mochida Seiyaku Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4200436		19800429	<--
APPLICATION INFO.:	US 1977-837434		19770928	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1976-117621	19760930

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marantz, Sidney
LEGAL REPRESENTATIVE: Brisebois & Kruger
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immunochemical process of measuring antigenic substances such as human chorionic gonadotropin, **growth hormone**, insulin, immunoglobulins using a labeled antibody, which makes a monovalent bond to the antigen, and insolubilized antigen.

The labeled monovalent antibody used is a monovalent antibody obtained by digesting the antibody to an antigen to be measured with papain according to Porter's method or by reducing a fragment obtained by digesting the antibody with pepsin according to Peterman's method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 118 OF 146 USPATFULL
ACCESSION NUMBER: 80:18590 USPATFULL
TITLE: Enkephalin analogues
INVENTOR(S): Hudson, Derek, 23A Elm Rd., Wembley, Middlesex, United States
Sharpe, Robert, 99 King House, Ducane Rd., London W12 OHS, United States
Szelke, Michael, 10 North Drive, Ruislip, Middlesex, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4198398		19800415	<--
APPLICATION INFO.:	US 1978-923478		19780710	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1977-29207	19770712
	GB 1977-51159	19771208

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Larson, Taylor and Hinds
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds corresponding in structure to enkephalin or polypeptide analogues thereof, wherein one or more peptide links of the enkephalin or analogue is represented by a group or groups the same or different selected from dimethylene, methylene-imino and keto-methylene groups.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 119 OF 146 USPATFULL
ACCESSION NUMBER: 80:13908 USPATFULL
TITLE: Labeled liposome particle compositions and immunoassays therewith
INVENTOR(S): Ullman, Edwin F., Atherton, CA, United States
Brinkley, John M., Oakland, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4193983		19800318	<--
APPLICATION INFO.:	US 1978-906514		19780516	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fagelson, Anna P.
LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1

LINE COUNT: 1469
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention concerns novel compositions for use in immunoassays, as well as immunoassays employing such novel compositions. The compositions comprise discrete charged colloidal particles comprised of small molecules which particles are capable of retaining their discrete character in an aqueous medium and composed of aggregates of lipophilic and/or amphiphilic organic molecules to which are bound non-covalently a label capable of producing a detectible signal and a ligand or an analog of the ligand capable of competing with a ligand for a ligand receptor. The discrete colloidal particle serves as a hub or nucleus for retaining the ligand or its analog and the label within a limited locus.

The compositions are prepared by individually covalently bonding the ligand and the label, when not naturally lipophilic, to a lipophilic (includes amphiphilic) compound, normally a phospholipid. Depending upon the nature of the particle, the amphiphilic conjugated ligand and label are combined with the particle or alternatively may be combined with the compounds employed for preparing the particle under particle forming conditions. Particles are then obtained having the analog of the ligand and the label bound to the particle.

The compositions find use in immunoassays where an interaction between the label and receptor provides a means for modulating a detectible signal. The interaction can be as a result of quenching or modification of fluorescence, where the label is a fluorescer, steric inhibition of the approach of a signal modifier to the label, such as a label receptor or with an enzyme label, an antienzyme or enzyme inhibitor, the inhibition of cleavage of an enzyme labile bond or the cooperative interaction of two labels, such as two enzymes, where the product of one enzyme is a substrate of another enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 120 OF 146 USPATFULL
ACCESSION NUMBER: 80:10223 USPATFULL
TITLE: Homogeneous enzyme assay for antibodies
INVENTOR(S): Rubenstein, Kenneth E., Menlo Park, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PATENT ASSIGNEE(S): Syva Company, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4190496		19800226	<--
APPLICATION INFO.:	US 1977-802683		19770602	(5)

DISCLAIMER DATE: 19910618
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1977-760499, filed on 19 Jan 1977, now Defensive Publication No. which is a continuation-in-part of Ser. No. US 1976-722964, filed on 13 Sep 1976, now patented, Pat. No. US 4067774 which is a continuation of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned And a continuation-in-part of Ser. No. US 1976-689234, filed on 24 May 1976, now patented, Pat. No. US 4046636 which is a continuation-in-part of Ser. No. US 1974-481022, filed on 20 Jun 1974, now abandoned which is a division of Ser. No. US 1972-304157, filed on 6 Nov 1972, now patented, Pat. No. US 3852157 which is a continuation-in-part of Ser. No. US 1971-143609, filed on 14 May 1971, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tanenholtz, Alvin E.

LEGAL REPRESENTATIVE: Rowland, Bertram I.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 3567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as "ligands") and binding an enzyme to the ligand or ligand counterfeit to provide an "enzyme-bound-ligand", an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efficiencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

The subject method may also be used for determining receptors, employing the same procedure, except for not including receptor as a reagent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 121 OF 146 USPATFULL
ACCESSION NUMBER: 80:7970 USPATFULL
TITLE: Immunological detection of Neisseria bacteria via labelled antibodies
INVENTOR(S): Weetall, Howard H., Big Flats, NY, United States
PATENT ASSIGNEE(S): Corning Glass Works, Corning, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4188371		19800212	<--
APPLICATION INFO.:	US 1977-837362		19770928	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Padgett, Benjamin R.
ASSISTANT EXAMINER: Nucker, Christine M.
LEGAL REPRESENTATIVE: Maycock, William E., Janes, Jr., Clinton S.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 516
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is concerned with two closely related assay methods for detecting the presence of Neisseria bacteria in a fluid sample. Both of the methods utilize radiolabelled antibodies specific to the enzyme released upon lysis of the bacteria. In the first method, denominated immunoradiometric assay (IRMA), the enzyme is reacted with soluble purified radioactive antibodies. In the second method, known variously as "two-site IRMA", "junction test", or "sandwich technique", contemplates initial insolubilization of the enzyme and thereafter the reaction with soluble purified radioactive antibodies.

The structure and composition of the enzyme released upon lysis of Neisseria bacteria are not fully comprehended but it has the capability of oxidizing 1,2-propanediol and reducing nicotinamide-adenine-dinucleotide (NAD). This has led to the name 1,2-propanediol dehydrogenase being proposed for the enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L440 ANSWER 122 OF 146 USPATFULL
ACCESSION NUMBER: 80:4484 USPATFULL
TITLE: Immunochemical measuring method using second antigenic substance
INVENTOR(S): Mochida, Ei, Tokyo, Japan
Ogawa, Nobuhisa, Omiya, Japan
Shinkai, Hiroyuki, Kawagoe, Japan
Hashimoto, Masakatsu, Tokyo, Japan
PATENT ASSIGNEE(S): Mochida Seiyaku Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4185084		19800122	<--
APPLICATION INFO.:	US 1977-838846		19771003	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1976-120623	19761007

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Sebastian, Leland A.
LEGAL REPRESENTATIVE: Brisebois & Kruger
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1,4
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 568
AB An immunochemical measuring method using a second antigenic substance and a labeled antibody to the second antigenic substance.

An unknown amount of an antigen (Ag 1) to be measured and a given amount of a conjugate (Ag 1-Ag 2) coupled a second antigen (Ag 2) to the Ag 1 are reacted with a given amount of an antibody (Ab 1) to the Ag 1. Ag 1-Ag 2 bind to the Ab 1 in proportion to their respective amount, forming an Ab 1-Ag 1-Ag 2 complex. Then, by reaction of the complex with a labeled antibody (labeled Ab 2) to the Ag 2, Ab 1-Ag 1-Ag 2-labeled Ab 2 is formed. It is possible to estimate the amount of Ag 1 to be measured by determining the activity of labeled Ab 2 attached to the complex.

L440 ANSWER 123 OF 146 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 85:94935 SCISEARCH
THE GENUINE ARTICLE: ACE28
TITLE: **GROWTH HORMONE**-PRODUCING PITUITARY-ADENOMA WITH **CRYSTAL**-LIKE AMYLOID IMMUNOHISTOCHEMICALLY POSITIVE FOR **GROWTH-HORMONE**
AUTHOR: MORI H (Reprint); MORI S; SAITOH Y; MORIWAKI K; IIDA S; MATSUMOTO K
CORPORATE SOURCE: OSAKA UNIV, SCH MED, DEPT PATHOL, 3-57 NAKANOSHIMA 4, KITA KU, OSAKA 530, JAPAN (Reprint); OSAKA UNIV, SCH MED, DEPT NEUROSURG, OSAKA 530, JAPAN; OSAKA UNIV, SCH MED, DEPT INTERNAL MED 2, OSAKA 530, JAPAN
COUNTRY OF AUTHOR: JAPAN
SOURCE: CANCER, (**1985**) Vol. 55, No. 1, pp. 96-102.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE; CLIN
LANGUAGE: ENGLISH
REFERENCE COUNT: 21

L440 ANSWER 124 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:438433 CAPLUS
DOCUMENT NUMBER: 113:38433
TITLE: Effects of transgenes for human and bovine

growth hormones on age-related changes in ovarian morphology in mice

AUTHOR(S): Mayerhofer, Artur; Weis, Judith; Bartke, Andrzej; Yun, June S.; Wagner, Thomas E.

CORPORATE SOURCE: Sch. Med., South. Illinois Univ., Carbondale, IL, 62901-6512, USA

SOURCE: Anat. Rec. (**1990**), 227(2), 175-86
CODEN: ANREAK; ISSN: 0003-276X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The expression of human **growth hormone** (GH) in female transgenic mice (TM) is accompanied by sterility, whereas females expressing the bovine GH gene are fertile. A light and electron microscopic study was conducted to examine whether expression of these foreign GH genes in mice is assocd. with structural changes in the ovaries of young adult (3-mo-old) or middle-aged (7-mo-old) mice. One ovary was serially sectioned for light microscopy, and the contralateral ovary was used for electron microscopy. The nos. of preantral (PAF) and antral (AF) follicles, with and without signs of atresia, as well as the no. of corpora lutea (CL), were detd. As expected, body wts. of both young and middle-aged TM of either kind were significantly increased over those of their normal littermates. However, the ovarian wts. of TM and control mice did not differ. In the 3-mo-old TM, the ovaries were grossly normal at the light microscopic level. However, significantly more CL were counted in the ovaries of human GH-TM than in those of the other two groups. The percentage of PAF with signs of atresia was significantly reduced in ovaries of bovine GH-TM compared with the other groups, while the percentages of AF undergoing atresia were significantly different in all groups, with the highest values in normal animals, intermediate ones in human GH-TM, and the lowest in bovine GH-TM. In the ovaries of 7-mo-old human GH-TM, conspicuous clusters of large, foamy light cells were present in the cortex and the medulla. Ultrastructurally, these cells appeared as interstitial cells in various stages of degeneration, accumulating cholesterol **crystal**-like inclusions. Although degeneration of interstitial cells was obsd. also in the other types of animals, it involved usually only single cells and no cytoplasmic **crystal** inclusions. Moreover, in the ovaries of 7-mo-old human GH-TM the percentages of PAF were significantly reduced and the percentages of AF significantly increased compared with those in the two other groups, which did not differ from each other with respect to these parameters. No significant differences in the nos. of CL were found between the groups. Percentages of atretic PAF were significantly reduced in bovine GH-TM and comparable in the other two groups, while percentages of atretic AF were not different between normal and bovine GH-TM, but were significantly increased in human GH-TM. The results support the idea that the ovary, although not enlarged in either type of TM, is affected by chronic exposure to heterologous GH. Bovine GH, which in the mouse exhibits isolated somatotrophic activity, reduced the morphol. signs of atresia in TM. Human GH, which in the mouse has addnl. lactotrophic activity, caused complex, age-related changes, including acceleration of follicular development, increased atresia, and massive degeneration of interstitial cells. These results suggest that the expression of human GH transgene leads to accelerated aging of the mouse ovary and that this effect is likely due to the combination of somatotrophic and lactotrophic activities of human GH in this species.

L440 ANSWER 125 OF 146 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:809 CAPLUS

DOCUMENT NUMBER: 112:809

TITLE: Steric structure of human somatotropin at a 3 .ANG. resolution

AUTHOR(S): Pavlovskii, A. G.; Borisova, S. N.; Strokopytov, B. V.; Vagin, A. A.; Vainshtein, B. K.; Alkimavicius, G.; Naktinis, V.; Janulaitis, E.; Rubtsov, P. M.

CORPORATE SOURCE: Inst. Mol. Biol., Moscow, USSR

SOURCE: Dokl. Akad. Nauk SSSR (**1989**), 305(4), 861-4 [Crystallogr.]
CODEN: DANKAS; ISSN: 0002-3264
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB The **crystal** structure of human somatotropin was detd. by x-ray anal. at 3.ANG.. The compd. has 4 .alpha.-helixes, with 3 irregular sections.

L440 ANSWER 126 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:567535 CAPLUS
DOCUMENT NUMBER: 111:167535
TITLE: Crystallization and x-ray data collection on human **growth hormone**
AUTHOR(S): Clarkson, Judy; Korber, Fritjof; Christensen, Thorkild; Junker, Flemming; Pedersen, John; Hansen, Finn Benned
CORPORATE SOURCE: Dep. Chem., Univ. York, Heslington/York, YO1 5DD, UK
SOURCE: J. Mol. Biol. (**1989**), 208(4), 719-21
CODEN: JMOBAK; ISSN: 0022-2836
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Single **crystals** of natural sequence human **growth hormone** were grown from media contg. ethanol, acetone, or paraldehyde. Recombinant **growth hormone** in its native and desamidated form and pituitary hormone were crystd. A full native set of diffraction data extending to 3.5 .ANG. resoln. was obtained with synchrotron radiation for **crystals** of recombinant human **growth hormone** grown from ethanol. The identity of the material in these **crystals** was established by anion-exchange chromatog.

L440 ANSWER 127 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1988:504954 CAPLUS
DOCUMENT NUMBER: 109:104954
TITLE: Crystallization and preliminary x-ray diffraction study of human somatotropin synthesized in bacteria by genetic engineering
AUTHOR(S): Borisova, S. N.; Pavlovskii, A. G.; Naktinis, V.; Janulaitis, E.; Rubtsov, P. M.; Skryabina, K. G.; Baev, A. A.; Vainshtein, B. K.
CORPORATE SOURCE: Inst. Kristallogr. im. Shubnikova, Moscow, USSR
SOURCE: Dokl. Akad. Nauk SSSR (**1988**), 301(2), 474-6 [Biochem.]
CODEN: DANKAS; ISSN: 0002-3264
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Human somatotropin produced by Escherichia coli was crystd. by the hanging drop method using 2-methyl-2,4-pentanediol as the pptg. agent. The primary **crystals** were subjected to x-ray diffractometry.

L440 ANSWER 128 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1988:180523 CAPLUS
DOCUMENT NUMBER: 108:180523
TITLE: Exocytosis in normal anterior pituitary cells. Quantitative correlation between **growth hormone** release and the morphological features of exocytosis
AUTHOR(S): Draznin, Boris; Dahl, Rolf; Sherman, Nancy; Sussman, Karl E.; Staehelin, L. Andrew
CORPORATE SOURCE: Health Sci. Cent., VA Med. Cent., Denver, CO, 80220, USA
SOURCE: J. Clin. Invest. (**1988**), 81(4), 1042-50
CODEN: JCINAO; ISSN: 0021-9738
DOCUMENT TYPE: Journal

LANGUAGE: English

AB High-pressure freezing techniques were used to study exocytosis in rat anterior pituitary cells. The cells were either unstimulated or exposed to 1 nM **growth hormone** releasing factor (GRF) for 10 min before ultrarapid freezing. The magnitude of **growth hormone** (GH) release was then correlated with the no. of exocytotic events obsd. with freeze-fracture electron microscopy. High-pressure freezing of unfixed and uncryoprotected specimens permits cryofixation of samples <1 mm diam (0.5-mm thick) without ice **crystal** damage, and arrests exocytotic events within 10 ms. These studies comparing conventionally fixed specimens with those prepd. by high-pressure freezing confirm that areas of intramembrane particle clearing at potential exocytotic sites are an artifact of conventional fixation and(or) cryoprotection techniques. The cells exposed to 1 nM GRF released .apprx.5-fold more GH than did unstimulated cells. Morphol., a 3.3-fold increase in the no. of exocytotic events was obsd. in GRF-stimulated cells, 33.7 events/100 .mu.m2 compared with 10.4 events/100 .mu.m2 for unstimulated cells. In addn. the effects of 2 inhibitors of GRF-induced exocytosis, somatostatin and Na isethionate were studied. Both compds. elicit the same response, a parallel decrease in exocytotic events and in secreted product. Thus, high-pressure freezing, combined with freeze-fracture and freeze-substitution processing techniques, is an excellent tool for studying the morphol. aspects of exocytosis. In the present investigation, it demonstrated a quantity relation between the biochem. and morphol. of exocytosis in anterior pituitary cells.

L440 ANSWER 129 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:568943 CAPLUS
DOCUMENT NUMBER: 107:168943
TITLE: Three-dimensional structure of a genetically engineered variant of porcine **growth hormone**
AUTHOR(S): Abdel-Meguid, Sherin S.; Shieh, Huey Sheng; Smith, Ward W.; Dayringer, Henry E.; Violand, Bernard N.; Bentle, Larry A.
CORPORATE SOURCE: Monsanto, Chesterfield Village, MO, 63198, USA
SOURCE: Proc. Natl. Acad. Sci. U. S. A. (**1987**), 84(18), 6434-7
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The 3-dimensional structure of a genetically engineered variant of porcine **growth hormone**, methionyl porcine somatotropin (MPS), was detd. at 2.8-.ANG. resoln., using single **crystal** x-ray diffraction techniques. Phases were obtained by use of a single isomorphous K2OsCl6 deriv. and were improved by use of the d. modification procedure. The MPS structure is predominantly helical. It consists mainly of 4 antiparallel .alpha.-helixes arranged in a left-twisted helical bundle, a structural motif obsd. in a no. of other unrelated proteins. However, the way the 4 helixes are connected in the bundle is unusual and has never been reported before. Alignment of the amino acid sequence of MPS with that of other **growth hormones** reveals that residues within the .alpha.-helixes are predominantly invariant and thus these invariant residues are necessary to maintain the structural integrity of these proteins.

L440 ANSWER 130 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:509576 CAPLUS
DOCUMENT NUMBER: 107:109576
TITLE: Crystallization of authentic recombinant human **growth hormone**
AUTHOR(S): Jones, Noel D.; DeHoniesto, Juel; Tackitt, Patricia M.; Becker, Gerald W.
CORPORATE SOURCE: Lilly Res. Lab., Eli Lilly and Co., Indianpolis, IN, 46285, USA

SOURCE: Bio/Technology (**1987**), 5(5), 499-500
CODEN: BTCHDA; ISSN: 0733-222X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Large single **crystals** of natural-sequence recombinant human **growth hormone** (rhGH) were grown from a medium contg. polyethylene glycol and a nonionic detergent, .beta.-octyl glucoside. The identity of the **crystals** was confirmed by gel electrophoresis and anion exchange chromatog. The electrophoretic mobility of the dissolved **crystals** was identical to that of uncrystd. rhGH. Likewise, the retention time of the dissolved **crystals** on a Mono Q column was the same as that of the uncrystd. protein. On the basis of these assays, it is concluded that the **crystals** are recombinant human **growth hormone**.

L440 ANSWER 131 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:133062 CAPLUS
DOCUMENT NUMBER: 106:133062
TITLE: Alkaline phosphatase mediated processing and secretion of recombinant proteins, DNA sequences for use therein and cells transformed using such sequences
INVENTOR(S): Chang, Shing; Lin, Leo Shun Lee; Chang, Sheng Yung; Wang, Alice Ming
PATENT ASSIGNEE(S): Cetus Corp., USA
SOURCE: Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 196864	A2	19861008	EP 1986-302201	19860325 <--
EP 196864	A3	19880323		
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 62055087	A2	19870310	JP 1986-64995	19860325 <--

PRIORITY APPLN. INFO.: US 1985-715653 19850325
US 1985-763932 19850807

AB Expression systems which are capable of secreting sol., biol. active forms of proteins which are susceptible to processing in prokaryotes under the influence of bacterial leader sequences is described. Vectors successful in effecting this expression encode a fusion protein having an N-terminal sequence comprising the phoA (alk. phosphatase) leader peptide and as a C-terminal sequence the desired protein. This fusion protein encoding sequence is placed under the control of a suitable bacterial promoter, preferably the alk. phosphatase promoter. Terminator sequences may also be included in the vectors for efficient expression.

L440 ANSWER 132 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:27890 CAPLUS
DOCUMENT NUMBER: 106:27890
TITLE: Crystallization of methionyl porcine somatotropin, a genetically engineered variant of porcine **growth hormone**
AUTHOR(S): Abdel-Meguid, Sherin S.; Smith, Ward W.; Violand, Bernard N.; Bentle, Larry A.
CORPORATE SOURCE: Monsanto, Chesterfield Village, MO, 63198, USA
SOURCE: J. Mol. Biol. (**1986**), 192(1), 159-60
CODEN: JMOBAK; ISSN: 0022-2836
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **Crystals** of methionyl porcine somatotropin [102733-72-2] were grown out of (NH4)2SO4 by the hanging drop method of vapor diffusion. The **crystals** belong to the trigonal space group P3121 or P3221, with a

.alpha. = 87.7 .ANG. and c = 58.7 .ANG., and diffract beyond 2.1 .ANG. resoln.

L440 ANSWER 133 OF 146 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1985:465105 CAPLUS
DOCUMENT NUMBER: 103:65105
TITLE: Crystallization and preliminary x-ray characterization of bovine **growth hormone**. Purification of bovine prolactin and **growth hormone**
AUTHOR(S): Bell, Jeffrey A.; Moffat, Keith; Vonderhaar, Barbara K.; Golde, David W.
CORPORATE SOURCE: Sect. Biochem., Mol. Cell Biol., Cornell Univ., Ithaca, NY, 14853, USA
SOURCE: J. Biol. Chem. (**1985**), 260(14), 8520-5
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new purifn. scheme for both prolactin [9002-62-4] and **growth hormone** [9002-72-6] from bovine pituitaries was developed which avoids the use of potentially damaging soln. conditions. Both hormones were >95% pure as judged by SDS-polyacrylamide gel electrophoresis, and had specific activities similar to or greater than std. samples of the same hormone as judged by several bioassays. Small single **crystals** of bovine **growth hormone** were obtained by vapor diffusion techniques. Examn. of these **crystals** by x-ray diffraction, using the Cornell High Energy Synchrotron Source, showed that they were well ordered, and exhibited diffraction to 2.8-.ANG. resoln. on still photographs. Precession and oscillation photographs showed that they belonged to the orthorhombic space group P212121 (or P21212) with unit cell dimensions .alpha. = 219 .ANG., b = 51.9 .ANG., c = 68.9 .ANG.. The d. of the **crystals** was 1.19 g/mL from which the presence of 8 45,000-dalton dimers/unit cell was deduced. The protein content of the **crystals** was shown by isoelec. focusing to be identical to that of purified **growth hormone** in soln. These **crystals** appear suitable for use in the x-ray structure detn. of bovine **growth hormone** to at least 3.2-.ANG. resoln.

L440 ANSWER 134 OF 146 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1986:127770 BIOSIS
DOCUMENT NUMBER: BA81:38186
TITLE: ULTRASTRUCTURE OF THE INTERSTITIAL CELLS OF LEYDIG STIMULATED AND UNSTIMULATED.
AUTHOR(S): GOLDBLATT P J; GUNNING W T
CORPORATE SOURCE: DEP. PATHOL., MEDICAL COLLEGE OHIO, C.S. 10008, TOLEDO, OHIO 43699.
SOURCE: ANN CLIN LAB SCI, (1985) 15 (6), 441-450.
CODEN: ACLSCP. ISSN: 0091-7370.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB The interstitial cells of Leydig which lie in small groups or individually between the seminiferous tubules of the testes, or at the hilum in the ovary, are known to be active in production of androgenic substances, as well as being sensitive to the influence of various trophic hormones. Among the hormones known to be produced by these cells are testosterone, dihydrotestosterone, and estradiol. Responsiveness of the function of the Leydig cells has been demonstrated with luteinizing hormone (LH), **growth hormone**, follicle stimulating hormone (FSH), and probably estrogen as well as prolactin. Human chorionic gonadotrophin also may have a marked effect. Attempts to correlate the cytologic appearance of Leydig cells with various states of stimulation have revealed a number of ultrastructural appearances. Since a spectrum of cellular morphology is apparent, both in the normal and in altered physiologic states, it is hazardous to ascribe a particular ultrastructural variation to the

influence of a given hormonal stimulus. Nevertheless, in normal males, three types of cells can frequently be seen: (1) fusiform cells with ovoid nuclei, small aggregates of smooth endoplasmic reticulum (SER), and variable amounts of cytoplasmic filaments, probably representing resting cells, since they are most abundant in pre-pubertal males; (2) light cells, the most frequent type, with well developed SER, scant rough endoplasmic reticulum (RER), and mitochondria which vary in size and shape, contain abundant lipid and frequent lipochrome deposits; and (3) dark interstitial cells which are variable in number, derive their density from stacks of tubular SER, and may represent merely an altered response to fixation or an involutional form. In addition to immature cells and normal mature cells, two additional cell types are described in various primary testicular disorders: (1) abnormally differentiated Leydig cells with features such as grouped mitochondria, whorls of endoplasmic reticulum, absent or fragmented Reinke's **crystals** and paracrystalline arrays and deficiency of lipid droplets as well as masses of microfilaments; and (2) a multivacuolated cell type characterized by swelling of cytoplasmic organelles and absence of Reinke's **crystals** or paracrystalline arrays. It is also clear that the interstitial cells respond in systemic diseases, are injured by alcohol ingestion, and show involutional changes in aging. While these ultrastructural changes are now well documented, there is still a need to correlate them exactly with the various stimuli may affect testicular function.

L440 ANSWER 135 OF 146 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1989-003152 [01] WPIDS
DOC. NO. NON-CPI: N1989-002279
DOC. NO. CPI: C1989-001442
TITLE: New cyclic peptide having somatostatin-like activity - prepd. from D-tryptophan methyl ester and phenylalanine deriv..
DERWENT CLASS: B02
PATENT ASSIGNEE(S): (MITU) MITSUBISHI CHEM IND LTD
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 63280099	A	19881117	(198901)*		5 <--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 63280099	A	JP 1987-114857	19870513

PRIORITY APPLN. INFO: JP 1987-114857 19870513
AN 1989-003152 [01] WPIDS
AB JP 63280099 A UPAB: 19930923
Cyclic peptide of fomrula (1). (1) can be prepd. from D-tryptophan Me ester and N-t-butoxycarbon-phenylalanine.

USE/ADVANTAGE - (I) inhibits release of **growth hormone** similar to the way somatostatin does.

In an example, (14.8mg) was dissolved in 0.1 ml AcOH contg. 25- HBr, to which 0.1 ml anisole was added, and the mixt. was stood at room temp. for 90 mins.. 30 ml dry ether was added and the pptd. **crystals** were collected by filtration and dried in a desiccator, then dissolved in MeOH and passed through a column of Sephadex LH-20 (Pharmacia AB) to give 7.1mg. (I) as crude **crystals**. This was purified by reverse phase HPLC and then with a Sephadex LH-20 column and lyophilised to give (I) as white powder, m.pt. 193-200 deg.C..
0/0

L440 ANSWER 136 OF 146 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1986-279978 [43] WPIDS
DOC. NO. CPI: C1986-120917
TITLE: Compsn. for treatment of bone fractures and osteotomy - comprises 24, 25 di hydroxy vitamin-D3 combined with vehicle of e.g. bone wax, or implant comprising e.g. gel-foam.
DERWENT CLASS: A96 B01 B05 C03 D22 P32 P34
INVENTOR(S): DEKEL, S; EDELSTEIN, S; LIDOR, C; MEYER, M S
PATENT ASSIGNEE(S): (YEDA) YEDA RES & DEV CO LTD
COUNTRY COUNT: 14
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	
EP 198213	A	19861022	(198643)*	EN	23	<--
R: BE DE FR GB IT NL SE						
AU 8654261	A	19860918	(198645)			<--
JP 61222452	A	19861002	(198646)			<--
ZA 8601658	A	19860903	(198649)			<--
IL 74617	A	19881115	(198909)			<--
EP 198213	B	19900808	(199032)			<--
R: BE DE FR GB IT NL SE						
DE 3673211	G	19900913	(199038)			<--
CA 1289882	C	19911001	(199146)			
US 5069905	A	19911203	(199151)			
JP 06042903	B2	19940608	(199421)		14	
KR 9407920	B1	19940829	(199623)			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 198213	A	EP 1986-103205	19860311
JP 61222452	A	JP 1986-55147	19860314
ZA 8601658	A	ZA 1986-1658	19860305
US 5069905	A	US 1989-385816	19890726
JP 06042903	B2	JP 1986-55147	19860314
KR 9407920	B1	KR 1986-1878	19860314

FILING DETAILS:

PATENT NO	KIND		PATENT NO
JP 06042903	B2	Based on	JP 61222452

PRIORITY APPLN. INFO: IL 1985-74617 19850315
AN 1986-279978 [43] WPIDS
AB EP 198213 A UPAB: 19930922
A compsn. for the treatment of bone fractures and osteotomies in warm blooded animals, comprises 0.002-0.2 wt.% of 24,25(OH)2D3 in combination with a vehicle.

Pref. the compsn. comprises 0.005-0.05 wt.% of 24,25(OH)2D3 and the carrier is bone-wax, bone-cement, bone sealant, demineralised bone powder or a conventional orthopaedic implant. The implant if used is gel-foam, dacron mesh or kiel bone. Auxiliary substances may be included such as 1a(OH)D3, 1,25(OH)2D3, oestradiol, hydroxy-apatite **crystals**, fluoro-apatite **crystals** or **growth hormone**.

USE/ADVANTAGE - 24,25(OH)2D3 affects the maturation and differentiation of cartilage cells, the initial stages in bone formation, resulting in faster formation of the callus and consequently faster bone healing. The effect is considerably superior to those obtd. by conventional treatments. The compsn. is suitable for use in orthopaedic surgery for local applicn. to a site of bone fracture or osteotomy or for applicn. to solid or semi-solid implant conventional in orthopaedic

surgery and to prostheses.
0/19
ABEQ EP 198213 B UPAB: 19930922
A composition for the treatment of healing of bone fractures and osteotomies in warm blooded animals including humans, which comprises from 0.002 to 0.2% by weight, of 24.25 (OH)2D3 (24,25-dihydroxychlocalciferol) in combination with a physiologically compatible vehicle suitable for use in orthopedic surgery for local application to a site of bone fracture or osteotomy or for application to solid or semi-solid implants conventional in orthopedic surgery and to protheses, characterised in that the vehicle comprises bone wax, a bone cement or one of the components thereof, a bone sealant, demineralised bone powder, dacron mesh, gel-foam, or kiel bone.
ABEQ US 5069905 A UPAB: 19930922
Compsn. for treating and promotion of healing of bone fractures and osteotomies by direct topical contact or local application comprises as carrier an orthopaedic implant or prosthesis with 0.002-0.2 (0.05-0.5) % wt. of the vitamin D deriv. 24,25(OH)2D3 incorporated in combination with a vehicle for use in orthopaedic surgery.

The carrier may be bone-waxes, -cements, -sealants, or demineralised bone powder. The implant may be gelfoam, dacron mesh, or kiel bone. Auxiliary substances include 1alpha(OH)D3, 1,25(OH)2D3, estradiol, hydroxyapatite or fluoroapatite **crystals** and **growth hormone**. The vehicle may be an oil (arachis oil).

The compsn. may be applied during open surgery, or a soln. may be injected into the cartilage growth plate of the bone to be treated.

ADVANTAGE - Local admin. gives excellent healing by encouraging differentiation of cartilage cells, formation of blood vessels and formation or trabeculae by mineralisation. @

L440 ANSWER 137 OF 146 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1984-036880 [06] WPIDS
DOC. NO. CPI: C1984-015547
TITLE: Carbohydrate particles contg. biologically active substances - stabilised by crystallisation of the carbohydrate.
DERWENT CLASS: A96 A97 B04 B07 C03 D16
INVENTOR(S): SHRODER, U
PATENT ASSIGNEE(S): (SCHR-I) SCHRODER U
COUNTRY COUNT: 18
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	
WO 8400294	A	19840202	(198406)*	EN	17	<--
RW: AT BE CH DE FR GB LU NL SE						
W: AU DK FI JP NO US						
SE 8204244	A	19840213	(198409)			<--
AU 8317760	A	19840208	(198417)			<--
NO 8400676	A	19840430	(198424)			<--
EP 113749	A	19840725	(198430)	EN		<--
R: AT BE CH DE FR GB LI LU NL SE						
JP 59501213	W	19840712	(198434)			<--
FI 8400923	A	19840307	(198450)			<--
DK 8400952	A	19840323	(198502)			<--
ES 8505250	A	19850901	(198602)			<--
CA 1222457	A	19870602	(198726)			<--
US 4713249	A	19871215	(198806)			<--
EP 113749	B	19880601	(198822)	EN		<--
R: AT BE CH DE FR GB LI LU NL SE						
DE 3376797	G	19880707	(198828)			<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 8400294	A		WO 1983-SE268	19830704
EP 113749	A		EP 1983-902308	19830704
JP 59501213	W		JP 1983-502406	19830704
US 4713249	A		US 1984-789993	19840222

PRIORITY APPLN. INFO: SE 1981-6723 19811112; SE 1982-4244 19820709

AN 1984-036880 [06] WPIDS

AB WO 8400294 A UPAB: 19930925

Carbohydrate spheres or particles have a particle size of 0.01-1000 microns and contain 0.001-50 wt.% of enclosed, adsorbed or covalently bonded biologically active substances. The novel feature is that the spheres or particles are stabilised by crystallisation.

The carbohydrate is esp. dextran, starch, alginate, chitosan, agarose, carrageenan, cellulose, glucogen, pullulan or their derivs. The particle size is pref. less than 1 micron.

The prods. may be used for admin. of medicaments or vaccines or as carriers for pesticicides, enzymes, etc. Use of the prods. with antigens, insulin or allergens is specifically claimed.

0/0

ABEQ EP 113749 B UPAB: 19930925

A process of producing a stable carbohydrate sphere or particle in the size range of 0.01 to 1,000 micro m, characterised in that a carbohydrate polymer is dissolved in one or more solvents having a dielectricity constant of more than 35 to a concentration within the range of 0.1 to 20% (weight/volume) to form a clear soln. whereupon the thus obtained hydrophilic carbohydrate polymer soln. is emulsified in a hydrophobic emulsion medium to form spherical droplets of the carbohydrate soln., whereafter the emulsion is stabilised by transferring it to a liquid capable of crystallising the carbohydrate polymer to a complex relatively insoluble in water.

ABEQ US 4713249 A UPAB: 19930925

New prolonged-release compsn. for biologically active substances comprises 0.01-1000 (0.01-1) micron sphere or ptcl. of non-covalently cross-linked cryst.polymeric carbohydrate matric contg 0.001-50% wt adsorbed or covalently bonded biological substance.

Pref. carbohydrate is dextran or starch deriv., otherwise alginate, chitosan, agarose, carrageenan, cellulose, glycogen, pullulan, and derivs. Biological substance is antigen, insulin, allergen, **growth hormone**.

Prepn is effected e.g. by dissolving carbohydrate and biological substance in hydrophilichydrophillic solvent, emulsifying in hydrophobic medium at 4-40 deg C and cryst. emulsion e.g. by addn. acetone, ethanol, methanol, etc.

ADVANTAGE - Steady release from exretable non-toxic matrix at rate controlled by dissoln. of crysts. i.e. pref. independent of enzymes.

L440 ANSWER 138 OF 146 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 1978-50726A [28] WPIDS

TITLE: Steviol prepn. having plant **growth hormone** activity - by oxidising stevioside or steviobioside with meta-periodate or lead tetra-acetate and hydrolysing prod. with alkali.

DERWENT CLASS: C03

PATENT ASSIGNEE(S): (TAKS) TAKASAGO PERFUMERY CO LTD

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 53063364	A	19780606	(197828)*		
JP 59017096	B	19840419	(198420)		<--

PRIORITY APPLN. INFO: JP 1976-138035 19761117
AN 1978-50726A [28] WPIDS
AB JP 53063364 A UPAB: 19930901
Steviol is prepd. by oxidising stevioside or steviobioside with metaperiodate or lead tetracetate, and then hydrolysing the resulting prod. with alkali. Steviol can be obtd. without formation of isosteviol,.
As stevioside there can be used the commercial prod. obtd. by extn. of the plant. Steviobioside can be obtd. by treating stevioside in 10% alkali hydroxide solution at 100 degrees C for 1 hour and then acidifying the reaction liquid. Recrystallization from methanol gives the pure **crystal**, m.pt. 188-192 degrees C.

L440 ANSWER 139 OF 146 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
ACCESSION NUMBER: 1990-0111156 PASCAL
TITLE (IN ENGLISH): Structure and activity of artificial mutant variants of human **growth hormone**
AUTHOR: NISHIKAWA S.; NISHIDA Y.; UEMURA H.; YAMADA Y.; TANAKA T.; UESUGI S.; MORIKAWA M.; UCHIDA E.; HAYAKAWA T.; IKEHARA M.
CORPORATE SOURCE: Osaka univ., fac. pharmaceutical sci., Osaka 565, Japan
SOURCE: Protein engineering, **(1989)**, 3(1), 49-53, 28 refs.
ISSN: 0269-2139 CODEN: PRENE9
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: United Kingdom
LANGUAGE: English
AVAILABILITY: CNRS-21350
AN 1990-0111156 PASCAL
AB In this report we describe the construction of two types of variant. One variant is mutant at Trp86, which is the single Trp residue in hGH, and moreover, is conserved in all **growth hormones** known so far. The other type of variant has a deletion in the long loop region that connects helices I and II, according to the **crystal** structure. We prepared these variants of hGH by in vitro mutagenesis and studied their biological activities and physicochemical characteristics

L440 ANSWER 140 OF 146 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 90:54532 PROMT
TITLE: POG microgravity experiments flying high
Some 24 proteins will be subjects of microgravity experiments on space shuttle launch in 1/90
SOURCE: Bio/Technology, (**Feb 1990**) pp. 97.
ISSN: 0733-222X.
LANGUAGE: English
AB Some 24 proteins will be the subjects of microgravity experiments on the Space Shuttle Columbia launched in 1/90. Some experiments will be repeats of those conducted on the space shuttle flight of 9/88. The studies will focus on conditions affecting protein **crystal** growth, but the production of high-resolution **crystals** would help further rational drug design projects. The results from the 9/88 experiments found that there were significant improvements in the procedures for growing more ordered **crystals** in microgravity for 3 of 11 proteins. Two gamma interferon **crystals** grown in space on behalf of Schering-Plough were markedly larger than those grown on earth. One of the **crystals** was 50% larger than any previously made on earth. It was also found that the **crystal** grown in space possessed a higher internal order. Results for porcine elastase and isocitrate lyase **crystals** were also promising. A **crystal** of porcine elastase grown in space yielded more data at all resolution ranges. Six of the other 8 proteins studied failed to yield **crystals** large

enough for diffraction analysis. Due to the many variables involved in protein crsytal growth, temperature is used as a constant. The space shuttle mission of 1/90 will conduct 120 experiments on protein **crystals**, 50% at 22C and 50% at 4C. Proteins that will be studed in space for the 1st time include Eli Lilly's human **growth hormone**, the U of California's (Riverside) satellite tobacco mosaic virus and Biocryst's and the U of Alabama's aldose reductase.

L440 ANSWER 141 OF 146 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 87:116793 PROMT
TITLE: Crystallization of authentic recombinant human **growth hormone**
Large single **crystals** of recombinant human **growth hormone** are grown
SOURCE: Bio/Technology, (**May 1987**) pp. 499-500.
ISSN: 0733-222X.
LANGUAGE: English
AB Large single **crystals** of natural sequence recombinant human **growth hormone** have been grown from a medium containing polyethylene glycol and a nonionic detergent, beta-octyl glucoside, according to ND Jones et al of Eli Lilly. The identity of the **crystals** was confirmed by gel electrophoresis and anion exchange chromatography.

L440 ANSWER 142 OF 146 INVESTEXT COPYRIGHT 2002 TFS

Accession No.: 84:043375 INVESTEXT(tm) REPORT NUMBER: 408679
Page No.: PAGE 1 OF 1
Document No.: 408679
Title: Healthcare -- Biotechnology Monthly
Author: Masterson, M., et al
Corp. Source: DREXEL BURNHAM LAMBERT INC.; NEW YORK
Region: MID-ATLANTIC/MIDDLE ATLANTIC STATES; UNITED STATES OF AMERICA; NORTH AMERICA
Corp. So. Type: Financial center investment bank-broker
Publication Date: **28 Aug 1984**
Report Type: INDUSTRY REPORT
File Segment: Text Page; INDUSTRY REPORT
Text Word Count: 664

L440 ANSWER 143 OF 146 JICST-EPlus COPYRIGHT 2002 JST
ACCESSION NUMBER: 870294414 JICST-EPlus
TITLE: Elucidation of the correlation between the structure and function of proteins. An aspect of protein technology.
AUTHOR: HONDA KOICHI; MATSUI IKUO
CORPORATE SOURCE: Agency of Industrial Science and Technology, National Chemical Lab. for Industry
SOURCE: Kagaku Kogyo Shiryo, Tsukuba, (1987) vol. 21, no. 6, pp. 184-207. Journal Code: G0511A (Fig. 13, Tbl. 6, Ref. 74)
ISSN: 0288-8882
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
STATUS: New

L440 ANSWER 144 OF 146 PHIN COPYRIGHT 2002 PJB

ACCESSION NUMBER: 90:6043 PHIN
DOCUMENT NUMBER: S0026114
DATA ENTRY DATE: 19 Jan 1990
TITLE: US space shuttle experiments
SOURCE: Scrip (**1990**) No. 1481 p17
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L440 ANSWER 145 OF 146 PHIN COPYRIGHT 2002 PJB

ACCESSION NUMBER: 87:17923 PHIN
DOCUMENT NUMBER: S00138724
DATA ENTRY DATE: 5 Nov 1987
TITLE: Biotechnology - China's plans
SOURCE: Scrip (**1987**) No. 1256 p20
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L440 ANSWER 146 OF 146 ANABSTR COPYRIGHT 2002 RSC

AB The following items of analytical interest are included. The compendial definition of thyronine and polypeptide hormones in the US: present and future, Bransome, E. D., jun.; pp. 20-24. Peptide hormones: questions of identity, Bangham, D. R.; pp. 25-35. Use of human leucocytic pyrogen assay for detection of exogenous pyrogenic materials, Dinarello, C. A.; pp. 36-47. Cytochemical bio-assay and its potential place in compendial definitions: a method that offers sensitivity as well as specificity, Chayen, J.; pp. 48-58. Scientific and medical background for compendial definition of insulins, Horwitz, D. L.; pp. 63-67. Link between description, nomenclature and assays of insulins: compendial and regulatory considerations, Weis-Fogh, O.; pp. 68-71. Procedure for detection of potential Escherichia coli peptides (ECPs) in biosynthetic human insulin (BHI), antibodies to ECPs in patients treated with BHI, and measurement of bacterial endotoxins in BHI, Ross, J. W.; Baker, R. S.; Hooker, C. S.; Johnson, I. S.; Schmidtke, J. R.; Smith, W. C.; pp. 127-138. Estimation of insulin purity in light of developments in analytical methods, Joergensen, K. H.; Hallund, O.; Heding, L. G.; Tronier, B.; Falholt, K.; Damgaard, U.; Thim, L.; Brange, J.; pp. 139-147. Applications of high-performance liquid chromatography for analysis of insulins, Kroeff, E. P.; Chance, R. E.; pp. 148-162. Characterization of insulin and insulin-like substances by high-performance liquid chromatography, Welinder, B. S.; Andresen, F. H.; pp. 163-177. Radio-immunological determinations of comtaminants in insulins, Kappelgaard, A.-M.; Balschmidt, P.; Kristensen, O.; Lernmark, A.; Vikelsoee, J.; Hansen, B.; 178-186. Inherent problems in radio-immunoassay exemplified by determination of proinsulin-like immunoreactivity in bovine insulin, Damgaard, U.; Kruse, V.; pp. 187-191. Quantitation of insulin by radio-receptor assay, Sjodin, L.; Holmberg, K.; Stadenberg, I.; Viitanen, E.; pp. 192-199. Assessment of insulin potency by chemical and biological methods, Pingel, M.; Voelund, A.; Soerensen, E.; Soerensen, A. R.; pp. 200-207. Differential potency of pork and beef insulins in the USP rabbit bio-assay system, Voelund, A.; Pingel, M.; Soerensen, E.; pp. 208-215. Radio-immunoassays for determination of proinsulin content in purified insulin **crystals**, Chiu, Y.-Y. H.; Gueriguian, J. L.; pp. 216-225. Comparison of biological response curves in rabbits following injection of various insulin formulations, Collins, J. E.; Dieter, C. T.; pp. 226-233. Variability of the glucose nadir induced by intravenous or sub-cutaneous insulin: comparative study, Kowarski, C. R.; Kowarski, A. A.; pp. 234-238. International studies for replacement of the 4th International Standard for insulin, Bangham, D. R.; Bristow, A. F.; Gaines Das, R. E.; pp. 239-243. Report of the consensus-forming session on insulins, pp. 254-281. Background for a rational approach to compendial definition of somatropins [**growth hormones**], Daughaday, W. H.; pp. 283-286. Somatotrophic [**growth-hormone**] assays in the rat and in man, Rudman, D.; Chawla, R. K.; pp. 287-295. Comparative study of various somatotrophins [**growth hormones**], biological potency and radio-receptor assay, Overpeck, J. G.; Jordan, A. W.; Chiu, Y.-Y. H.; Gueriguian, J. L.; pp. 296-300. Selection of material, design of an international collaborative study and preliminary analysis of assays for a proposed international standard for human **growth hormone** for bio-assay, Bangham, D. R.; Gaines Das, R. E.; Schulster, D.; pp. 301-312. Report of the consensus-forming session on somatropins [**growth**

hormones], pp. 382-403. Present compendial condition of thyroid hormones and thyroid-hormone preparations, Larsen, P. R.; pp. 405-408.

=>